UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

Form 10-K

 

(Mark One)

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934.

  
 

For the fiscal year ended December 31, 20162018

  

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the transition period from _______ to _____

 

Commission file number: 1-16525

 

CVD EQUIPMENT CORPORATION

(Exact name of registrant as specified in its charter)

 

New York

11-2621692

(State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer Identification No.)

Incorporation or Organization)

355 South Technology Drive

Central Islip, New York 11722

(Address including zip code of registrant’s Principal Executive Offices)

 

(631) 981-7081
(Registrant’s Telephone Number, Including Area Code)

 

Securities registered under Section 12(b) of the Act:

 

Title of each class

Name of each exchange on which registered

Common Stock, Par value $0.01

NASDAQ Capital Market

 

Securities registered under Section 12(g) of the Act:
None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.                     Yes ☐    No ☑

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.                  Yes ☐    No ☑

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                                                                                                                                        Yes ☑    No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months/(or for such shorter period that the registrant was required to submit and post such files).Yes. Yes ☑     No ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.                                                                                       ☐   

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.company or an emerging growth company . See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer Smaller reporting company ☐   Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).                              Yes ☐ No ☑

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $44,511,547$34,195,157 at June 30, 20162018

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 6,363,6906,538,388 shares of Common Stock, $0.01 par value at March 15, 2017.22, 2019.

 

DOCUMENTS INCORPORATED BY REFERENCE: None.

 

 

 

 

PART I

 

INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS

 

Except for historical information contained herein, this Annual Report on Form 10-K contains forward–looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. These statements involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on various factors and are derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include, but are not limited to: competition in our existing and potential future product lines of business; our ability to obtain financing on acceptable terms if and when needed; uncertainty as to our future profitability, uncertainty as to the future profitability of acquired businesses or product lines, uncertainty as to any future expansion of the Company. Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. We assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting such forward-looking statements. Past performance is no guaranty of future results.

 

Item 1.          Description of Business.

 

The use of the words “CVD,” “we,” “us” or “our” refers to CVD Equipment Corporation, a New York corporation incorporated on October 13, 1982, and its wholly owned subsidiaries, CVD Materials Corporation (including its wholly owned subsidiarysubsidiaries CVD Tantaline ApS, and CVD MesoScribe Technologies Corporation) collectively “CVD Materials”) and, FAE Holdings 411519R LLC and 555 N Research Corporation except where the context otherwise requires.

 

We design, develop and manufacture a broad range of chemical vapor deposition, gas control and other state-of-the-art equipment and process solutions used to develop and manufacture materials and coatings for research and industrial applications. This equipment is used by our customers to research, design, and manufacture these materials or coatings for aerospace engine components, medical implants, semiconductors, solar cells, smart glass, carbon nanotubes, nanowires, LEDs, MEMS and other applications. Through CVD Materials and our Application Laboratory, we develop new material systems, provide material coatings,coating services, process development support and process startup assistance with the focus on enabling tomorrow’s technologiesTM.


 

Based on more than 3436 years of experience, we use our capabilities in engineering, manufacturing and process development to transform new applications into leading-edge manufacturing solutions.


This enables university, research and industrial scientists at the cutting edge of technology to develop next generation aerospace, medical, solar, nano, LEDs, semiconductors and other electronic components. We develop, manufacture and provide equipment for research and production based on our proprietary designs. We have built a significant library of design expertise, know-how and innovative solutions to assist our customers in developing these intricate processes and to accelerate their commercialization. This library of solutions, along with our vertically integrated manufacturing facilities, allows us to provide superior design, process and manufacturing solutions to our customers on a cost effectivecost-effective basis.

 

Our strategy is to target opportunities in the research, and development and production equipment market, with a focus on higher-growth applications such as aerospace, medical, solar, smart glass, carbon nanotubes, nanowires, graphene, MEMS and LEDs. To expand our penetration into these growth markets, we have developed a line of proprietary standard products and custom systems. Historically, we manufactured products for research and development on a custom one-at-a-time basis to meet an individual customer’s specific research requirements. Our new proprietary systems leverage the technological expertise that we have developed through designing these custom systems onto a standardized basic core. This core is easily adapted through a broad array of available add-on options to meet the diverse product and budgetary requirements of the research community. By manufacturing the basic core of these systems in higher volumes, we are able to reduce both the cost and delivery time for our systems. These systems, which we market and sell under the EasyTube® and CVD product line,lines, are sold to researchers at universities, research laboratories, and startup companies in the United States and throughout the world.

 

Sales of our proprietary standard, custom systems and process solutions have been driven by our installed customer base, which includes several Fortune 500 companies. The strong performance and success of our products has historically driven repeat orders from existing customers as well as business from new customers. However, with our proprietary solutions and expanded focus on “acceleratingaccelerating the commercialization of tomorrow’s technologies”technologiesTM we have been developing a new customer base in addition to growing with our existing customers. We have generally gained new customers through word of mouth, limited print advertising and trade show attendance. We are now also gaining new customers by their awareness of our company in the marketplace with results from our Application Laboratory, partnershipsrelationships with startup companies, increased participation in trade shows and expanded internet advertising.

 

The core competencies we have developed in equipment and software design, as well as in systems manufacturing and process solutions, are used to engineer our finished products and to accelerate the commercialization path of our customer base. Our proprietary-real-time, software allows for rapid configuration, and provides our customers with powerful tools to understand, optimize and repeatedly control their processes. Our vertically integrated structure allows us to control the manufacturing process, from bringing raw metal and components into our manufacturing facilities to shipping out finished products. These factors significantly reduce cost, improve quality and reduce the time it takes from customer order to shipment of our products. Our Application Laboratory allows selected customers to testbring up their process tools in our Application Laboratory and to work together with our scientists and engineers to optimize process performance.

 


 

Business Developments

 

CVD Materials Segment:

On December 16, 2016, we purchased certain assets formerly owned by Tantaline A/S of Nordborg, Denmark (“Tantaline A/S”)October 31, 2017, through our wholly ownednewly formed and wholly-owned subsidiary, CVD Materials.MesoScribe Technologies Corporation (“CVD MesoScribe Technologies”), we acquired substantially all of the operating assets and business of MesoScribe Technologies, Inc. (“MTI”). Formed in 2007, as2002, by a spin offgroup from The Danfoss Group, Tantaline A/SStony Brook University, MTI established itself as a pioneer and leader in the commercializationdirect deposition of tantalum treated partsthermal sensors, heaters, and instrumentation for corrosion resistance. We have now establishedharsh environments.

MTI specialized in Denmark a newmaterials processing using Direct Write MesoPlasma™ printing technology. This technology is an enabling additive manufacturing process whereby materials are printed onto conformal components in precise patterns. MTI has provided MesoPlasma™ printing services and wholly owned CVD subsidiary operating under the name Tantaline CVD ApS (“Tantaline”).products to its customers for use in aerospace, power generation, satellite, and defense markets, focusing on developing and manufacturing innovative products for advanced sensing, heating, and communication.

 

This asset acquisition wasprovides CVD access to additional materials deposition technology, a significant steppresence in new markets, a broader presence in aviation and defense markets and additional end user applications. In addition, the proprietary MesoPlasma™ technology complements our Tantaline® business which we acquired in the fourth quarter of 2016. The two technologies when combined provide a treatment and coating which can provide both corrosion and wear resistance. This is consistent with our strategic plan to leverage our equipment know-how, business infrastructure and proven ability to scale up deposition processes intonew technologies, all offering high value addedvalue-added materials, products, and services. This innovative tantalum chemical vapor technology, called Tantaline® treatment,services and is usedanother step in our combined organic and acquisition growth strategy.

To support the expected growth of CVD Materials and to create a tantalum surface alloy on parts including valves, fittings, autoclaves, process chambers, flow reactors, fasteners, mixers, flowmeters, and medical devices,relocate the California MesoScribe operations as well as other parts that are proneTantaline USA business on November 30, 2017, we purchased the premises located at 555 North Research Place, Central Islip, NY (the “Premises”). The purchase price of the building was $13,850,000, exclusive of closing costs. On November 30, 2017, the Company’s newly formed wholly-owned subsidiary, 555 N Research Corporation (the “Assignee”) and the Islip IDA, entered into a Fee and Leasehold Mortgage and Security Agreement (the “Loan”) with HSBC Bank USA, N.A. (the “Bank”) in the amount of $10,387,500, which was used to corrosionfinance a portion of the purchase price to acquire the Premises. The Loan was evidenced by the certain Note, dated November 30, 2017 (the “Note”), by and between Assignee and the Bank, and secured by a certain Fee and Leasehold Mortgage and Security Agreement, dated November 30, 2017 (the “Mortgage”), as well as a collateral Assignment of Leases and Rents (“Assignment of Leases”).

The Loan is payable in harsh environments. These parts are used across a broad rangesixty consecutive equal monthly installments of industries$62,481, including chemical processing, oil & gas, mining, pharmaceutical, and medical. In hot corrosive acidic environments (>150°C) such as sulfuric, nitric, and hydrochloric acids, Tantaline® treated parts outperform most high priced specialty alloys nearlyinterest. The Loan bears interest for each Interest Period (as defined in the Note), at the levelfixed rate of more expensive solid tantalum parts. Tantaline® treatment therefore provides solid tantalum like superior corrosion resistance at a lower part cost. We believe that3.9148%. The maturity date for the acquisition of these assets will further CVD’s corrosion resistant technology and applications base and provide access to new markets and applications. Additionally, sales and manufacturing operations in Denmark expand our geographic footprint.Note is December 1, 2022.

 

OperatingUnitsAs a condition of the Bank making the Loan, the Company was required to guaranty Assignee’s obligations under the Loan pursuant to that certain Unlimited Guaranty, dated November 30, 2017 (the “Guaranty”).

 

In 2016, we conducted our operations through two divisions: (1) CVD/First Nano, and (2) Stainless Design Concepts (“SDC”). Each division operates with divisional management supported by product development, sales and administration which are managed at the corporate level.


 

With the acquisitioncompleted purchase of certain assets formerly ownedthe additional facility, we now have the manufacturing space to accelerate our capabilities of providing materials, coatings and surface treatments to meet our customers’ needs. We have now positioned ourselves for the expansion of our carbon composites and electronic materials, Tantaline® and MesoScribe Technologies product lines. Our expectation is to have operations for Tantaline® and MesoScribe commencing in the second or third quarter of 2019.

It is common and required to have coating services located near or at least in the country or territory of the customers being service. With regard to Tantaline® our Demark facility provides both local and global deposition services. The majority of the business though has been in Europe. The Central Islip, NY facility will primarily support the US customer base as well as serve as our application and technology center. This is an essential element of our growth strategy for Tantaline®. With respect to CVD MesoScribe Technologies group, we are in the process of consolidating the manufacturing and development operations in Central Islip by Tantaline A/S, we set up Tantaline,mid 2019. This will result in a wholly owned subsidiaryreduction of CVD Materials where we operate a facilityour operating expenses associated with our leased space in Denmark. There was minimal activity in 2016California and is included in CVD/First Nano.will further provide synergy with the Central Islip sales and marketing functions and place the operations near the local Thermal Spray Center of Excellence located at Stony Brook University.

Segments

 

CVD/First Nanosupplies state-of-the-art chemical vapor deposition systems for use in the research, development and manufacturing of aerospace and medical components, semiconductors, LEDs, carbon nanotubes, nanowires, solar cells and a number of other industrial applications. We utilize our expertise in the design and manufacture of chemical vapor deposition systems to work with laboratory scientists to bring state-of-the-art processes from the research laboratory into production, as well as to provide production equipment and process solutions based on our designs. CVD/First Nano also operates our Application Laboratory where our personnel interact effectively with the scientists and engineers of our customer base. CVD/First Nano operates out offrom our main facility in Central Islip, New York.

 


SDCdesigns and manufactures ultra-high purity gas and chemical delivery control systems for state-of-the-art semiconductor fabrication processes, solar cells, LEDs, carbon nanotubes, nanowires, and a number of industrial applications. Our SDC products are sold on either a stand-alone basis, or together with our CVD/First Nano systems. SDC operates out offrom a 22,000 square foot facility fitted with Class 10 and Class 100 clean room manufacturing space located in Saugerties, New York.

 

Principal ProductsCVD Materials Has several elements and product groups. These are the Tantaline corrosion resistant surface treatment, the MesoScribe robust material direct write, the Electronic Materials for advance electronics and Carbon Composite products.

Tantaline® treatment is a diffusion bonded protective layer of tantalum formed by chemical vapor deposition on the surface of common materials. Tantalum is the most corrosion resistant metal commercially available. This surface layer provides protection against many of the most aggressive environments, including high temperature concentrated acid. Global sales and technical support is provided by our facility in Central Islip, New York with production provided from our European facility located in Nordborg, Denmark. Future expansion of production capacity in the US has previously been announced and is expected in the second or third quarter of 2019. We continue to develop new Tantalum processes to improve the corrosion resistance of additional base material such as Nickel based alloys. In 2018, we announced that two patents applications were filed.


MesoScribe Technologies provides MesoPlasma™ printing services and products (heaters, antennas, & sensors) to aerospace, satellite, power generation, defense, and other markets requiring high performance. MesoScribe Technologies operated from a 22,000 square foot facility located in Huntington Beach, CA, which is relocating to Central Islip, New York by 2019, with sales and marketing support from our main facility in Central Islip, New York.

 

Carbon Composites

Our applications for the Carbon composite business come from achievements in our applications laboratory. In the fourth quarter of 2018, we announced the development of a family of advanced Fluid Reactors based on our innovations in nanotechnology and chemical vapor deposition technology. The Fluid Reactor is enabled by a novel reactor core element which allows the efficient transfer of gases into and out of liquids. The market adoption of this technology could supplant existing hollow fiber membrane technology for applications including filtration and liquid gasification or degasification. One such application is blood oxygenation cartridges, known as Extra Corporeal Membrane Oxygenators, which are typically used during cardio pulmonary bypass (CPB) surgery and are essential for life support. CVD has a patent pending embodying this technology. While holding promise the technology is in the evaluation phase and is not expected to generate revenue in near future.

The applications lab along with the sales and marketing team are exploring other possible Carbon based products that can be made from this technology.

Principal Equipment Products

Chemical Vapor Deposition - A process which passes a gaseous compound over a target material surface that is heated to such a degree that the compound decomposes and deposits a desired layer onto substrate material. The process is accomplished by combining appropriate gases in a reaction chamber, of the kind produced by the Company, at elevated temperatures (typically 150-1,800°150-1,600° Celsius). Our chemical vapor deposition systems are complete and include all necessary instrumentation, subsystems and components and include state-of-the-art process control software. We provide both standard and specifically engineered products for particular customer applications. Some of the standard systems we offer are for silicon, silicon-germanium, silicon dioxide, silicon nitride, polysilicon, liquid phase epitaxial, metalorganic chemical vapor deposition, carbon nanotubes, graphene nanowires, solar cell research and solar material quality control.

 

Chemical Vapor Deposition Systems - Used in a variety of models for laboratory research and production. All models are offered with total system automation, a microprocessor control system by which the user can measure, predict and regulate gas flow, temperature, pressure and chemical reaction rates, thus controlling the process in order to enhance the quality of the materials produced. Our standard microprocessor control system is extremely versatile and capable of supporting the complete product line and most custom system requirements.


These chemical vapor deposition systems are typically priced between $80,000 and $1,500,000,$2,000,000, but can gobe significantly higher.higher for plant size chemical vapor deposition systems.

 

Rapid Thermal Processing (“RTP”) - Used to heat semiconductor materials to elevated temperatures of up to 1,0001,200° Celsius at rapid rates of up to 200° Celsius per second. Our RTP systems are offered for implant activation, oxidation, silicide formation and many other processes. We offer systems that can operate both at atmospheric or reduced pressures. Our RTP systems are priced up to $600,000.

 

Annealing, Diffusion and Diffusion Low Pressure Chemical Vapor Deposition (LPCVD) Furnaces - Used for diffusion, oxidation, implant anneal, solder reflow, solar cell manufacturing and other processes. The systems are normally operated at atmospheric and/or reduced pressure with gaseous atmospheres related to the process. An optional feature of the system allows for the heating element to be moved away from the process chamber allowing the wafers to rapidly cool or be heated in a controlled environment. Our cascade temperature control system enables more precise control of the wafers. The systems are equipped with an automatic process controller, permitting automatic process sequencing and monitoring with safety alarm provisions. Our annealing and diffusion furnace systems are priced up to $900,000.

 

Ultra-high Purity Gas and Liquid Control Systems - Our standard and custom designed gas and liquid control systems, which encompass gas cylinder storage cabinets, custom gas and chemical delivery systems, gas and liquid valve manifold boxes and gas isolation boxes, provide safe storage and handling of pressurized gases and chemicals. Our system design allows for automatic or manual control from both a local and remote location. A customer order often includes multiple systems and can total up to $1,000,000.

 


Principal Materials Products

 

Quartz-ware - We provide standard and custom fabricated quartz-ware used in our equipment and other customer tools. We also provide repair and replacement of existing quartz-ware. The business volume is favorably impacted by introduction of our CVD/First Nano systems and equipment into production applications, as quartz is a consumable item.

 

MesoPlasma™ Direct Write Printing: A materials deposition process that provides high definition traces, fine feature patterns, and coatings onto conformal components. Powder materials are injected into a thermal plasma where they are rapidly heated and deposited onto the substrate or component. A 6-axis robotic system ensures pattern placement accuracy and manufacturing consistency. The versatility of the process enables a wide range of materials to be deposited including ceramic dielectrics, nickel-based sensor alloys, metallic conductors, precious metals, and protective coatings. Products include temperature sensors, heaters, antennas and patterns per customer specifications.

Tantaline® Corrosion Resistant Coating: Tantaline® treatment is provided as part of either a finished product or as a service applied to customer sourced components. These include valves, fittings, fasteners, vessels, bellows, and a wide range of custom designed items. The Tantaline® treatment drastically improves the corrosion resistance of these base stainless steel parts extending the service life and increasing value in a wide range of applications.


Markets and Marketing

 

We serve multiple global markets including aerospace, defense, biomedical implants, microelectronic and micromechanical devices, semiconductor, universities and research centers. Due to the highly technical nature of our products, we believe it is essential to contact customers directly through our sales personnel and through a network of domestic and international independent sales representatives and distributors specializing in the type of equipment, products and services that we sell. In addition to our traditional customer base, we are now accessing new markets and new customers through Tantaline,® MesoScribe,® and other components of our expanding materials business. Our primary marketing activities include direct sales contacts, participation in trade shows and our internet websites.websites www.cvdequipment.com, cvdmaterialscorporation.com, www.stainlessdesign.com, www.firstnano.com, tantaline.com and www.mesoscribe.com. We are also focusing our efforts on being in the top listings on many search engines in order to increase the number of “hits” to our websites.

 

Customers

 

We are continuingcontinue to work on expanding our product and service offerings. Many of theseOur systems and products are used in research and in production applications. We market and sell our products primarily to electronic component manufacturers, institutions involved in electronic component research (such as universities, government and industrial laboratories) and to industries such as aerospace and medical that require specialized coatings. We have both a domestic and international customer base with hundreds of installed systems.

 

Given the complexity of some of the systems we sell, revenue from a single customer in any one year can exceed 10.0% of our total sales. In fiscal years 20162018 and 20152017 one customer represented 45.3%38.2% and 49.6%66.1% of our annual revenues respectively. Another customer represented 13.7% of our annual revenues for 2015. The loss of currentsuch a key customers,customer, if not replaced by others with a similar amount of revenue, may have a material adverse effect on our business and financial condition.

 

For the twelve months ended December 31, 2016,2018, approximately 11.9%$2.4 million or 9.9% of our revenues were generated by sales to customers outside the U.S., compared to 9.0%approximately $3.9 million or 9.6% for the twelve months ended December 31, 2015.2017.

 

Warranties

 

Warranties on our equipment are typically for twelve months but can range up to twenty-four months from shipment and we pass alongwith extended contracts. We furnish any warranties from original manufacturers of components used in our products. We provide service and support for our installed base of equipment with in-house field service personnel. Warranty costs, including those incurred in fiscal years 20162018 and 2015,2017, have been historically insignificant and expensed as incurred.

 


 

Competition

 

We are subject tocan experience intense competition.direct competition from both domestic and international competitors in all of our equipment segments. Our MesoScribe operations, which is in the adoption phase, faces barriers from established indirect competitors of existing solution providers. We are aware of other competitors that offer a substantial number of products and services comparable to ours. Many of our competitors (including customers who may elect to manufacture systems for internal use) have financial, marketing and other resources greater than ours. To date, we believe that each of our two operating divisionsproduct and service segments has been able to compete favorably in markets that include these competitors, primarily on the basis of know-how, technical performance, quality, delivery, and price and aftermarket support.

 

CVD/First Nano competes primarilywith companies located in Asia, Europe and the US in the research market. These companies have limited support and safety and system design capabilities. For the academia market, we also compete with laboratory built systems. Our equipment for production applications competes with in-house design and engineering personnel at researchcapability and university laboratories with the capacity to design and build their own equipment internally. Additionally, there are large, established companies who compete with us and pose a competitive risk in the market. Due to budgetary and funding constraints, many of these customers are extremely price sensitive. We believe that our systems are among the most advanced available for the targeted market space.market. and coupled with our vertical integration in engineering and manufacturing, we can be very competitive.

 

SDC’s gas management and chemical delivery control systems are among the most advanced available. We further believe that SDC is differentiated from our competitors through our intimate understanding of how the systems in which our products are incorporated are actually used in field applications. We have gained this understanding as a result of having designed and built complex process gas systems for CVD/First Nano as well as for a number of the world’s leading semiconductor, aerospace, medical, solar manufacturers, research laboratories and universities.

 

Sources of Supply

 

Many of the components used in producing our products are purchased from unrelated suppliers. We have OEM status with our suppliers but we are not obligated to purchase a pre-determined quantity. We are not dependent on a principal or major supplier and alternate suppliers are available. Subject to lead times, the components and raw materials we use in manufacturing our products are readily obtainable.

 

We havemaintain a fully-equipped machine shop that we use to fabricate mosta significant portion of our metal components in-house, including the most complex designed parts of our equipment. OurThe investment in CNC machines for our machine shop has increasedsignificantly helped in increasing our efficiencies while significantly reducing labor costs and time in production. Similarly, our quartz fabrication capability is sufficient to meet our quartz-ware needs.

 

Materials procured from the outside and/or manufactured internally undergo a rigorous quality control process to ensure that the parts meet or exceed our requirements and those of our customers. Upon final assembly, all equipment undergoes a final series of complete testing to ensure maximum product performance.

 


 

Backlog

 

As of December 31, 2016,2018, our order backlog was approximately $27.8 million compared to approximately $6.1 million at December 31, 2015, an increase of $21.7 million, or 355.7%. We received approximately $42.6 million in orders for the twelve months ended December 31, 2016 compared to $24.0 million in orders for the twelve months ended December 31, 2015, an increase of $18.6 million or 77.5%. The CVD/First Nano division received orders totaling $39.9$3 million and, the SDC divisionsince that time, we have received $2.7additional orders in excess of $6 million. The December 31, 2016 backlog consists of $23.3 million or 84% from one customer as a result of multiple orders that are still in process. The increase inAlthough our overall backlog is relatedlower than our historical high, we continue to an increase in orders,work at diversifying our customer base away from any one customer as we focus on new opportunities with new and existing customers.customers within our existing marketplaces and in new applications, including the start-up of the CVD Materials operations expected in the second or third quarter of 2019. The timing for completion of the backlog varies depending on the product mix and can be as long as two years. Included in the backlog are all accepted purchase orders with the exception of those that are included in our percentage-of-completion. Order backlog is usually a reasonable management tool to indicate expected revenues, and projected profits, however, it does notprovidenotprovide an assurance of future achievement or profits as order cancellations or delays are possible.

 

Intellectual Property

 

Our success is dependent, in part onupon our proprietary technology and other proprietary rights. We have historically protected our proprietary information and intellectual property such as design specifications, blueprints, technical processes and employee know-how through the use of non-disclosure agreements.  In addition, where we deem appropriate, we have, and will continue to file for patent and trademark protection of our proprietary technology and intellectual property that we believe has the potential to be incorporated into our products and can be sold to multiple customers.  We also maintain and/or assert rights in certain trademarks relating to certain of our products and product lines, and claim copyright protection for certain proprietary software and documentation.

In the fourth quarter of 2018, we announced the development of a family of advanced Fluid Reactors based on our innovations in nanotechnology and chemical vapor deposition technology. The Fluid Reactor is enabled by a novel reactor core element which allows the efficient transfer of gases into and out of liquids. The market adoption of this technology could supplant existing hollow fiber membrane technology for applications including filtration and liquid gasification or degasification. One such application is blood oxygenation cartridges, known as Extra Corporeal Membrane Oxygenators, which are typically used during cardio pulmonary bypass (CPB) surgery and are essential for life support. CVD has a patent pending embodying this technology.

In addition to the above, we continue to develop new Tantalum processes under our Tantaline line to improve the corrosion resistance of additional base material such as Nickel-based alloys. In 2018, we announced that two patents applications were filed.

 

While patent, copyright and trademark protections for our intellectual property are important to different degrees for our various products and solutions, we believe our future success in highly dynamic markets is most dependent upon the technical competence and creative skills of our personnel and our ability to accelerate the commercialization of next generation intellectual properties. We attempt to protect our trade secrets and other proprietary information through non-disclosure agreements with our customers, suppliers, employees and consultants and other security measures.

 


Research and Development

 

The university research community is at the forefront of nanotechnology research, and we are focused on providing state-of-the-art systems to this market that will help bridge the gap between pioneering research and marketable products. Our Application Laboratory, together with a number of leading universities and startup companies with whom we partner from time to time, conducts cutting-edge research on the growth and infiltration of carbon nanotubes, graphene and nanowires as well as on selected solar cellaerospace manufacturing processes and smart glass coating processes. The results of this research could have far reaching implications concerning the use and manufacture of carbon nanotubes, graphene, nanowires and nanowires, solar cell and glassaerospace coatings for many markets. Our intention is that together with these leading edge universities and start-up companies and major aerospace/defense companies, we will leverage our collective expertise in this field, which will allow us to capitalize on commercial opportunities in the future. This relationship has thus far produced leading edge results, including what we believe are the tallest carbon nanotube arrays yet developed.

 

In 2016,2018, we incurred approximately $2.4 million$607,000 in research and development expenses of which $434,000 was independent of external customer ordersas compared to 2015, when we incurred $1.8 million of research and development expenses, $605,000 of which was independent of external customer orders.$437,000 in 2017.

 


Government Regulation

 

We are subject to a variety of federal, state and local government regulations, such as environmental, labor and export control. We believe that we have obtained all necessary permits to operate our business and that we are in material compliance with all laws and regulations applicable to us.

 

We are not aware of any government regulations or requirements necessary for the sale of our products, other than certain approvals or permits which may be required for us to export certain of our products to certain foreign countries.

Insurance

 

Our products are used in our customers’ manufacturing processes which in some cases contain explosive, flammable, corrosive and toxic gases. There are potential exposures to personal injury as well as property damage, particularly if operated without regard to the design limits of the systems and components. Additionally, the end products of some of our customers are used in areas such as aerospace and high techhigh-tech devices where safety is of great concern. Management reviews its insurance coverage on an annual basis or more frequently if appropriate and we believe we have the types and amounts of insurance coverage that are sufficient for our business.

 

Employees

 

At December 31, 2016,2018, we had 173 employees, with all but one being full time personnel.197 employees. We had 95 people96 employees in manufacturing, 3244 in engineering (including research and development and efforts related to product improvement) 79 in field service, 1016 in sales and marketing and 2932 in general management, maintenance and administration.administration, compared to 231 employees as of December 31, 2017.


 

Item 1A.     Risk Factors

 

In addition to the other information set forth in this Annual Report on Form 10-K, our shareholders should carefully consider the risk factors described below. The risks set forth below may not be the only risk factors relating to the company.Company. Any of these factors, many of which are beyond our control, could materially adversely affect our business, financial condition, operating results, cash flow and stock price.

 

We have significant investments in our CVD Materials segment, which could be met with further delays and ongoing losses that could materially and adversely impact our financial results and cash flow.

To support the expected growth of our CVD Materials segment and to house the US based business, on November 30, 2017, we purchased the premises located at 555 North Research Place, Central Islip, NY (the “Premises”). The purchase price of the building was $13,850,000, exclusive of closing costs. We have monthly principle and interest payments of $62,481 and we have invested $2.5 million during 2018, principally for capital improvements and equipment for this business. We anticipate investing approximately $1.5 to $2 million for additional building improvements and machinery.

Expenses for this building totaled $750,000 in 2018 related to interest expense of $405,000 and real estate taxes and other operating costs $345,000. If we are unable to reach profitable operations and not recover our investment, it could have a material adverse effect on our financial condition.

We have a highly concentrated customer base so that changes in ordering patterns, delays or order cancellations could have a material adverse effect on our business and results of operations.

In fiscal 2018 and 2017, approximately 38.2% and 66.1% of our net sales, respectively, was accounted for by one customer. We expect that contracts or orders from a relatively limited number of customers will continue to account for a substantial portion of our business. The mix and type of customers, and sales to any single customer, may vary significantly from quarter to quarter and from year to year. If any of our significant customers do not place orders, or they substantially reduce, delay or cancel orders, we may not be able to replace the business in a timely manner or at all, which can and has had a material adverse effect on our results of operations and financial condition. Major customers may also seek, and on occasion receive, pricing, payment, intellectual property-related, or other commercial terms that are less favorable to us and can hurt our competitive position.

Our lengthy and variable sales cycle makes it difficult to predict our financial results.

The marketing, sale and manufacture of our products, often requires a lengthy sales cycle ranging from several months to over one year before we can complete production and delivery. The lengthy sales cycle makes forecasting the volume and timing of sales difficult, and raises additional risks that customers may cancel or decide not to enter into contracts. The length of the sales cycle depends on the size and complexity of the project, the customer’s in-depth evaluation of our products, and, in some cases, the protracted nature of a bidding process.


Because a significant portion of our operating expenses are fixed, we may incur substantial expense before we earn associated revenue. If customer cancellations occur, they could result in the loss of anticipated sales without allowing us sufficient time to reduce our operating expenses.

Our success is highly dependent on the technical, sales, marketing and managerial contributions of key individuals, including Leonard A. Rosenbaum, Chairman of the Board of Directors, Chief Executive Officer and President, and we may be unable to retain these individuals or recruit others.

We depend on our senior executives, including Leonard A. Rosenbaum, our Chairman of the Board of Directors, Chief Executive Officer and President, and certain key managers as well as, engineering, research and development, sales, marketing and manufacturing personnel, who are critical to our business. We do not have long-term employment agreements with our key employees. We presently have a key person life insurance policy on the life of Leonard A. Rosenbaum, for a total insured amount of $5 million, which may not be sufficient to cover our loss of Mr. Rosenbaum’s services. Furthermore, larger competitors may be able to offer more generous compensation packages to our executives and key employees, and therefore we risk losing key personnel to those competitors. If we were to lose the services of any of our key personnel, our engineering, product development, manufacturing and sales efforts could be slowed. We may also incur increased operating expenses, and be required to divert the attention of our senior executives to search for their replacements. The integration of any new personnel could disrupt our ongoing operations.

Acquisitions can result in an increase in our operating costs, divert management’s attention away from other operational matters and expose us to other associated risks.

We continually evaluate potential acquisitions of businesses and technologies, and we consider targeted acquisitions that expand our core competencies to be an important part of our future growth strategy.  In the past, we have made acquisitions of other businesses with synergistic products, services and technologies, and plan to continue to do so in the future. 

Acquisitions involve numerous risks, which include but are not limited to:

difficulties and increased costs in connection with the integration of the personnel, operations, technologies, services and products of the acquired companies into our existing facilities and operations;

diversion of management’s attention from other operational matters;

failure to commercialize the acquired technology;

the potential loss of key employees of the acquired companies;

lack of synergy, or inability to realize expected synergies, resulting from the acquisitions;

the risk that the issuance of our common stock, if any, in an acquisition or merger could be dilutive to our shareholders;

the inability to obtain and protect intellectual property rights in key technologies and

the acquired assets becoming impaired as a result of technological advancements or worse-than-expected performance of the acquired assets.


If demand declines for chemical vapor deposition, gas control and related equipment, or for carbon nanotube and nanowire deposition systems, our financial position and results of operations could be materially adversely affected.


Our products are utilized to develop and manufacture materials and coatings for industrial and research applications that are used in numerous markets including but not limited to aerospace, medical, solar, nano and advanced electronic components. A significant part of our growth strategy involves continued expansion of the sales of our products for industrial as well as research and development purposes by companies, universities and government-funded research laboratories. The availability of funds for these purposes may be subject to budgetary and political restrictions, as well as cost-cutting measures by manufacturers in the markets in which we operate.

 

If the availability of funds or the demand for capital equipment in the markets in which we operate declines, the demand for our products would also decline and our financial position and results of operations could be harmed.

 

We face risks associated with selling our products to a highly concentrated customer base.

In fiscal 2016, approximately 53.5% of our net sales was accounted for by 2 customers. We expect that contracts or orders from a relatively limited number of customers will continue to account for a substantial portion of our business. The mix and type of customers, and sales to any single customer, may vary significantly from quarter to quarter and from year to year. If any of our significant customers do not place orders, or they substantially reduce, delay or cancel orders, we may not be able to replace the business in a timely manner or at all, which could have a material adverse effect on our results of operations and financial condition. Major customers may also seek, and on occasion receive, pricing, payment, intellectual property-related, or other commercial terms that are less favorable to us.

The conditions of the markets in which we operate are volatile. The demand for our products and the profitability of our products can change significantly from period to periodas a result of numerousfactors.

 

The industries in which we operate are characterized by ongoing changes, including:

 

 

the availability of funds for research and development;

 

global and regional economic conditions;

 

governmental budgetary and political constraints;

 

changes in the capacity utilization and production volume for research and industrial applications in the markets in which we operate;

 

the profitability and capital resources of manufacturers in the markets in which we operate; and

 

changes in technology.

 

For these and other reasons, our results of operations for past periods may not necessarily be indicative of future operating results.

 

Volatile and cyclical demand for our products may make it difficult for us to accurately budget our expense levels, which are based in part on our projections of future revenues.

 

Demand for our equipment and related consumable products may be volatile as a result of sudden changes in supply and demand, and other factors in the manufacturing process. Our orders tend to be more volatile than our revenue, as any change in demand is reflected immediately in orders booked, which are net of cancellations, while revenue, tends to be recognized over multiple quarters as a result of procurement and production lead times, and the deferral of certain revenue under our revenue recognition policies. The fiscal period in which we are able to recognize revenue is also at times subject to the length of time that our customers require to evaluate the performance of our equipment. This could cause our quarterly operating results to fluctuate.

 


 

When cyclical fluctuations result in lower than expected revenue levels, operating results may be materially adversely affected and cost reduction measures may be necessary in for us to remain competitive and financially sound. During a down cycle, we must be able to make timely adjustments to our cost and expense structure to correspond to the prevailing market conditions. In addition, during periods of rapid growth, we must be able to increase manufacturing capacity and the number of our personnel to meet customer demand, which may require additional liquidity. We can provide no assurance, that these objectives can be met in a timely manner in response to changes within the industry cycles in which we operate. If we fail to respond to these cyclical change,changes, our business could be seriously harmed.

 

We do not have long-term volume production contracts with our customers, and we do not control the timing or volume of orders placed by our customers. Whether and to what extent our customers place orders for any specific products, and the mix and quantities of products included in those orders are factors beyond our control. Insufficient orders would result in under-utilization of our manufacturing facilities and infrastructure, and will negatively affect our financial position and results of operations.

 

We face significant competition and we are relatively small in size and have fewer resources in comparison with many of our competitors.

 

We face significant competition throughout the world, which may increase as certain markets in which we operate continue to evolve. Some of our competitors have greater financial, engineering, manufacturing and marketing resources than us to develop new products and to support customers worldwide. Our future performance depends, in part, upon our ability to continue to compete successfully worldwide. Some of our competitors are diversified companies that have substantially greater financial resources and more extensive research, engineering, manufacturing, marketing and customer service and support capabilities than we can provide. We face competition from companies whose strategy is to provide a broad array of products, some of which compete with the products and services that we offer, as well as companies, universities and research laboratories that have the capacity to design and build their own equipment internally. These competitors may bundle their products and services in a manner that may discourage customers from purchasing our products. In addition, we face competition from smaller emerging processing equipment companies, whose strategy is to provide a portion of the products and services that we offer at often lower prices than ours, using innovative technology to sell products into specialized markets. Loss of competitive position could impair our prices, customer orders, revenue, gross margin and market share, any of which would negatively affect our financial position and results of operations. Our failure to compete successfully with these other companies would seriously harm our business. There is a risk that larger, better financed competitors will develop and market more advanced products than those we currently offer, or that competitors with greater financial resources may decrease prices, thereby putting us under financial pressure.

 


The health and environmental effects of nanotechnology are unknown, and this uncertainty could adversely affect the expansion of our business.

 

The health and environmental effects of nanotechnology are unknown. There is no scientific agreement on the health effects of nanomaterials in general and carbon nanotubes, in particular, but some scientists believe that in some cases, nanomaterials may be hazardous to an individual’s health or to the environment.


The science of nanotechnology is based on arranging atoms in such a way as to modify or build materials not made in nature; therefore, the effects are unknown. Future research into the effects of nanomaterials in general, and carbon nanotubes in particular, on health and environmental issues, may have an adverse effect on products incorporating nanotechnology. Since part of our growth strategy is based on sales of research equipment for the production of carbon nanotubes and the sale of such materials, the determination that these materials are harmful could adversely affect the expansion of our business.

 

We may experience increasing price pressure.

 

Our historical business strategy for many of our products has focused on product performance and customer service rather than on price. As a result of budgetary constraints, many of our customers are extremely price sensitive when purchasing of capital equipment. If we are unable to obtain prices that allow us to continue to compete on the basis of product performance and customer service, our profit margins will be reduced.

 

We may not be able to keep pace with the rapid change in the technology we use in our products.

 

We believe that our continued success in the markets in which we operate depends, in part, on our ability to continually improve existing technologies and to develop and manufacture new products and product enhancements on a timely and cost-effective basis. We must be able to introduce these products and product enhancements into the market in a timely manner, in response to customer’s demands for higher-performance research and assembly equipment, customized to address rapid technological advances in capital equipment designs.

 

Technological innovations are inherently complex, and require long development cycles and appropriate professional staffing. Our future business success depends on our ability to develop and introduce new products, or new uses for existing products, that successfully address changing customer needs. Our success also depends on our ability to achieve market acceptance of our new products. In order to maintain our success in the marketplace, we may have to substantially increase our expenditures on research and development. If we do not develop and introduce new products, technologies or uses for existing products in a timely manner and continually find ways to reduce the cost of developing and producing them in response to changing market conditions or customer requirements, our business could be seriously harmed.

 

Manufacturing interruptions or delays could affect our ability to meet customer demand and lead to higher costs, while the failure to estimate customer demand accurately could result in excess or obsolete inventory.


 

Our business depends on timely supply of equipment, services and related products that meet the rapidly changing technical and volume requirements of our customers. Some key parts to our products are subject to long lead-times and/or obtainable only from a single supplier or limited group of suppliers. Cyclical industry conditions and the volatility of demand for manufacturing equipment increase capital, technical, operational and other risks for us and for companies throughout our supply chain. Further, these conditions may cause some suppliers to scale back operations, exit businesses, merge with other companies, or file for bankruptcy protection and possibly cease operations.


We may also experience significant interruptions of our manufacturing operations, delays in our ability to deliver products or services, increased costs or customer order cancellations as a result of:

 

 

The failure or inability of suppliers to timely deliver sufficient quantities of quality parts on a cost-effective basis;

 

Volatility in the availability and cost of materials, including rare earth elements;

 

Difficulties or delays in obtaining required import or export approvals;

 

Information technology or infrastructure failures; and

 

Natural disasters or other events beyond our control (such as earthquakes, floods or storms, regional economic downturns, pandemics, social unrest, political instability, terrorism, or acts of war).

 

If a supplier fails to meet our requirements concerning quality, cost, socially-responsible business practices, or other performance factors, we may transfer our business to alternative sources, which could entail manufacturing delays, additional costs, or other difficulties. In addition, if we need to rapidly increase our business and manufacturing capacity to meet increases in demand or expedited shipment schedules, this may exacerbate any interruptions in our manufacturing operations and supply chain and the associated effect on our working capital.

 

If any of our customers cancel or fail to accept a large system order, our financial position and results of operations could be materially and adversely affected.

 

Our backlog, largely consists of orders for customized systems including our chemical vapor deposition equipment and annealing and diffusion furnaces which are built to client specifications. We also have a significant concentration of revenue in a single customer. In 2018, our largest customer accounted for 38.2% of our revenue as compared to 66.1% in 2017. These customized systems can have prices that range from $100,000 to several million dollars, depending on the configuration, specific options included and any special requirements of the customer.  Because our orders are subject to cancellation or delay by the customer, our backlog at any particular point in time is not necessarily representative of actual sales for succeeding periods, nor does our backlog provide any assurance of achievement of revenues or that we will realize a profit from completing these orders.  Since revenues on long-term contracts are recognized by the percentage-of-completion method, if a contract is canceled, we may have to reverse revenue at such time.  Our financial position and results of operations could be materially and adversely affected should any large system order be cancelled prior to shipment, or not be accepted by the customer due to alleged non-conformity with product specifications or otherwise. Likewise, a significant change in the liquidity or financial position of any of our customers that purchase large systems, could have a material impact on the collectability of our accounts receivable and our future operating results.  Our backlog does not provide any assurance that we will realize a profit from those orders, or indicate in which period revenue will be recognized.

 


 

Our success is highly dependent on the technical, sales, marketing and managerial contributions of key individuals, including Leonard A. Rosenbaum, Chairman of the Board of Directors, Chief Executive Officer and President, and we may be unable to retain these individuals or recruit others.

We depend on our senior executives, including Leonard A. Rosenbaum, our Chairman of the Board of Directors, Chief Executive Officer and President, and certain key managers as well as, engineering, research and development, sales, marketing and manufacturing personnel, who are critical to our business. We do not have long-term employment agreements with our key employees. We presently have a key person life insurance policies on the life of Leonard A. Rosenbaum, for a total insured amount of $5 million, which may not be sufficient to cover our loss of Mr. Rosenbaum’s services. Furthermore, larger competitors may be able to offer more generous compensation packages to our executives and key employees, and therefore we risk losing key personnel to those competitors. If we were to lose the services of any of our key personnel, our engineering, product development, manufacturing and sales efforts could be slowed. We may also incur increased operating expenses, and be required to divert the attention of our senior executives to search for their replacements. The integration of any new personnel could disrupt our ongoing operations.

We may not be able to hire or retain the number of qualified personnel, particularly engineering personnel, required for our business, which would harm the development and sales of our products and limit our ability to grow.

 

Competition in our industry for senior management, technical, sales, marketing and other key personnel is intense. If we are unable to retain our existing personnel, or attract and train additional qualified personnel, our growth may be limited due to a lack of capacity to develop and market our products.

 

In particular, we have, from time to time, experienced difficulty in hiring and retaining skilled engineers with appropriate qualifications to support our growth strategy. Our success depends on our ability to identify, hire, train and retain qualified engineering personnel with experience in equipment design. Specifically, we need to continue to attract and retain mechanical, electrical, software and field service engineers to work with our direct sales force to technically qualify and perform on new sales opportunities and orders, and to demonstrate our products.

 

The substantial lead-time required for ordering parts and materials may lead to inventory problems.

The lead-time for ordering parts and materials for some of our products can be several months. As a result, we must order some components based on forecasted demand. If demand for our products lags significantly behind our forecasts, we may order more components than we require, which would result in cash flow problems as well as excess or obsolete inventory.


Acquisitions can result in an increase in our operating costs, divert management’s attention away from other operational matters and expose us to other associated risks.

In December 2016, we purchased certain assets formally owned by Tantaline A/S, which we incorporated into a facility in Denmark which is operated by our subsidiary, Tnataline CVD ApS. We continually evaluate potential acquisitions of businesses and technologies, and we consider targeted acquisitions that expand our core competencies to be an important part of our future growth strategy.  In the past, we have made acquisitions of other businesses with synergistic products, services and technologies, and plan to continue to do so in the future.  Acquisitions involve numerous risks, which include but are not limited to:

difficulties and increased costs in connection with the integration of the personnel, operations, technologies, services and products of the acquired companies into our existing facilities and operations;

diversion of management’s attention from other operational matters;

failure to commercialize the acquired technology;

the potential loss of key employees of the acquired companies

lack of synergy, or inability to realize expected synergies, resulting from the acquisitions;

the risk that the issuance of our common stock, if any, in an acquisition or merger could be dilutive to our shareholders;

the inability to obtain and protect intellectual property rights in key technologies;

the acquired assets becoming impaired as a result of technological advancements or worse-than-expected performance of the acquired assets.

Our financial position and results of operations may be materially harmed if we are unable to recoup our investment in research and development.

 

The rapid change in technology in our industry requires that we continue to make substantial investments in research and development and selective acquisitions of technologies and products, in order to enhance the performance and functionality of our product line, to keep pace with competitive products and to satisfy customer demands for improved performance, features and functionality.  These efforts include those related to the development of technology for the commercialization of carbon nanotubes. There can be no assurance that revenue from future products or enhancements will be sufficient to recover the development costs associated with such products, enhancements or acquisitions, or that we will be able to secure the financial resources necessary to fund future research and development or acquisitions.  Research and development costs are typically incurred before we confirm the technical feasibility and commercial viability of a product, and not all development activities result in commercially viable products.  In addition, we cannot ensure that products or enhancements will receive market acceptance, or that we will be able to sell these products at prices that are favorable to us.  Our business could be seriously harmed if we are unable to sell our products at favorable prices, or if our products are not accepted by the markets in which we operate.

 


We have made investments in our proprietary technologies.If third parties violate our proprietary rights, or accuse us of infringing upon their proprietary rights, such events could result in a loss of value of some of our intellectual property or costly litigation.

 

Our success is dependent in part on our technologies and our other proprietary rights.  We believe that while patents can be useful and may be utilized by us in the future, they are not always necessary or feasible to protect our intellectual property. The process of seeking patent protection is lengthy and expensive, and we cannot be certain that applications will actually result in issued patents or that issued patents will be of sufficient scope or strength to provide meaningful protection or commercial advantage to us.  In addition to patent protection, we have also historically protected our proprietary information and intellectual property such as design specifications, blueprints, technical processes and employee know-how, by limiting access to this confidential information and trade secrets and through the use of non-disclosure agreements. Other companies and individuals, including our larger competitors, may develop technologies that are similar or superior to our technology, or design around the intellectual property that we own or license.  Our failure to adequately protect our intellectual property, could result in the reduction or extinguishment of our rights to such intellectual property. We also assert rights to certain trademarks relating to certain of our products and product lines. We have not filed trademark applications to protect such marks with any governmental agency, including, but not limited to the U.S. Patent and Trademark Office. We claim copyright protection for certain proprietary software and documentation, but we have not filed any copyright applications with the U.S. Copyright Office in connection with those works.  As a result, we can give no assurance that our trademarks and copyrights will be upheld or successfully deter infringement by third parties. 

 


While patent, copyright and trademark protection for our intellectual property may be important, we believe our future success in highly dynamic markets is most dependent upon the technical competence and creative skills of our personnel.  We attempt to protect our trade secrets and other proprietary information through confidentiality agreements with our customers, suppliers, employees and consultants, and through other internal security measures.  However, these employees, consultants and third parties may breach these agreements, and we may not have adequate remedies for wrongdoing.  In addition, the laws of certain territories in which we sell our products may not protect our intellectual property rights to the same extent as do the laws of the United States.

 

Occasionally, we may receive communications from other parties asserting the existence of patent rights or other intellectual property rights that they believe cover certain of our products, processes, technologies or information.  If such cases arise, we will evaluate our position and consider the available alternatives, which may include seeking licenses to use the technology in question on commercially reasonable terms, or defending our position.  Nevertheless, we cannot ensure that we will be able to obtain licenses, or, if we are able to obtain licenses, that related terms will be acceptable, or that litigation or other administrative proceedings will not occur.  Defending our intellectual property rights through litigation could be very costly.  If we are not able to negotiate the necessary licenses on commercially reasonable terms or successfully defend our position, our financial position and results of operations could be materially and adversely affected.


Our reputation and operating performance may be negatively affected if our products are not

timely delivered.

 

We provide complex products that often require substantial lead-time for design, ordering parts and materials, and for assembly and installation. The time required to design, order parts and materials and to manufacture, assemble and install our products, may in turn lead to delays or shortages in the availability of some products. If a product is delayed or is the subject of shortage because of problems with our ability to design, manufacture or assemble the product on a timely basis, or if a product or software otherwise fails to meet performance criteria, we may lose revenue opportunities entirely, or experience delays in revenue recognition associated with a product or service. In addition, we may incur higher operating expenses during the period required to correct the problem.

Our lengthy and variable sales cycle may make it difficult to predict our financial results.

 

The marketing, sale and manufacture of our products, often requires a lengthy sales cycle ranging from several months to over one year before we can complete production and delivery. The lengthy sales cycle makes forecasting the volume and timing of sales difficult, and raises additional risks that customers may cancel or decide not to enter into contracts. The length of the sales cycle depends on the size and complexity of the project, the customer’s in-depth evaluation of our products, and, in some cases, the protracted nature of a bidding process. Because a significant portion of our operating expenses are fixed, we may incur substantial expense before we earn associated revenue. If customer cancellations occur, they could result in the loss of anticipated sales without allowing us sufficient time to reduce our operating expenses.


 

We anticipate continued growth in our revenues and operations during the next few years. If we failneed to manage our growth effectively or we may experience difficulty in filling customer orders, declining product quality, increased costs or other operating challenges.

 

We anticipate that continued growth of our operations will be required to satisfy our projected increase in demand for our products and to avail ourselves of new market opportunities. The expanding scope of our business and the growth in the number of our employees, customers and products have placed and will continue to place a significant strain on our management, information technology systems, manufacturing facilities and other resources. To properly manage our growth, we may need to hire additional employees, upgrade our existing financial and reporting systems and improve our business processes and controls. We may also be required to expand our manufacturing facilities or add new manufacturing facilities. Failure to effectively manage our growth could make it difficult to manufacture our products and fill orders, as well as lead to declines in product quality or increased costs; any of these would adversely impact our business and results of operations.

 

Historically, we have only manufactured in unit or small batch quantities. If we receive orders for a large number of our systems, we may not have the internal manufacturing capacity to fill these orders on a timely basis, if at all, and may be forced to subcontract or outsource some of the fabrication of these systems to third parties. We cannot assure you that we will be able to successfully subcontract or outsource the fabrication of our systems at a reasonable cost to us, or that such third parties will adhere to our quality control standards.

 


Our business might be adversely affected by our dependence on foreign business.

 

During the year ended December 31, 2016, 11.9%2018, approximately $2.4 million or 9.9% of our revenues came from foreign exports aswere generated by sales to customers outside the U.S. compared with 9.0%to approximately $3.9 million or 9.6% for the year ended December 31, 2015.2017.

 

Because a significant amountportion of our revenues are derived from international customers, our operating results could be negatively affected by a decline in the economies of any of the countries or regions in which we do business.  Each region in the global semiconductor and electronics equipment market exhibitscan exhibit unique characteristics, which can cause capital equipment investment patterns to vary significantly from period to period.  Periodic local or international economic downturns, trade balance issues and political instability, as well as fluctuations in interest and currency exchange rates, could negatively affect our business and results of operations.

 

All of our sales to date have been primarily priced in U.S. dollars. While our business has not been materially affected in the past by currency fluctuations, there is a risk that it may be materially adversely affected in the future.  Such risks include possible losses due to both currency exchange rate fluctuations and from possible social and political instability. 

 


Failure to comply with the United States Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.

 

We are subject to the United States Foreign Corrupt Practices Act, which generally prohibits United States companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. We have agreements with third parties and make sales in countries known to experience corruption, extortion, bribery, pay-offs, theft and other fraudulent practices. We can make no assurance, however, that our employees or other agents will not engage in such conduct for which we might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations.

If our critical suppliers fail to deliver sufficient quantities of quality materials and components in a timely and cost-effective manner, it could negatively affect our business.

 

We do not manufacture many components used in the production of our products, and consequently, we use numerous unrelated suppliers of materials and components.  We generally do not have guaranteed supply arrangements with our suppliers.  Because of the variability and uniqueness of our customer’s orders, we try to avoid maintaining an extensive inventory of materials and components for manufacturing. While we are not dependent on any principal or major supplier for most of our material and component needs, switching over to an alternative supplier may take significant amounts of time and added expense, which could result in a disruption of our operations and adversely affect our business.


 

It is not always practical or even possible to ensure that component parts are available from multiple suppliers; accordingly, we procure some key parts from a single supplier or a limited group of suppliers.  At certain times, increases in demand for capital equipment can result in longer lead-times for many important system components, which may cause delays in meeting shipments to our customers.  The delay in the shipment of even a few systems could cause significant variations in our quarterly revenue, operating results and the market value of our common stock. 

 

We cannot assure you that our financial position and results of operations will not be materially and adversely affected if, in the future, we do not receive in a timely and cost-effective manner a sufficient quantity of quality component parts and materials to meet our production requirements.

 

We might require additional financing to expand our operations.

 

We mayAlthough we recently purchased an additional facility, we could require additional financing to support our investment in our CVD Materials segment and to further implement our overall growth plans.  We cannot assure youIf any additional financing will beis not available if and when required on commercially reasonable terms, if at all, or, even if available thatand we issue additional common stock, it would notmay materially dilute the ownership percentageinterests of the then existing shareholders.

 

Cost of compliance with Section 404 of the Sarbanes-Oxley Act could adversely affect future operating results, the trading price of our common stock and failure to comply could result in loss of our stock market listing, civil penalties and other liabilities.

Section 404 of the Sarbanes-Oxley Act requires management to certify that it has tested and found the company’s internal controls to be effective.  It also requires, for accelerated filers, that a company’s independent auditors attest that such management representations are reasonably founded.  The adequacy of internal controls generally takes into consideration that the anticipated benefits of a control should outweigh the cost of that control.  Auditing standards related to the internal control requirements of Section 404 of the Sarbanes Oxley Act will significantly increase the cost and time needed to comply with the requirements of Section 404.  Complying with these requirements is very complex, costly and time consuming and, if we are required to comply under the existing regulations, will have a material impact on our operating results.  Failure to comply could result in civil penalties, loss of our listing on NASDAQ, and the imposition of possible litigation. 

Changes in accounting pronouncements or taxation rules or practices may adversely affect our financial results.

Changes in accounting pronouncements or taxation rules or practices can have a significant effect on our reported results. New accounting pronouncements or taxation rules and varying interpretations of accounting pronouncements or taxation practices have occurred and may occur in the future. New rules, changes to existing rules, or the questioning of our current or past practices may adversely affect our reported financial results.


We may be required to take additional impairment charges on assets.

 

We are required to assess goodwill and indefinite-lived intangible assets annually for impairment, or on an interim basis, whenever certain events occur or circumstances change, such as an adverse change in business climate or a decline in the overall industry, that would more likely than not reduce the fair value below its carrying amount. We are also required to test our long-lived assets, including acquired intangible assets and property, plant and equipment, for recoverability and impairment whenever there are indicators or impairment, such as an adverse change in business climate.

 

As part of our long-term strategy, we have pursued acquisitions of other companies or assets, such as our recent acquisitions of assets owned by Tantaline ApS and MesoScribe Technologies, Inc. and may pursue future acquisitions of other companies or assets which could potentially increase our assets. Adverse changes in business conditions could materially impact our estimates of future operations and result in impairment charges to these assets. If our assets were impaired, our financial condition and results of operations could be materially and adversely affected.

 


The price of our common shares is volatile and could decline significantly.

 

The stock market in general and the market for technology stocks in particular has experienced volatility. If those industry-based market fluctuations continue, the trading price of our common shares could decline significantly independent of the overall market, and shareholders could lose all or a substantial part of their investment. The market price of our common shares could fluctuate significantly in response to several factors, including, among others:

 

 

difficult macroeconomic conditions, unfavorable geopolitical events, and general stock market uncertainties, such as those occasioned by a global liquidity crisescrisis and a failure of large financial institutions;

 

receipt of large orders or cancellations of orders for our products;

 

issues associated with the performance and reliability of our products;

 

actual or anticipated variations in our results of operations;

 

announcements of financial developments or technological innovations;

 

changes in recommendations and/or financial estimates by investment research analysis;

 

strategic transactions, such as acquisitions, divestitures, or spin-offs; and

 

the occurrence of major catastrophic events

trading volume is low

Significant price and value fluctuations have occurred with respect to our publicly traded securities and technology companies generally. The price of our common shares is likely to be volatile in the future. In the past, securities class action litigation often has been brought against a company following periods of volatility in the market price of its securities. If similar litigation were pursued against us, it could result in substantial costs and a diversion of management’s attention and resources, which could materially and adversely affect our financial condition, results of operations, and liquidity.

 

We face the risk of product liability claims.

 

The manufacture and sale of our products, which in operation maysometimes involve the use of toxic materials and extreme temperatures, involve the risk ofand could result in product liability claims.  For example, our rapid thermal processing systems are used to heat semiconductor materials to temperatures in excess of 1000º Celsius. In addition, aCelsius have certain inherent risks.  A failure of one of our productsproduct(s) at a customer site could interruptalso result in losses due to interruption of the business operations of our customer. OurWhile we regularly evaluate the nature and limits of our insurance coverages, there can be no assurance that our existing policies of insurance coverage limits may notwill be adequate to protect us from all liabilities that we might incur in connection with the manufacture and sale of our products ifin the event of a successful product liability claim or series of product liabilitysuccessful claims were brought against us.

 


We are subject to environmental regulations, and our inability or failure to comply with these regulations could adversely affect our business.

 

We are subject to environmental regulations in connection with our business operations, including regulations related to the development and manufacture of our products and our customers’ use of our products. Our failure or inability to comply with existing or future environmental regulations could result in significant remediation liabilities, the imposition of fines or the suspension or termination of development, manufacturing or use of certain of our products, or affect the operation of our facilities, use or value of our real property, each of which could damage our financial position and results of operations.

 

If we are subject to cyber-attacks we could incur substantial costs and, if such attacks are successful, we could incur significant liabilities, reputational harm, and disruption to our operations.

 

We manage, store and transmit proprietary information and sensitive data relating to our operations. We may be subject to breaches of the information technology systems we use for these purposes. Experienced computer programmers and hackers may be able to penetrate our network security and misappropriate and/or compromise our confidential information (and or third partythird-party confidential information), create system disruptions, or cause shutdowns. Computer programmers and hackers also may be able to develop and deploy viruses, worms, and other malicious software programs that attack our systems or our products, or that otherwise exploit any security vulnerabilities.

 

The costs to address the foregoing security problems and security vulnerabilities before or after a cyber-incident could be significant. Our remediation efforts may not be successful and could result in interruptions, delays, or cessation of service, and loss of existing or potential customers, impeding our sales, manufacturing, distribution, or other critical functions. In addition, breaches of our security measures and the unapproved dissemination of proprietary information or sensitive data about us, our customer, or other third parties, could expose us, our customers, or other third parties to a risk of loss or misuse of this information, result in litigation and potential liability for us, damage our reputation, or otherwise harm our business.

 

Regulations related to conflict minerals will force us to incur additional expenses, may make our supply chains more complex, and may result in damage to our relationships with customers.


Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, the SEC adopted requirements for companies that manufacture products that contain certain minerals and metals known as conflict minerals.“conflict minerals”. These rules require public companies to perform diligence and to report annually to the SEC whether such minerals originate from the Democratic Republic of Congo and adjoining countries. The implementation of these requirements could adversely affect the sourcing, availability, and pricing of minerals we use in the manufacture of our products. In addition, we have incurred and will continue to incur additional costs to comply with the disclosure requirements, including costs related to determining the source of any of the relevant minerals used in our products. Given the complexity of our supply chain, we may not be able to ascertain the origins of these minerals used in our products through the due diligence procedures that we implement, which may harm our reputation. We may also face difficulties in satisfying customers who may require that our products be certified as conflict mineral free, which could harm our relationships with these customers and lead to a loss of revenue. These requirements could limit the pool of suppliers that can provide conflict-free minerals, and we may be unable to obtain conflict-free minerals at competitive prices, which could increase our costs and adversely affect our manufacturing operations and our profitability.


Failure to comply with the United States Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.

We are subject to the United States Foreign Corrupt Practices Act, which generally prohibits United States companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. We have agreements with third parties and make sales in countries known to experience corruption, extortion, bribery, pay-offs, theft and other fraudulent practices. We can make no assurance, however, that our employees or other agents will not engage in such conduct for which we might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations.

Item 1B.Unresolved Staff Comments

Unresolved Staff Comments

 

None.

Item 2.Description of Property.

Description of Property.

 

Owned LocationsLocations

 

Size (sf)

DivisionSegment

Mortgage/Loan

 

Principal use

Central Islip, NY

 

130,000

CVD/First NanoCVD Equipment

Yes

 

Corporate: R&D; Mfg.Manufacturing

Central Islip, NY

179,000

CVD Materials

Yes

Manufacturing and R&D

       

Saugerties, NY

 

22,000

SDC

YesNo

 

Admin; Mfg.Manufacturing

       

Leased Locations

Size (sf)

Segment

Lease term

Principal use

Nordborgvej, Denmark

7,793

CVD Materials

2 years

Process coatings, Admin

       

Leased LocationsHuntington Beach Ca.

 

Size (sf)22,142

SubsidiaryCVD Materials

Lease term5 months

 

Principal use

Nordborgvej,

Denmark

7,793

Tantaline AsP

5 Years

Process coatings; adminManufacturing

 

 

Item 3.Legal Proceedings.

Legal Proceedings.

 

None

 

Item 4.Mine Safety Disclosures.

Mine Safety Disclosures.

 

Not applicable.

 


 

PART II

 

Item 5.          Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Our common stock is listed on the NASDAQ Capital Market under the symbol “CVV.” The following table sets forth, for the periods indicated, the high and low closing prices of our common stock on the NASDAQ Capital Market.

 

 

High

  

Low

  

High

  

Low

 

Year Ended December 31, 2016:

        

Year Ended December 31, 2018:

        

1st Quarter

 $9.95  $7.79  $11.97  $8.75 

2nd Quarter

  8.74   6.27   9.95   6.39 

3rd Quarter

  9.27   8.33   7.78   5.25 

4th Quarter

  8.83   7.70   6.33   3.35 

 

 

High

  

Low

  

High

  

Low

 

Year Ended December 31, 2015:

        

Year Ended December 31, 2017:

        

1st Quarter

 $16.48  $13.05  $10.94  $8.27 

2nd Quarter

  13.62   10.52   12.68   9.88 

3rd Quarter

  12.94   9.80   11.90   9.80 

4th Quarter

  13.18   9.70   13.50   10.16 

 

As of March 22, 20172019, there were approximately 8393 holders of record and approximately 1,2261,200 beneficial owners of our common stock, and the closing sales price of our common stock as reported on the NASDAQ Capital Market was $10.17$4.03.

 

Dividend Policy

 

We have never paid dividends on our common stock and we do not anticipate paying dividends on common stock at the present time. We currently intend to retain earnings, if any, for use in our business. There can be no assurance that we will ever pay dividends on our common stock. Our dividend policy with respect to our common stock is within the discretion of the Board of Directors and its policy with respect to dividends in the future will depend on numerous factors, including earnings, financial requirements and general business conditions. We are also prohibited from paying dividends under the terms of our Revolving Line of Credit Agreement with HSBC Bank, USA, N.A.

 


 

Equity Compensation Plan Information Table

 

The following table provides information about shares of our common stock that may be issued upon the exercise of options under all of our existing compensation plans as of December 31, 2016.2018.

 

  

Number of

securities to be 

issued upon exercise 

of outstanding 

options, warrants 

and rights(1)

  

Weighted-average

exercise price of

outstanding options,

warrants and rights(2)

  

Number of 

securities remaining

available for future

issuance

 

Plan Category

            

Equity compensation plans approved by security holders

  284,730  $8.40   237,200 

Equity compensation

plans not approved by security holders

  --   N/A   -- 
             

Total

  284,730  $8.40   237,200 

(1)

Reflects aggregate options and restricted stock awards outstanding under our 1989 Key Employee Stock Option Plan, 2001 Stock Option Plan and 2007 Share Incentive Plan.

(2)

Calculation is exclusive of the value of any unvested restricted stock awards.

  

Number of

securities to be

issued upon exercise

of outstanding

options, warrants

and rights(1)

  

Weighted-average

exercise price of

outstanding options,

warrants and

rights(2)

  

Number of

securities remaining

available for future

issuance

 

Plan Category

            

Equity compensation plans approved by security holders

  407,930   $11.74   660,410 

Equity compensation plans not approved by security holders

  --   N/A   -- 
             

Total

  407,930   $11.74   660,410 

 

(1)     Reflects aggregate options and restricted stock awards outstanding under our 2001 Stock Option Plan, 2007 Share Incentive Plan and 2016 Equity Incentive Plan.

(2)     Calculation is exclusive of the value of any unvested restricted stock awards.

Recent Sales of Unregistered Securities

 

None.

 

Issuer Purchasesof Equity Securities

 

None.


 

Item 6.          Selected Financial Data.

 

Not applicable.

  

2018

  

2017

 
         

Revenue

 $24,334,331  $41,128,639 
         

Cost of revenue

  19,156,201   23,528,427 
         

Gross profit

  5,178,130   17,600,212 
         

Operating expenses

        

Research and development

  606,618   437,157 

Selling and shipping

  1,620,089   1,404,938 

General and administrative

  8,205,942   8,539,244 
         

Total operating expenses

  10,432,649   10,381,339 
         

Operating (loss) income

  (5,254,519)  7,218,873 
         

Other income (expense):

        

Interest income

  159,953   80,518 

Interest expense

  (463,017)  (106,280)

Other income (expense)

  -   2,244 

Total other expense, net

  (303,064)  (23,518)
         

(Loss) income before income tax

  (5,557,583)  7,195,355 
         

Income tax (benefit) expense

  (356,562)  1,933,944 
         

Net (loss) income

 $(5,201,021) $5,261,411 

  


 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Except for historical information contained herein, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include but are not limited to: competition in the Company’s existing and potential future product lines of business; the Company’s ability to obtain financing on acceptable terms if and when needed; uncertainty as to the Company’s future profitability, uncertainty as to the future profitability of acquired businesses or product lines, uncertainty as to any future expansion of the Company. Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. Past results are no guaranty future performance. You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used with this Report, the words “believes,” “anticipates,” ”expects,” “estimates,” “plans,” “intends,”“believes”, “anticipates”, ”expects”, “estimates”, “plans”, “intends”, “will” and similar expressions are intended to identify forward-looking statements.

 

Executive Level Summary

We design, develop and manufacture a broad range of chemical vapor deposition, gas control and other state-of-the-art equipment and process solutions used to develop and manufacture materials and coatings for research and industrial applications with the focus onenabling tomorrow’s technologiesTM. These coatings are used in numerous fields including but not limited to aerospace, medical, solar, nano and advanced electronic components. We offer a broad range of chemical vapor deposition, gas control and otherapplications. This equipment that is used by our customers to research, design, and manufacture these materials or coatings for turbine blades,aerospace engine components, medical implants, semiconductors, solar cells, smart glass, carbon nanotubes, nanowires, LEDs, MEMS and other applications. Through CVD Materials and our Application Laboratory, we develop new material systems, provide material coating services, process development support and process startup assistance andwith the focus on developing higher efficiency material manufacturing for a wide variety of growth markets. We look to accelerate the introduction of nano materials into a range of products and applications to help create a demand for our equipment or which we can market through our wholly owned subsidiary, CVD Materials Corporation. Our proprietary technology products are generally customized to meet the particular specifications of individual customers and to accelerate the commercialization of their proprietary intellectual property. We also offer standard products that are based on the expertise and know-how we have developed in designing and manufacturing our customized products.enabling tomorrow’s technologiesTM.

 

Based on more than 3436 years of experience, we use our capabilities in engineering, manufacturing and process development to transform new applications into leading-edge manufacturing solutions. This enables university, research and industrial scientists at the cutting edge of technology to develop next generation chemical vapor deposited products for use in solar,aerospace, medical, nano, materials, LEDs, semiconductors and other applications.electronic components. We also develop, manufacture and manufactureprovide equipment for research and production equipment based on our proprietary designs. We have built a significant library of design expertise, know-how and innovative solutions to assist our customers in developing these intricate processes and to accelerate their commercialization of chemically deposited materials.commercialization. This library of solutions, along with our vertically integrated manufacturing facilities, allows us to provide superior design, process and manufacturing solutions to our customers on a cost effectivecost-effective basis.

 


Our strategy is to target opportunities in the research, development and production equipment market, with a focus on higher-growth applications such as aerospace, medical, smart glass, carbon nanotubes, nanowires, graphene, MEMS and LEDs. To expand our penetration into these growth markets, we have developed a line of proprietary standard products and custom systems. Historically, we manufactured products for research and development on a custom one-at-a-time basis to meet an individual customer’s specific research requirements. Our proprietary systems leverage the technological expertise that we have developed through designing these custom systems onto a standardized basic core. This core is easily adapted through a broad array of available options to meet the diverse product and budgetary requirements of the research community. By manufacturing the basic core of these systems in higher volumes, we are able to reduce both the cost and delivery time for our systems. These systems, which we market and sell under the EasyTube® and CVD product lines, are sold to researchers at universities, research laboratories, and startup companies in the United States and throughout the world.

Sales of our proprietary standard, custom systems and process solutions have been driven by our installed customer base, which includes several Fortune 500 companies. The strong performance and success of our products has historically driven repeat orders from existing customers as well as business from new customers. However, with our proprietary solutions and expanded focus on “accelerating the commercialization of tomorrow’s technologiesTM we have been developing a new customer base in addition to growing with our existing customers. We have generally gained new customers through word of mouth, limited print advertising and trade show attendance. We are now also gaining new customers by their awareness of our company in the marketplace with results from our Application Laboratory, relationships with startup companies, increased participation in trade shows and expanded internet advertising.

The core competencies we have developed in equipment and software design, as well as in systems manufacturing and process solutions, are used to engineer our finished products and to accelerate the commercialization path of our customer base. Our proprietary-real-time, software allows for rapid configuration, and provides our customers with powerful tools to understand, optimize and repeatedly control their processes. Our vertically integrated structure allows us to control the manufacturing process, from bringing raw metal and components into our manufacturing facilities to shipping out finished products. These factors significantly reduce cost, improve quality and reduce the time it takes from customer order to shipment of our products. Our Application Laboratory allows selected customers to bring up their process tools in our Application Laboratory and to work together with our scientists and engineers to optimize process performance.

Current Developments

As a result of past delays in the permitting process for construction of modifications needed for our new CVD Materials facility in Central Islip, NY, which have now been received, we expect that we will initiate operations at this facility in the second or third quarter of 2019 and we believe the CVD Materials segment will contribute to the Company’s future success.

Revenue for the fourth quarter of 2018 remains below expectation. Additionally, the level of new orders from customers has not been received as anticipated, and without these orders, we believe our level of revenue for the first two quarters of 2019 may approximate our revenue in the last two quarters of 2018. As a result, we expect to report operating losses for the first and second quarters of 2019 and the timing for a return to profitability depends upon, among other things, the receipt of new orders, the ramp up of the materials business, as well as reviewing our planned expenditures and operating expenses for potential cost savings to minimize these losses, including our ability to sublet the new facility. At December 31, 2018, we have reduced our employees 15% to 197.  We continue to monitor our staffing level to support current operations and level of current and expected orders.


 

ResultsAs previously reported, our line of Operations

Twelve Months Endedcredit expired by its terms in September 2018.  We have elected not to renew our credit line at that time because (a) renewal terms were not acceptable to us, (b) we have not borrowed on our line of credit in the past 10 years, and (c) we have sufficient cash and cash equivalents (approximately $11.4 million as of December 31, 2016 vs Twelve Months Ended December 31, 20152018 and approximately $11.2 million at March 22, 2019) to meet our working capital and capital expenditure requirements over the next twelve months.

 

 

 

 

 

Twelve Months Ended

         
  

December 31

         
  

2016

  

2015

  

Change

  

% Change

 

Revenue

                

CVD (net of eliminations)

 $18,560  $35,461  $(16,901)  (47.7)

SDC (net of eliminations)

  2,395   3,504   (1,109)  (31.6)

Total Revenue

  20,955   38,965   (18,010)  (46.2)
                 

Cost of Goods Sold

  13,851   23,820   (9,969)  (41.9)
                 

Gross Profit

  7,104   15,145   (8,041)  (53.1)

Gross Margin

  33.9%  38.9%      (5.0)
                 

Research & Development

  434   605   (171)  (28.3)

Selling and Shipping

  1,098   1,208   (110)  (9.1)

General & Administrative

  6,926   7,745   (819)  (10.6)
   8,458   9,558   (1,100)  (11.5)

Litigation settlement

  ---   995   (995)    

Gain on settlement

  (629)  ---   (629)    

Total Operating expenses

  7,829   10,553   (2,724)  (25.8)
                 

Operating (loss)/income

  (724)  4,592   5,316   115.8 
                 

Other income/(expense)

  71   (67)  138   206.0 
                 

(Loss)/income before taxes

  (653)  4,525   (5,178)  114.4 
                 

Income tax (benefit)/expense

  (504)  1,320   (1,824    
                 

Net (loss)/income

  (149)  3,205   (3,354)  104.6 
                 

Net (loss)/income per share

                

Basic

  (0.02)  0.52         

Diluted

  (0.02)  0.51         

During the fourth quarter, we continued our mission to develop and enable the commercialization of next-generation technologies, by incorporating our technology into equipment built for customers’ manufacturing processes. Our endeavors in applications for LED materials, medical implants and coatings, aerospace coatings, carbon composites for MEMs and medical devices are some of the areas we have been working on.

We continued to make a significant investment in our CVD Materials business. In November 2018, we filed a provisional patent application for afamily of advanced Fluid Reactors based on our innovations in nanotechnology and chemical vapor deposition technology. The Fluid Reactor is enabled by a novel reactor core element which allows the efficient transfer of gases into and out of liquids. The market adoption of this technology could supplant existing hollow fiber membrane technology for applications including filtration and liquid gasification or degasification. One application is blood oxygenation cartridges known as an Extra Corporeal Membrane Oxygenator which is typically used during cardio pulmonary bypass (CPB) surgery and is essential for life support.

Our MesoScribe™ Direct Write Technology continues to make progress in specialized applications for temperature sensors, conformal antennas, flexible electronics and heaters for applications in aerospace and electronics where standard solutions have been unable to meet the physical constraints that need to be addressed. MesoScribe™ has been notified that they have been selected for three (3) government sponsored awards, two of which were received in the first quarter of 2019, and one is anticipated to be received in the second quarter 2019.

Investments in our Application Laboratory and CVD Materials are necessary and not related to our quarterly revenue fluctuations. We continue to believe that expansion and innovation in key markets like aerospace, medical, MEMs, semiconductors is the key to securing our growth over the long-term.

We continue to dedicate significant portions of our technical and manufacturing resources to new materials development and opening of the new CVD Materials facility. They pave the way for future expansion across our portfolio and to improve and streamline revenue growth and profitability over the longer term.

 


 

Constant investment in expansion and innovation is necessary, even during times of reduced order levels, to strengthen and secure our competitive position and open up new opportunities in the markets we serve. We believe we are well capitalized and will continue to work to produce increased yet stable revenue, productivity and profitability over the long-term.

RevenueRevenue

  

2018

  

2017

  

Change

  

%Change

 

CVD Equipment

 $17,860,025  $34,964,365  $(17,104,340)  (48.9%)

SDC

  4,731,638   5,626,267   (894,629)  (15.9%)

CVD Materials

  1,742,668   538,007   1,204,661   223.9%

Total

 $24,334,331  $41,128,639  $(16,794,308)  (40.8%)

 

Our revenue for the year ended December 31, 20162018 was $21$24.3 million compared to $39$41.1 million for the year ended December 31, 2015,2017, resulting in a decrease of 46.2%. This decrease40.8% which was primarily attributable to the protracted negotiationscompletion of orders received from our largest customer. This customer, in the aerospace industry from which we have secured multiple orders, represented $9.3 million or approximately 38.2% of our revenue for the twelve months ended December 31, 2018 compared to $27.2 million or approximately 66.1% of our revenue for the year ended December 31, 2017. We continue to receive additional orders and opportunities with anew and current customers, and exclusive of our largest customer, a major aviation component supplier, which caused a delay in receiving a large anticipated follow-on order. sales increased $.8 million from $7.8 million to $8.6 million at December 31, 2018.

The revenue contributed for the year ended December 31, 2016,2018, by the CVD/First Nano division,CVD Equipment segment, of $18.6$17.8 million, which totaled 88.6%73.4% of our overall revenue, was 47.7%48.9% or $16.9$17.1 million less than the division’s $35.5segment’s $34.9 million contribution made in the prior year, which totaled 91%85% of our overall revenue.

 

Annual revenue for theour SDC divisionsegment decreased to $2.4$4.7 million in 20162018 as compared to $3.5$5.6 million in 2015. This was2017, a resultdecrease of 15.9%. The decrease is primarily attributable to a general slowdownhigher sales activity level from one customer in the industry. However, we are beginning to see an increase in activity, as some of the expected orders from earlier are now being received.prior year. The SDC divisionsegment represented 11.4%19.4% and 9%13.7% of our total revenue during the years ended December 31, 20162018 and December 31, 20152017, respectively.

 

Revenues for our CVD Materials segment were $1.7 million in the year ended December 31, 2018 as compared to $.5 million for 2017. The increase of $1.2 million was comprised of a $.9 million increase from MesoScribe, due to a full year of revenue since the acquisition on October 31, 2017, as well as an increase in sales from Tantaline of $.3 million.

Gross Profit

 

Gross profit for the year ended December 31, 20162018 amounted to $7.1$5.2 million, with a gross profit margin of 33.9%,21.3 %, compared to a gross profit of $15.1$17.6 million and a gross profit margin of 38.9%42.8% for the year ended December 31, 2015.2017. The reduceddecreased gross profit and gross profit margin waswere the result of the lower revenue and the costs associated with maintaining production staffreduction in anticipation of the large follow-on ordersales from our largest customer.customer and delays in receiving new orders, while costs principally remained at levels to support our anticipated expansion of the CVD Materials segment and future growth.

 


Research and Development, Selling and General and Administrative Expenses

Research and Development:

 

Due to the technical development required on our custom orders, our research and development team and their expenses are charged to costs of goods sold when they are working directly on a customer project. When they are not working on a customer project, they work in our Application Laboratory and their costs are charged to research and development. In 2016,2018 and 2017, we incurred $0.6 million and $0.4 million respectively of internal research and development costs compared to $0.6 million of internal research and product development expenses incurred in 2015. The Company had temporarily curtailed independent research and development activities during the first six months of 2016, however, it has begun to expand those activities during the last half of the year.costs.

Selling:

 

Selling and shipping expenses were $1.1$1.6 million or 5.2%6.7 % of the revenue for the year ended December 31, 20162018 as compared to $1.2$1.4 million or 3.1%3.4% for the year ended December 31, 2015.2017. The decrease in actual expensesincrease was a result of reduced personneladditional employees and shipping coststrade show related expenses in the current period. The increaseperiod as a percentage of revenue was duewell as increased expenses related to CVD Materials, including its recently established subsidiaries CVD Tantaline ApS and CVE MesoScribe Technologies effective with the reduced revenues for the current year.October 31, 2017 acquisition.

General and Administrative:

 

General and administrative expenses for the year ended December 31, 20162018 were $6.9$8.2 million or 33.7% of revenue compared to $7.7$8.5 million or 20.8% during the year ended December 31, 2015,2017, a decrease of $0.8$.3 million. In 2016, we incurred general legal feesThe decrease attributable to the CVD Equipment segment was primarily the result of $75,000 compared to $619,000$1.2 million reduction in legal feessalary and related costs as a result of the overall lower sales demand, offset in part by $.4 million increased consulting costs related to litigation that was settled in 2015.systems implementation and accounting services. CVD Materials incurred increased costs of $.4 million from its new facility purchased on November 30, 2017 related to real estate taxes, insurance and other operating costs, as well as $.2 million increased costs at its recently established subsidiaries CVD Tantaline ApS and CVD Mesoscribe Technologies.


Litigation Settlement

Pursuant to a settlement agreement, in September 2015, the Company paid the sum of $995,000 to Development Specialists, Inc. an Illinois corporation, solely in its capacity as assignee for the benefit of creditors of CM Manufacturing, Inc., f/k/a Stion Corporation, a Delaware corporation in full settlement and satisfaction of all claims asserted in a previously disclosed proceeding. Each party released all claims of any nature which it had against the other.

Gain on Settlement

The Company has included the results of a negotiated reduction to legal fees and expenses

in connection with the settlement of the previously disclosed Taiwan Glass litigation. The final negotiated sum was $1.1 million, resulting in a reduction of the amount that was previously billed and accrued and a gain on the statement of operations of $629,000 during the period.

Operating Income/(Loss)/Income

 

As a result of the decreased revenues and gross margins, we incurred arecorded an operating loss from operations of $0.7$5.3 million for the year ended December 31, 20162018 as compared to operating income of $4.5$7.2 million for the year ended December 31, 2015.2017, which was driven primarily by the reduced revenue from our largest customer.

 

Other Income/(Expenses)/Income

 

DuringOther expenses were $303,000 and $24,000 for the years ended December 31, 2018 and 2017, respectively. This increase was the result of higher interest expense of $463,000 in 2018 from our building purchased for our CVD Materials group on November 30, 2017, offset partially by increased interest income.


Income Taxes

For the year ended December 31, 2016, we received a payment from our insurance company on a property damage claim that exceeded the repair costs by $119,000.

Income Taxes

For the twelve months ended December 31, 2016,2018, we recorded an income tax benefit of approximately $504,000. This is primarily the result of available research and development and other tax credits to a pre-tax loss of $654$357,000 as compared to an income tax expense of $1.3$1.9 million on pre-tax income of $4.5 million forin the twelve monthsyear ended December 31, 2015.2017. During 2018, our corporate tax rate was reduced to 21% as a result of The Tax Cuts and Jobs Act (“TCJA”) enacted December 22, 2017.  This rate was partially offset by permanent differences related to fixed and intangible assets, stock-based compensation and other items resulting in an effective tax rate of 6.4%.

 

Net (Loss)/IncomeDuring 2017, our corporate tax rate was 34%.  This rate was partially offset by the utilization of net operating losses.  In addition, we were required by TCJA to remeasure our deferred tax assets, primarily related to R&D tax credits and stock-based compensation, and incurred an additional expense in the amount of $689,000.  This resulted in an effective tax rate of 26.9%.

 

Net Income/(Loss)

As a result of the foregoing factors, for the year ended December 31, 2016,2018, we incurredhad a net loss of $149,000$5.2 million or $(0.02)$.80 per diluted share compared to a net income of $3.2$5.3 million or $0.51$0.82 per diluted share for the year ended December 31, 2015.2017.

 

Inflation

 

Inflation has not materially impacted our operations.

 

Liquidity and Capital Resources

 

As of December 31, 2016,2018, we had aggregate working capital of $20.5$15.4 million compared to aggregate working capital of $19.9$22.4 million at December 31, 2015 and had available2017. Our cash and cash equivalents of $21.7at December 31, 2018 and 2017 were $11.4 million compared to $13.1and $14.2 million, inrespectively. At March 22, 2019 our cash and cash equivalents at December 31, 2015.were approximately $11.2 million. The increasedecrease in working capital of $0.6$7 million is primarily attributable to an increasethe overall sales reductions and resulting operating loss for the year and debt service payments of approximately $1.2 million, including payments on our investment in the CVD Materials building on November 30, 2017. We have continued to invest in activities primarily related to preparing CVD Materials for operations which we anticipate will commence in the second or third quarter of 2019. Our total capital invested in 2018 was $2.5 million, primarily related to building improvements and machinery for the CVD Materials operations and we also incurred operating costs of approximately $.4 million, exclusive of interest expense. Further, there were decreases in contract assets of $7 million, cash that was partiallyof $2.8 million, inventories $1.1 million, offset in part by a reductionincreases in costsaccounts receivable of $2 million and estimated earningsdecreases in excessaccounts payable and accrued expenses of billings on contracts in progress as well as an increase in billings in excess of costs and estimated earnings on contracts in progress. Net cash increased by $8.6 million as a result of cash provided by operating activities of $8.8 million which was primarily attributed to an increase in billings in excess of costs and estimated earnings on contracts in progress. Net cash used in investing activities was $0.41.7 million.


 

Accounts receivable, net of allowance for doubtful accounts, decreasedincreased by $2.5$2 million or 80.6%97.5% at December 31, 20162018 to $0.6$4.1 million compared to $3.1$2.1 million at December 31, 2015.2017. This decreaseincrease is principally due to the timing of shipments and customer payments.

 

Inventories as of December 31, 20162018 were approximately $3.3$1.9 million representing an increasea decrease of approximately $0.2$1.1 million or 6.5%a decrease of 37.2% compared to the balance of approximately $3.1$3.0 million as of December 31, 20152017. The decrease was driven primarily by management’s efforts to better utilize existing inventories.


As previously reported, our Revolving Line of Credit expired on September 1, 2018. We have elected not to renew our credit line at this time because (a) renewal terms were not acceptable to us, (b) we have not borrowed on our line of credit in the past 10 years, and (c) we have sufficient cash and cash equivalents to meet our working capital and capital expenditure requirements over the next twelve months.

 

We maintain a revolving credit facility with HSBC Bank, USA, N.A. (“HSBC”) providing up to $7 million, although we have never utilized this facility. This credit facility remains available until September 1, 2018. The credit facility also contains certain financial covenants, all of which we were in compliance with at December 31, 2016.

On August 1, 2016 we made the final payment on a $2.1 million term loan that was initially entered into in August 2011. The balance on that term loan at December 31, 2015 was $280,000.

The Company has a loan agreement with HSBC which is secured by a mortgage against our Central Islip facility.facility at 355 South Technology Drive. The loan is payable in 120 consecutive equal monthly installments of $25,000 in principal plus interest and a final balloon payment upon maturity in March 2022. The balances as of December 31, 20162018 and December 31, 20152017 were approximately $3.3$2.7 million and $3.6$3.0 million respectively. Interest accrues on the Loan, at our option, at the variable rate of LIBOR plus 1.75% which was 2.1765% and 1.9455% at December 31, 2016 and 2015 respectively.or Prime less 0.5%.

 

On December 16, 2016,November 30, 2017, we purchased certain assets formerly owned by Tantaline A/S of Nordborg, Denmark through our wholly owned subsidiary,the premises located at 555 North Research Place, Central Islip, NY which is intended to house the CVD Materials Corporation. Formedsegment. The purchase price of the land and the building was $13,850,000 exclusive of closing costs.

As part of the acquisition, our newly formed wholly-owned subsidiary, 555 N Research Corporation (the” Assignee”) and the Islip IDA, entered into a Fee and Leasehold Mortgage and Security Agreement (the ”Loan”) with HSBC USA, N.A. (the ”Bank”) in 2007,the amount of $10,387,500, which was used to finance a portion of the purchase price to acquire the premises located at 555 North Research Place, Central Islip, New York (the ”Premises”). The Loan was evidenced by the certain Note, dated November 30, 2017 (the ”Note”), by and between Assignee and the Bank, and secured by a certain Fee and Leasehold Mortgage and Security Agreement, dated November 30, 2017 (the “Mortgage”), as well as a spin off from The Danfoss Group, Tantaline A/S established itself as a leader in the commercializationcollateral Assignment of tantalum treated parts for corrosion resistance. We have now established in Nordborg a newLeases and wholly owned CVD subsidiary operating under the name Tantaline CVD ApSRents (“Tantaline”Assignment of Leases”).

 

The Loan is payable in 60 consecutive equal monthly installments of $62,481, including interest. The Loan shall bear interest for each Interest Period (as defined in the Note), at the fixed rate of 3.9148%. The maturity date for the Note is December 1, 2022. As a condition of the Bank making the Loan, we were required to guaranty Assignee’s obligations under the Loan.

At December 31, 2018, we were not in compliance with the only financial covenant (fixed charge coverage ratio) contained in the Mortgage. On March 26, 2019 the Company received a waiver from HSBC until April 1, 2020.

At December 31, 2018 we have reduced our employee headcount by 15% to 197.  We are continuing to evaluate our staffing levels to support the CVD Materials new building and related operations commencing during the second or third quarter of 2019, and the level of current and expected orders. We believe that our cash and cash equivalent positions and cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months.

 

We may also raise additional funds in the event we determine in the future to effect one or more acquisitions of businesses, technologies or products. In addition, we may elect to raise additional funds even before we need them if the conditions for raising capital are favorable. Any equity or equity-linked financing could be dilutive to existing shareholders.


 

Critical Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our significant estimates include accounting for certain items such as revenues on long-term contracts recognized on the percentage-of-completioninput method; valuation of inventories at the lower of cost or market; allowance for doubtful accounts receivable; recognition of stock-based compensation; estimated lives and recoverable value of our long-lived assets; costs associated with product warranties;assets and certain components of the current and deferred income tax provisions which ae based on estimates of future taxable events.

 

Revenue Recognition

 

ProductOn January 1, 2018, we adopted accounting standard ASC 606, Revenue from Contracts with Customers and service sales, including those basedall the related amendments using the modified retrospective method for all customer contracts not yet completed as of the adoption date. The adoption of ASC 606 did not have a significant impact on timeour Consolidated Financial Statements and, materials type contracts,as a result, comparisons of revenues and operating profits performance between periods are recognized when persuasive evidencenot affected by the adoption of an arrangement exists, product delivery has occurred or services have been rendered, pricing is fixed or determinable, and collection is reasonably assured. Service sales, principally representing repair, maintenance and engineering activitiesthis ASU. Results for reporting periods beginning January 1, 2018 are recognized over the contractualpresented under ASC 606, while prior period or as services are rendered.amounts were not adjusted.

 

We design, manufacture and sell custom chemical vapor deposition equipment through contractual agreements. These system sales require us to deliver functioning equipment that is generally completed within three to eighteen months from commencement of order acceptance. We recognize revenues and incomerevenue over time by using the percentage-of-completionan input method for certain custom production-type contracts. Profits on these custom production-type contracts are recorded on the basis of our total estimated costs over the percentage of total costs incurred on individual contracts commencing when progress reaches a point where experience is sufficient to estimate final results with reasonable accuracy. Under this method, revenues are recognized based on costs incurred as it depicts our progress toward satisfaction of the performance obligation. Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date compared withto the total estimated costs.costs at completion of the performance obligations.

 

Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process as required by the project’s engineering design. Cost based input methods of revenue recognition require us to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, we recognize the entire estimated loss in the period the loss becomes known and can be reasonably estimated.

We have been engaged in the production and delivery of goods on a continual basis under contractual arrangements for many years. Historically, we have demonstrated an ability to accurately estimate total revenues and total expenses relating to our long-term contracts. However, there exist many inherent risks and uncertainties in estimating revenues, expenses and progress toward completion, particularly on larger or longer-term contracts. If we do not estimate the total sales, related costs and progress toward completion on such contracts, the estimated gross margins may be significantly impacted or losses may need to be recognized in future periods. Any such resulting changes in margins or contract losses could be material to our results of operations and financial condition.


Stock-Based Compensation

 

We record stock-based compensation in accordance with the provisions set forth in the Financial Accounting Standard Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “Stock Compensation,” using the modified prospective method. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards.

 

Long-Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant and equipment. Intangibles consist of patents, copyrights, intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists pursuant to the requirements of ASC 360-10-35, “Impairment or Disposal of Long-Lived Assets.” If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value. We had no recorded long-lived asset impairment charges in the statement of operations during each of the years ended December 31, 20162018 and 2015.2017.

 


Off-Balance Sheet Arrangements

 

None.

Item 7A.Quantitative and Qualitative Disclosures About Market Risk.

Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

Item 8.Financial Statements and Supplementary Data.

Financial Statements and Supplementary Data.

 

The consolidated financial statements and supplementary data required by this item are included in this annual report beginning on page F-1.

Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.


Item 9A.

Controls and Procedures.

 

Item 9A.      Controls and Procedures.

Disclosure Controls and Procedures. We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). As required by Rule 13a-15(b) under the Exchange Act, management of the Company, under the direction of our Chief Executive Officer and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2016. 2018.

Based on that review and evaluation, theour Chief Executive Officer and Chief Financial Officer, along with theothers in our management, of the Company, have determined that as of December 31, 2016,the end of the period covered by the Report on Form 10-K, the disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and werenot effective to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer,officers, as appropriate to allow timely decisions regarding required disclosures. Specifically, we have identified the following material weaknesses in our disclosure controls: (1) The Company lacks sufficient internal controls over monitoring the accounting activity and consolidation of its foreign subsidiary into the Company’s consolidated financial statements. (2) Also, the Company has not fully integrated its new project accounting software into its general ledger accounting system and continues to rely on manual reconciliations using electronic spreadsheets. (3) The Company has a deficiency in internal controls regarding the estimation of costs on contracts in progress

To remediate such weaknesses, we have implemented the following changes: (1) established stricter formal procedures with respect to how and when our management will communicate to the auditors and Audit Committee on a more timely basis, (2) is adopting sufficient written policies and procedures for accounting and financial reporting, (3) we have appointed and /or designated additional qualified personnel to ensure timely filing of the reports that we file or submit under the Exchange Act, (4) added additional, multiple review levels, (5) receives from the staff of the foreign subsidiary financial information on a weekly and monthly basis in order to monitor more closely. During the year ended December 31, 2018, we integrated three more entities into its accounting software and is planning the integration of the remaining two entities shortly. In addition, we have reevaluated our internal controls regarding the estimation of costs on contracts in progress and have implemented changes as needed.

Changes in Internal Controls

There were no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) or Rule 15d-15(f) under the Exchange Act that occurred during the most recent fiscal year that have materially affected, or are reasonably likely to materially affect, the internal controls over financial reporting.

Limitations on the Effectiveness of Controls

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

 


 

Management’s Annual Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining effective internal control over financial reporting (as defined in Rule 13a – 15(f) of the Exchange Act). There are inherent limitations to the effectiveness of any internal control, including the possibility of human error and the circumvention or overriding of controls. Accordingly, even effective internal controls can provide only reasonable assurance with respect to financial statement preparation. Further, because of changes in conditions, the effectiveness of internal control may vary over time. We have assessed the effectiveness of our internal controls over financial reporting (as defined in Rule 13a -15(f) of the Exchange Act) as of December 31, 2016.2018. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control – Integrated Framework (2013)”. Management concluded that, as of December 31, 2016,2018, our internal control over financial reporting was effective based on the criteria established by the COSO Internal Control Framework.

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

 

Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B.Other Information.

Other Information.

 

None.

 


 

PART III

 

Item 10.

Directors, Executive Officers, and Corporate Governance.

 

Background and Experience of Directors

 

When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable the Board of Directors to satisfy its oversight responsibilities effectively in light of our business and structure, the Nominating, Governance and Compliance Committee focused primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth immediately below.  We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. As more specifically described in such person’s individual biographies set forth below, our directors possess relevant and industry-specific experience and knowledge in the engineering financial and business fields, as the case may be, which we believe enhances the Board’s ability to oversee, evaluate and direct our overall corporate strategy. The Nominating, Governance and Compliance Committee annually reviews and makes recommendations to the Board regarding the composition and size of the Board so that the Board consists of members with the proper expertise, skills, attributes, and personal and professional backgrounds needed by the Board, consistent with applicable regulatory requirements.

 

The Nominating, Governance and Compliance Committee believes that all directors, including nominees, should possess the highest personal and professional ethics, integrity, and values, and be committed to representing the long-term interests of our shareholders. The Nominating, Governance and Compliance Committee will consider criteria including the nominee’s current or recent experience as a senior executive officer, whether the nominee is independent, as that term is defined in existing independence requirements of the NASDAQ Capital Market and the Securities and Exchange Commission, the business, scientific or engineering experience currently desired on the Board, geography, the nominee’s industry experience, and the nominee’s general ability to enhance the overall composition of the Board.

 

The Nominating, Governance and Compliance Committee does not have a formal policy on diversity; however, in recommending directors, the Board and the Committee consider the specific background and experience of the Board members and other personal attributes in an effort to provide a diverse mix of capabilities, contributions and viewpoints which the Board believes enables it to function effectively as the Board of Directors of a company with our size and the nature of our business.

 

Director Service on other Boards

Lawrence J. Waldman has served as a director of Bovie Medical Corporation (“Bovie”) since 2011 and is currently the Chair of the Audit Committee and Lead Independent Director of Bovie’s Board. Mr. Waldman serves as a member of the Board of Directors of Northstar/RXR Metro Income Fund, a non-traded Real Estate Investment Trust, and has served as a member of its Audit Committee since 2014. Mr. Waldman also serves as a member of the Board of Directors of Comtech Telecommunications, Corp. since August of 2014, and has served as the Chairman of the Audit Committee since December 2015.

Raymond A. Nielsen has been a member of the Board of Directors of Bridgehampton National Bank and Bridge Bancorp Inc., its parent holding company since 2013. He currently serves on the Compensation Committee, Corporate Governance and Nominating Committee as well as on the ALCO and Loan Committees and the Compliance BSA & CRA Committee.


Legal Proceedings Involving Directors

 

None.

 


Board Leadership

 

While the Board has not separated the positions of Chairman and CEO, it has appointed Lawrence J. Waldman as the Lead Independent Director. The Lead Independent Director is appointed by the Board and is responsible for coordinating the activities of the independent directors and the Chief Executive Officer of the Company to set agendas for Board meetings and chair executive sessions of the independent directors. The Lead Independent Director is also responsible for meeting, from time to time, with the Company’s Compensation Committee to discuss the Chief Executive Officer’s performance.

Our Corporate Governance practices contain several features which we believe will ensure that the Board maintains effective and independent oversight of management, including the following:

Executive sessions without management and non-independent directors present are a standing Board agenda item. Executive sessions of the independent directors are held at any time requested by an independent director and, in any event, are held in connection with at least 100% of regularly schedule Board meetings.

The Board regularly meets in executive session with the CEO without other members of management present.

All Board committee members are independent directors. The committee chairs have authority to hold executive sessions with management and non-independent directors present.

While our Board has no formal policy with respect to separation of the positions of Chairman and CEO or with respect to whether the Chairman should be a member of management or an independent director, we believe that the creation of the position of Lead Independent Director properly facilitates better communication between the Independent Directors on the one hand and believes that these are matters that should be discussedthe non-Independent Directors and determinedmembers of management on the other hand and leads to improved oversight and discussions by the Board from time to time. Currently,as a whole. The Chief Executive Officer of the Company, Leonard A. Rosenbaum, serves as our Chairman, President and CEO. Given the fact that Mr. Rosenbaum, in his capacity as our President and CEO is tasked with the responsibility ofor implementing our corporate strategy, we believe he is best suited for leading discussions with input from the Lead Independent Director, at the Board level, regarding performance relative to our corporate strategy and these discussions accountthis discussion accounts for a significant portion of the time devoted at ourthe Board meetings.

 

Our Certificate of Incorporation and Bylaws provide for our Company to be managed by or under the direction of the Board of Directors. Under our Certificate of Incorporation and Bylaws, the number of directors is fixed from time to time by the Board of Directors. The Board of Directors currently consists of fivesix members. Directors are elected for a period of one year and thereafter serve, subject to the Bylaws, until the next annual meeting at which their successors are duly elected by the shareholders.

 


 

The following table sets for the names, ages and positions with the Company of each of our directors and executive officers, as of March 22, 2017.2019.

 

Name

Age

Position(s) with the Company

Leonard A. Rosenbaum

7173

Chairman of the Board of Directors, Chief Executive Officer, President

Martin J. Teitelbaum

6668

Director, General Counsel and Assistant Secretary

Conrad J. Gunther

7072

Director, Chairperson-AuditChairperson-Compensation Committee

Lawrence J. Waldman

7072

Lead Independent Director, Chairperson-Audit Committee

Robert M. Brill

72

Director, Chairperson-CompensationChairperson – Strategic Planning Committee

Raymond A. Nielsen

6668

Director, Chairperson-Nominating, Governance and

Compliance Committee

Glen R. CharlesThomas McNeill

6356

Chief Financial Officer, Secretary and Treasurer

Steven Aragon

5557

Chief Operating Officer

Karlheinz Strobl

5759

Vice President of Business Development

William S. Linss

59

Vice President of Operations-CVD/First Nano Division

Kevin R. Collins

5153

Vice President and General Manager-SDC Division

Emmanuel Lakios

5557

Vice President of Sales and Marketing

 


Leonard A. Rosenbaum

 

Leonard A. Rosenbaum founded the Company in 1982 and has been our President, Chief Executive Officer and has served as Chairman of the Board of Directors since that time. From 1971 until 1982, Mr. Rosenbaum was president, director and a principal stockholder of Nav-Tec Industries, a manufacturer of semiconductor processing equipment similar to the type of equipment we manufacture. From 1966 to 1971, Mr. Rosenbaum was employed by a division of General Instrument, a manufacturer of semiconductor materials and equipment.

 

Martin J. Teitelbaum, Esq.

 

Martin J. Teitelbaum has served as a member of our Board of Directors and General Counsel since 1985 and as our in-house General Counsel since May 16, 2011. Mr. Teitelbaum is an attorney, who prior to May 16, 2011, conducted his own private practice, the Law Offices of Martin J. Teitelbaum. Prior to establishing his own firm in 1988, Mr. Teitelbaum was a partner at Guberman and Teitelbaum from 1977 to 1987. In addition, Mr. Teitelbaum currently acts as our Assistant Secretary. Mr. Teitelbaum earned a B.A. in Political Science from the State University of New York at Buffalo and a Juris Doctor from Brooklyn Law School. Mr. Teitelbaum has served as our outside General Counsel for many years and his legal expertise makes him an asset to the Company’s board of directors.

 

Conrad J. Gunther

 

Conrad J. Gunther has served as a member of our Board of Directors since 2000. Mr. Gunther has extensive experience in mergers and acquisitions and in raising capital through both public and private means. He has been an executive officer and director of several banks, both public and private, and has served on the boards of two other public companies. He most recently served on the board of GVC Venture Corp., a public company from June 2004 until it merged with the Halo Companies in September 2009. Since January 2008, Mr. Gunther has served as an Executive Vice President and Senior Loan Officer for Community National Bank, a Long Island, New York based commercial bank, where he is responsible for all commercial lending. Mr. Gunther qualifies to serve on our board of directors as a result of his experience and expertise in the financial community.

 


 

Lawrence J. Waldman 

 

Lawrence J. Waldman was appointed a member of the Board of Directors on October 5, 2016.2016 and serves as Chairman of the Audit Committee as well as the Lead Independent Director. Mr. Waldman has over forty years of experience in public accounting. He joined First Long Island Investors LLC, an investment and wealth management firm, as a Managing DirectorSenior Advisor in May 2016. Prior to that Mr. Waldman served as an advisor to the accounting firm of EisnerAmper LLP, where he was previously the Partner-in-Charge of Commercial Audit Practice Development for Long Island since September 2011. Prior to joining EisnerAmper LLP, Mr. Waldman was the Partner-in-Charge of Commercial Audit Practice Development for Holtz Rubenstein Reminick, LLP from July 2006 to August 2011. Mr. Waldman was the Managing Partner of the Long Island office of KPMG LLP from 1994 through 2006, the accounting firm where he began his career in 1972. Mr. Waldman has served as a director of Apyx Medical Corporation, formerly Bovie Medical Corporation, since 2011 and he is currently the Chair of the audit committeeAudit Committee and Lead Independent Director of the Board. Mr. Waldman serveshas served as a member of the Board of Directors of Northstar/RXR Metro Income Fund, a non-traded Real Estate Investment Trust, and has served as a member of its audit committee since 2014.from 2014 until October of 2018. Mr. Waldman was elected to the Board of Directors of Comtech Telecommunications Corp. in August of 2015, and since December 2015, serves as Chair of its Audit Committee. Mr. Waldman is also a memberthe Chair of the Supervisory Committee of Bethpage Federal Credit Union. Mr. Waldman also servespreviously served as a member of the State University of New York's Board of Trustees and as chair of its audit committee. He also previously served as the Chairman of the Board of Trustees of the Long Island Power Authority and as Chair and a member of the finance and audit committee of its Board of Trustees. Mr. Waldman is a Certified Public Accountant.

 

Raymond Nielsen

 

Raymond Nielsen was appointed a member of the Board of Directors on October 5, 2016. Mr. Nielsen is currentlywas the Director of Finance for The Beechwood Organization until January 2019 and has been responsible for Project and Corporate Finance including Strategic Planning Initiatives since 2014. He has been a member of the Board of Directors of Bridgehampton National Bank and Bridge Bancorp Inc., its Parent holding company since 2013, serving on the Compensation Committee, Corporate Governance & Nominating Committee, ALCO, Loan, and the Compliance, BSA & CRA Committees. Mr. Nielsen is the former CEO of Reliance Federal Savings Bank and Herald National Bank, and a 45 year veteran of the banking industry. Mr. Nielsen also served as a Director of North Fork Bancorporation and its subsidiary North Fork Bank for 6 years where he chaired both the Compensation Committee and Audit Committee as well as having served as Lead Independent Director. Mr. Nielsen’s extensive public company, banking and real estate development experience will provide a valuable resource to the Board of Directors and Executive Management.

 

Glen R. Charles

Glen R. Charles has been the Chief Financial Officer and Secretary of the Company since January, 2004. From 2002 until he joined the Company, he was the Director of Financial Reporting for Jennifer Convertibles, Inc., the owner and licensor of the largest group of sofabed specialty retail stores in the United States. From 1994 to 2002, he was the Chief Financial Officer of Trans Global Services, Inc., a public company providing temporary technical services to the aerospace, aircraft, electronics and telecommunications markets. Mr. Charles has also had his own business in the private practice of accounting. Mr. Charles earned his B.S. in Accounting from the State University of New York at Buffalo.


 

Robert M. Brill

Robert M. Brill was appointed a member of the Board of Directors on April 12, 2018. Dr. Brill is a co-founder and managing partner of Newlight Management since 1997, which manages venture capital funds that focus on early stage technology companies. Prior to co-founding Newlight, Dr. Brill was a general partner of Poly Ventures, a Long Island based venture capital fund. Newlight and Poly Ventures have collectively invested in over 50 private companies including Long Island based Fatwire, Invision and Globecomm. He is a member of the Board of Directors of the L.I. Angel Network, the L.I. High Tech Incubator and several private companies. Prior to joining Poly ventures, Dr. Brill was a successful turnaround CEO at both private and public companies. Dr. Brill served as General Manager of Harris Corporation’s CMOS microprocessors. He also held various technical and management positions at IBM’s semiconductor operation. Dr. Brill holds a PhD in nuclear physics from Brown University and a B.A. and B.S. in engineering physics from Lehigh University. He is a member of Phi Beta Kappa and Tau Beta Pi. He is a founding member of the Technical Advisory Board of the Semiconductor Research Corporation and was elected to the L.I. Technology Hall of Fame. He holds multiple patents and invention disclosures. Mr. Brill’s extensive technical knowledge and experiences from serving on the boards of other companies provides a valuable resource to the Company.

Thomas McNeill

Thomas McNeill was appointed as the Company’s Chief Financial Officer, Secretary and Treasurer effective as of March 4, 2019. Mr. McNeill has been a Chief Financial Officer ("CFO") since 1996 and has seventeen years' of SEC reporting experience with two public companies, as well as a full range of financial and operational experience. Since April 2015, he has been CFO at Century Direct, LLC, a printing and mailing company serving the direct mail marketing industry. From November 2014 to April 2015, he was a consultant at Mailmen Inc. until its assets were purchased by Century Direct, LLC. Mr. McNeill was CFO/COO at Nina McLemore from July 2013 to June 2014, a woman's retail apparel Company. On the Public reporting side, he was CFO at DineWise, Inc. from April 2006 to April 2013, a direct to consumer prepared frozen foods company, and from October 1996 to April 2006, was CFO at Global Payment Technologies, Inc, a hi-tech manufacturing and engineering company. Mr. McNeill is a Certified Public Accountant who began his career at KPMG, achieving the position of audit manager. Mr. McNeill holds a BBA in accounting from Hofstra University.


Steven Aragon

 

Dr. Steven Aragon was appointed Chief Operating Officer by the Board of Directors on October 20, 2014. Dr. Aragon has over 25 years of thin-film process, materials, and system expertise applied to photovoltaic, optical, electronic, and magnetic device fabrication. He received his Ph.D. in Physical Chemistry from the University of California, Santa Cruz, in 1990 and his MBA from Santa Clara University in 1996. He is the holder of five process equipment design patents. Dr. Aragon was a co-founder of Optimus Energy Systems International Inc. and served as its Chief Technical Officer and Senior Vice-President – Engineering from November 2011 to October 2014. From June 2008 to October 2011, He has also served as Vice-President – Engineering at Stion Corp of San Jose, California, a maker of nanostructure-based CIGS (copper indium gallium sulphur-diselenide) thin-film photovoltaic panels and as the Vice President – Engineering at Day Star Technologies Inc. from June 2001 to June 2008.

 

Karlheinz Strobl

 

Dr. Karlheinz Strobl has been the Vice President of Business Development since October 2007. From 1997 to 2007, he was the founder and President of eele Laboratories, LLC, a technology and manufacturing solutions development company for a novel Light Engine for the video and data projection display market. Dr. Strobl holds over 14 patents and earned an MBA from Boston University, a PhD from the University of Innsbruck and an MS from both the University of Innsbruck and the University of Padova. He has also worked at the Max PlankPlanck Institute and at Los Alamos National Laboratory.

 

William S. Linss

William S. Linss is the Vice President, Operations for the CVD/First Nano Division of CVD. In addition to managing daily engineering and production operations, Bill is instrumental in expanding the company’s technology capabilities, developing new products and positioning CVD for growth. Prior to his promotion in 2013, Bill was the Division Manager for the CVD/First Nano Division since 2005. Bill has worked in semiconductor manufacturing and chemical vapor deposition for 25 years. From 1980 through 1988 Bill worked at Standard Microsystems Corp. in Hauppauge, NY, advancing to Equipment Engineering Manager with all capital equipment responsibilities for SMC’s MOS/VLSIC manufacturing. Bill was employed by CVD from 1988 through 1994, advancing through various positions as Electrical Systems Designer, Field Service Engineer and Production Manager. From 1994 through 2001 Bill served as a Software Quality Assurance (SQA) Manager with Otari Corporation, at their Long Island pro-audio R&D office; and later with AP Engines in Sacramento, CA, a Cable TV billing solutions start-up.  In 2001, Bill re-joined CVD to head the newly acquired Research International Division for SMT reflow oven manufacturing, which then resulted in CVD’s acquisition of the Conceptronic product line.

Kevin R. Collins

 

Prior to his appointment as Vice President and General Manager-SDC Division, Mr. Collins served as the General Manager of CVD’s SDC Division since 1999. From 1990 to 1999 he was employed by Stainless Design Corp. as Manager of Field Operations and Product Development Advisor. Mr. Collins attended Columbia University School of Engineering and Applied Science. 

 


Emmanuel Lakios

 

Mr. Lakios has over thirty (30) years of experience serving the semiconductor, data storage and optical device industries and is the holder of several patents in the field of process equipment and device structure. From 2015 until earlier this year, Mr. Lakios was the President and Chief Executive Officer at Sensor Electronic Technology, Inc., overseeing that company’s transition from R&D to a leading global commercial UV LED supplier. From 2003 to 2011 he was the Executive Vice President of Field Operations and President and Chief Operating Officer at Imago Scientific, bringing it from pre-revenue to a commercial leadership position in the 3D atomic scale tomography field. Mr. Lakios was previously employed at Veeco Instruments Inc. from 1984 until 2003, where he held several positions, including President of the Process Equipment Group and Executive Vice President of Field Operations. He has been involved in several acquisitions and numerous product line launches. He received his BE in Mechanical Engineering with focus in Material Science from SUNY Stony Brook in 1984.

 


Code Of Ethics

 

We have adopted a Corporate Code of Conduct and Ethics that applies to our employees, senior management and Board of Directors, including the Chief Executive Officer and Chief Financial Officer. The Corporate Code of Conduct and Ethics is available on our website,http://www.cvdequipment.com, by clicking on “About Us” and then clicking on “Corporate Overview.”

 

Audit Committee

 

Our Board of Directors has an Audit Committee that currently consists of, Lawrence J. Waldman, Chairman, Conrad J. Gunther, Lawrence J. Waldman and Raymond A. Nielsen.Nielsen and Dr. Robert M. Brill. During the fiscal year ended December 31, 2016,2018, the Audit Committee held four meetings. Pursuant to the Audit Committee Charter, the Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the work of any independent registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for us, and each such independent auditor shall report directly to the Committee. The Audit Committee also reviews with management and the independent auditors, our annual audited financial statements (including the disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”), the scope and results of annual audits and the audit and non-audit fees of the independent registered public accounting firm. Furthermore, the Audit Committee reviews the adequacy of our internal control procedures, the structure of our financial organization and the implementation of our financial and accounting policies. Messrs. Gunther, Waldman, Nielsen and NielsenBrill are “independent” under the requirements of the NASDAQ Stock Market.

 

The Board of Directors has determined that each of Messrs. Gunther and Waldman is an “audit committee financial expert” as that term is defined in the rules and regulations of the Securities and Exchange Commission.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

The rules of the Securities and Exchange Commission require us to disclose late filings of reports of stock ownership and changes in stock ownership by our directors, officers and ten percent shareholders. To our knowledge, based solely on our review of (a) the copies of such reports and amendments thereto furnished to us and (b) written representations that no other reports were required, during our fiscal year ended December 31, 2016,2018, all of the filings for our officers, directors and ten percent shareholders were made on a timely basis with the following exceptions: Lawrence Firestone, a former director of the Company, filed two late Form4’s; Bruce Swan, a former director of the Company, filed two late Form 4’s;except for Conrad J. Gunther, filed two late Form 4’s; Lawrence Waldman filed one late Form 3; and Raymond A. Nielsen who inadvertently failed to timely file a Form 4, by one lateday, showing one transaction and Robert M. Brill, who failed to timely file his Form 3.3 by one day.

 


Item 11.

Executive Compensation.

 

Item 11.     Executive Compensation.

Summary Compensation Table 

 

The following table sets forth the compensation of our chief executive officer and chief financial officer, and our “named executive officers,” for the years ended December 31, 20162018 and 2015.2017.

 

Name and
principal position

Year

 

Salary ($)

  

Bonus ($)

  

Option

Awards ($)

  

Stock

Awards ($)

  

All Other Compensation

  

Total ($)

 
            (1)    (1)          
                          

Leonard A. Rosenbaum

2016

  302,742   20,000   -   37,949   -   360,691 

President and ChiefExecutive Officer

2015  302,742   -   -       -   302,742 
                          

Glen R. Charles

2016

  163,942   15,000   -   28,469       192,411 
Secretary and Chief Financial Officer2015  163,942   -   -   -       163,942 
                          

Steven Aragon

2016

  193,462   15,000       53,469       218,459 

Chief Operating Officer

2015

  193,462       -   24,997       218,459 
                          

Martin J. Teitelbaum

2016

  266,126   15,000   -   28,469       309,595 

General Counsel andAssistant Secretary

2015

  261,968   -   -   48,040       310,008 

Name and principal position

 

Year

 

Salary ($)

  

Bonus ($)

  

Option

Awards ($)

  

Stock

Awards ($)

  

All Other

Compensation

  

Total

($)

 
            (1)  (1)         

Leonard A. Rosenbaum President and

 

2018

  314,008   -   -   21,912   11,923(2)   347,843 
Chief Executive Officer 2017  302,742   22,500   -   21,936   197,948(2)   545,126 
                           

Glen R. Charles (3)

Secretary and Chief Financial

 

2018

  165,481   -   -   21,912   9,519(2)   196,912 
Officer 

2017

  157,981   20,000   -   21,936   -   199,917 
                           

Steven Aragon

 

2018

  185,866   -   -   46,912   7,115(2)   239,893 
Chief Operating Officer 

2017

  181,731   20,000   -   46,936   -   248,667 
                           

Martin J. Teitelbaum

General Counsel and Assistant

 

2018

  277,170   -   -   21,912   -   299,082 
Secretary 

2017

  265,074   20,000   -   21,936   -   307,010 

 

(1)

Amounts shown do not reflect compensation actually received by the named executiveofficer. Instead, the amounts shown reflect the total remaining compensation on restricted stock and option awards granted, that have not previously been shown, as determined pursuant to ASC 718. The assumptions used to calculate the value of stock and option awards are set forth under Note 11 of the Notes to Consolidated Financial Statements. This column represents the grant date fair value of the awards as calculated in accordance with FASB ASC 718 (Stock Compensation). Pursuant to SEC rule changes effective February 28, 2010, we are required to reflect the total grant date fair values of the option grants in the year of grant, rather than the portion of this amount that was recognized for financial statement reporting purposes in a given fiscal year which was required under the prior SEC rules, resulting in a change to the amounts reported in prior Annual Reports, which was valued utilizing the grant date fair value in the year granted.

(2)

Represents payment for accrued and unused vacation time.

(3)

Glen Charles’ last day of employment with the company was March 1, 2019. Effective March 4, 2019, Thomas McNeill was appointed CFO, Secretary and Treasurer.

 


Employment Agreements and Potential Payments Upon Termination or Change in Control

 

There are no arrangements for compensation of directors and there are no employment contracts between the company and its directors or any change in control arrangements.

 


Outstanding Equity Awards atDecember 31, 20162018

 

The following table sets forth the outstanding equity awards held by our named executive officers as of December 31, 2016.2018.

 

              

OPTION

AWARDS

  

STOCK AWARDS

 
  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

 

Name

 

 

Number of

Securities

Underlying

Options

Exercisable

(#)

  

 

Number of

Securities

Options

Unexercisable

(#)

  

Exercise

Price

($)

  

Option

Expiration

Date

  

Number of

shares or

units of stock

that have not

Vested

(#)

  

Market

Value of

shares or

units of stock

that have not

Vested

($)

  

Equity Incentive

Plan Awards:

Number of

unearned shares

or units that have

not vested

(#)

  

Equity Incentive

Plan Awards:

Market or payout

value of

unearned shares

or units

that have

not vested

($)

 
                                 

Leonard ARosenbaum

  24,000   -   3.65  

12/12/2017

   -   -   4,347 (1)   37,732 

 

                                
                                 

Steven Aragon

  100,000   100,000   11.17   Various (6)           3,261 (2)  28,305 
                                 

Glen R. Charles

  -   -   -   -   -   -   6,811 (3)  59,119 
                           3,261 (2)  28,305 
                                 

Karlheinz Strobl

  -   -   -   -   -   -   6,009 (4)  52,158 
                           2,826 (5)  24,530 
                                 

Martin J.Teitelbaum

  -   -   -  

12/12/2017

   4,000   40,320   3,261 (2)  28,305 

 

  5,310   -   4.25  

1/15/2020

   -   -   -   - 
   1,400   -   7.90  

1/15/2021

   -   -   -   - 


  

OPTION AWARDS

STOCK AWARDS

 

Name

 

Number of

Securities

Underlying

Options

Exercisable

  

Number of

Securities

Options

Unexercisable

  

Exercise

Price

 

Option

Expiration

Date

Number

of

shares

or units

of stock

that

have

not

vested

Market

value of

shares

or units

of stock

that

have not

vested

 

Equity

Incentive Plan

Awards:

Number of

unearned

shares or units

that not vested

  

Equity

Incentive

Plan

Awards:

Market or

payout value

of unearned

shares or

units that

have not

vested

 

Leonard A. Rosenbaum

  -              3,049 (1) $10,824 
                        

Steven Aragon

  100,000   100,000  $11.17 

Various (3)

  2,687 (2) $9,539 
                        

Glen R. Charles (4)

  -              2,687 (4) $9,539 
                        

Martin J. Teitelbaum

  5,310      $4.25 

1/15/2020

  2,687 (2) $9,539 
   1,400      $7.90 

1/15/2021

          

 

 

(1)

Restricted stock units vest as to 1,449 shares respectively eachon July 1, 2017 through 2019.2019 and 800 shares respectively on October 1, 2019 and October 1, 2020.

 

(2)

Restricted stock units vest as to 1,087 shares respectively eachon July 1, 2017 through 2019.2019 and 800 shares respectively on October 1, 2019 and October 1, 2020.

 

(3)

Restricted stock units vest as to 3,205 shares and 3,606 shares respectively each on November 15, 2017 and November 15, 2018.

(4)

Restricted stock units vest as to 2,804 shares and 3,205 shares respectively each on November 15, 2017 and November 15, 2018.

(5)

Restricted stock units vest as to 942 shares respectively each July1, 2017 through 2019.

(6)

Options vest as to 20,000 shares on October 20 each year consecutively through 2019 and expire 10 years from date of issuance.

(4)

Glen Charles resigned as CFO of the company as of the close of business on March 1, 2019. Pursuant to a separation agreement, all Options became fully vested and exercisable. In addition, Mr. Charles received a payment of $25,000 in connection with the separation agreement. Effective March 4, 2019, Thomas McNeill was appointed CFO, Secretary and Treasurer.

 

20162018 Director Compensation

 

The following table sets forth a summary of the compensation we paid to our non-employee directors in 2016.2018.

 

 

Fees Earned or

  Option    

Restricted

Stock

     

Name

 

Fees Earned or

Paid in Cash

  

Option Awards (1)

  

Restricted Stock

Awards (1)

  

Total

  

Paid in Cash

  

Awards (1)

    Awards (1)  

Total

 

Conrad J. Gunther

  23,000   -   30,991   53,991  $23,000   -  $30,856  $53,856 

Bruce T. Swan (2)

  15,000   -   22,728   37,728 

Kelly S. Walters (3)

  20,000   -   30,991   50,991 

Lawrence D. Firestone (4)

  15,000   -   22,728   37,728 

Lawrence J. Waldman

  5,000   -   7,227   12,227   20,000   -   30,856   50,856 

Raymond A. Nielsen

  5,000   -   7,227   12,227   20,000   -   30,856   50,856 

Dr. Robert Brill

  15,000       23,218   38,218 

 

 

(1)

Amounts shown do not necessarily reflect compensation actually received by the named director. Instead, the amounts shown are the compensation costs recognized by CVD in fiscal 20162018 for awards as determined pursuant to ASC 718. The assumptions used to calculate the value of option awards are set forth under Note 12 of the Notes to Consolidated Financial Statements.

(2)

On August 27, 2016, Bruce T. Swan notified the Board of Directors of his retirement effective September 30, 2016

(3)

On October 5, 2016, Kelly S. Walters notified the Board of Directors that would not run for re-election at the next Annual Meeting of Shareholders held on December 9, 2016.

(4)

Lawrence D. Firestone resigned as a director effective October 5, 2016.


 

At a meeting of the Stock Option and Compensation Committee on November 19, 2008, a director compensation plan was adopted applicable to all nonemployee directors, providing for annual compensation in the sum of approximately forty thousand dollars ($40,000) to be payable to each director in a combination of cash, restricted stock grant and stock options. In 2011, the Committee amended the annual compensation of non-employee directors beginning in 2012 to include a combination of a cash and stock grant. On May 9, 2016, the Board of Directors adopted a Director Compensation Plan for all non-employee directors, which retroactively from January 1, 2016, provided for annual compensation of approximately fifty thousand dollars ($50,000) to each non-employee director in a combination of 40% cash and 60% stock grant.

 


On December 14, 2018, the Board of Directors approved a new Director Compensation Plan for all non-employee directors which is effective January 1, 2019 and provides for additional compensation to Committee Chairs as well as for the Independent Lead Director and ranging from amounts from $5,000 to $30,000 in a combination of cash and stock grants. 

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management andRelated Stockholder Matters.

 

The following table sets forth, as of March 22, 2017,2019, information regarding the beneficial ownership of our common stock by (a) each person who is known to us to be the owner of more than five percent (5%) of our common stock, (b) each of our directors, (c) each of the named executive officers, and (d) all directors and executive officers and executive employees as a group. For purposes of the table, a person or group of persons is deemed to have beneficial ownership of any shares that such person has the right to acquire within 60 days of March 22, 2017.2019.

 

Name and Address of Beneficial Owner(1)

 

Amounts and Nature of

Beneficial Ownership (2)

  

Percent of

Class (%)

 
         

Leonard A. Rosenbaum

  821,870 (3)   13.3 

Martin J. Teitelbaum

  79,046 (4)   1.3 

Conrad J. Gunther

  59,963 (5)   * 

Lawrence J. Waldman

  1,675 (6)   * 

Raymond A. Nielsen

  1,675 (6)   * 

Glen R. Charles

  17,685 (7)   * 

Steven Aragon

  43,976 (8)   * 

Karlheinz Strobl

  117,233 (9)   1.9 

William S. Linss

  9,819 (10)   * 

Kevin R. Collins

  66,814 (11)   1.0 

All directors and executive officers and executive employees as a group (ten (10) persons)

  1,204,606   19.4 

Name and Address of Beneficial Owner(1)

 

Amounts and

Nature of

Beneficial

Ownership (2)

  

Percent

of

Class

(%)

 
         

Leonard A. Rosenbaum

  830,568 (3)  12.7 

Martin J. Teitelbaum

  77,020 (4)  1.2 

Conrad J. Gunther

  62,188 (5)  1.0 

Lawrence J. Waldman

  9,650 (6)  * 

Raymond A. Nielsen

  8,900 (7)  * 

Dr. Robert M. Brill

  4,875 (8)  * 

Thomas McNeill

  - (9)  * 

Steven Aragon

  92,449 (10)  1.4 

Karlheinz Strobl

  121,779 (11)  1.9 

Kevin R. Collins

  89,556 (12)  1.4 

Emmanuel Lakios

  48,180 (13)  * 

All directors and executive officers and executive employees as a group (eleven) persons)

  1,345,165   20.6 

 

*Less  *Less than 1% of the outstanding common stock or less than 1% of the voting power

 


(1)

The address of Messrs. Rosenbaum, Teitelbaum, Gunther, Waldman, Nielsen, Charles,Brill, McNeill, Strobl, Linss, CollinsAragon and AragonLakios is c/o CVD Equipment Corporation, 355 South Technology Drive, Central Islip, New York 11722. The address of Mr. Collins is c/o Stainless Design Concepts, 1117 Old Kings Highway, Saugerties, NY 12477.

  

(2)

(2)

All of such shares are owned directly with sole voting and investment power, unless otherwise noted below.

  

(3)

(3)Includes options to purchase 24,000 shares of our common stock.

Does not include 4,3473,049 shares of unvested restricted stock units.

 

(4)

Includes 2,000 shares held by Mr. Teitelbaum’s wife as to which beneficial ownership thereof is disclaimed by Mr. Teitelbaum. Also includesDoes not include 2,687 shares of unvested restricted common stock units.

(5)

Does not include options to purchase 6,71015,000 shares of our common stock. Does not include 3,2616,300 shares of unvested restricted common stock.

(6)

Does not include options to purchase 15,000 shares of our common stock. Does not include 8,500 shares of unvested restricted common stock.

(7)

Does not include options to purchase 15,000 shares of our common stock. Does not include 6,300 shares of unvested restricted common stock.

(8)

Does not include options to purchase 15,000 shares of our common stock. Does not include 6,825 shares of unvested restricted common stock.

(9)

Does not include 10,000 shares of unvested restricted common stock units.

 

(5)(10)

IncludesDoes not include options to purchase 18,11020,000 shares of our common stock. Does not include 2,325 shares of unvested restricted common stock.


(6)

 Does not include 2,325 shares of unvested restricted common stock.

(7)

 Does not include 10,0722,687 shares of unvested restricted common stock units.

 

(8)(11)

Does not include 6,689 shares of unvested restricted common stock units.

(12)

Does not include 1,304 shares of unvested restricted common stock units.

(13)

Does not include unvested options to purchase 60,000 shares of our common stock. Does not include 3,261 shares of unvested restricted common stock units.

(9)

 Does not include 8,835 shares of unvested restricted common stock units.

(10)

 Does not include 16,150 shares of unvested restricted common stock units.

(11)

 Does not include 10,7231,200 shares of unvested restricted common stock units.

 

See Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities under the heading “Equity Compensation Plan Information” for information regarding our securities authorized for issuance under equity compensation plans.


Item 13.

Certain Relationships and Related Transactions, and Director Independence.

 

Item 13.     Certain Relationships and Related Transactions, and Director Independence.

Transactions with related persons, promoters and certain control persons.

 

None.

 

Director Independence

 

The current members of our Board of Directors are Leonard A. Rosenbaum, Martin J. Teitelbaum, Conrad J. Gunther, Lawrence J. Waldman and Raymond A. Nielsen. Messrs. Gunther, Waldman, Nielsen and NielsenDr. Brill have been determined to be “independent” as defined under Rule 4200 of the Nasdaq Stock Market.

 


Item 14.Principal Accountant Fees and Services.

Principal Accountant Fees and Services.

 

The following presents fees for professional audit services rendered by MSPC, Certified Public Accountants and Advisors, A Professional Corporation (“MSPC”), for the audit of our financial statements for the years ended December 31, 20162018 and December 31, 2015.2017.

 

 

Year Ended

  

Year Ended

  

2018

  

2017

 
 

December 31, 2016

  

December 31, 2015

         

Audit Fees

 $132,000  $132,000  $161,511  $138,000 

Audit-Related Fees (1)

  10,000   10,000   5,000   10,000 

Tax Fees

  --   -- 

All Other Fees

  --   --   -   9,000 

Total Fees

 $142,000  $142,000  $166,511  $157,000 

 

Audit-Related Fees

 

Audit-related fees consisted of the audit of the Company’s Defined Contribution Plan 401(k) for the years 20162018 and 20152017 by MSPC.

 

Tax Fees

Tax fees consisted of the preparation of the tax returns by Baker, Tilley, Virchow Krause, LLP. The aggregate fees billed in 2016 were $20,000. The aggregate fees billed in 2015 were $19,500.

All Other Fees

 

We did not incur any other fees in 2016.2018. In 2015,2017, the firm of Baker, Tilley, Virchow and Krause, LLP was retained to prepare a comprehensive appraisal report to determine the fair value of certain stock options granted to an officer of the corporation for a fee of $10,000.$9,000.

 

Audit Committee Approval

 

The engagement of the Company’s independent registered public accounting firm is pre-approved by the Company’s Audit Committee. The Audit Committee pre-approves all fees billed and all services rendered by the Company’s independent registered public accounting firm.

 


 

PART IV

 

Item 15.              Exhibits, Financial Statement Schedules

 

3.1

Certificate of Incorporation dated October 12, 1982 of Certificate of Corporation incorporated herein by reference to Exhibit 3.1 to our Form S-1 filed on July 3, 2007.

 

3.2

Certificate of Amendment dated April 25, 1985 of Certificate of Corporation incorporated herein by reference to Exhibit 3.1 to our Form S-1 filed on July 3, 2007.

 

3.3

Certificate of Amendment dated August 12, 1985 of Certificate of Corporation incorporated herein by reference to Exhibit 3.1 to our Form S-1 filed on July 3, 2007.

 

3.4

Certificate of Amendment of the Certificate of Incorporation, dated December 9, 2016 incorporated herein by reference to Exhibit 3.1 on our Current Report on Form 8-K filed on December 14, 2016.

 

3.5

Bylaws of CVD Equipment Corporation, incorporated herein by reference to Exhibit 3.2 to our Form S-1 filed on July 3, 2007.

 

3.6

Amended and restated By-laws of CVD Equipment Corporation, dated as of October 5, 2016, incorporated herein by reference to Exhibit 3.5 to our Current Report on Form 8-K filed on October 11, 2016.

 

10.1

Form of Non-Qualified Stock Option Agreement with certain directors, officers and employees of CVD Equipment Corporation incorporated herein by reference to our Registration Statement on Form S-8 No. 33-30501, filed August 15, 1989.*

10.2

Purchase Agreement relating to a 22,000 square foot facility from Kidco Realty incorporated herein by reference to our Form 8-K filed on December 31, 1998.

10.3

CVD Equipment Corporation 2001 Stock Option Plan incorporated herein by reference to Exhibit 3.110.2 to our Form S-1 filed on July 3, 2007.*

 

10.410.2

Form of Non-Qualified Stock Option Agreement incorporated herein by reference to Exhibit 3.1 to our Form 10-KSB filed on March 26, 2007.*

 

10.510.3

1989 Key Employee Stock Option Plan incorporated herein by reference to Amendment No. 1 to our Form S-1 filed on August 7, 2007.

10.6

CVD Equipment Corporation 2007 Share Incentive Plan incorporated herein by reference to our Schedule 14A filed November 5, 2007.

 

10.710.4

Lease Agreement, dated February 9, 2012, by and between FAE Holdings 411519R, LLC and the Company incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

 

10.810.5

Assignment Agreement, dated February 9, 2012, by and between FAE Holdings 411519R, LLC and the Company incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

 


10.910.6

Qualified Exchange Accommodation Agreement, dated February 9, 2012, by and between FAE Holdings 411519R, LLC and the Company incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

 

10.1010.7

Joint and Several Hazardous Material Guaranty and Indemnification Agreement, dated March 15, 2012, by and between FAE Holdings 411519R, LLC and the Company incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

 

10.1110.8

Assignment of Leases and Rents, dated March 15, 2012, by and among FAE Holdings 411519R, LLC, the Town of Islip Industrial Development Agency and HSBC Bank USA, National Association incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

 


10.1210.9

Amended and Restated Fee and Leasehold Mortgage, dated March 15, 2012, by and among FAE Holdings 411519R, LLC, the Town of Islip Industrial Development Agency and HSBC Bank USA, National Association incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.2012

 

10.1310.10

Amended and Restated Note, dated March 15, 2012, by and among FAE Holdings 411519R, LLC, the Town of Islip Industrial Development Agency and HSBC Bank USA, National Association incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

 

10.1410.11

Note and Mortgage Assumption Agreement, dated March 15, 2012, by and among FAE Holdings 411519R, LLC, the Town of Islip Industrial Development Agency and HSBC Bank USA, National Association incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

 

10.1510.12

Guaranty of Payment, dated March 15, 2012, by the Company incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012.

10.13

Agreement of Purchase and sale dated October 24, 2017, by and between the Company and Creative Bath Products, Inc., incorporated by reference to the Company’s Annual Report on Form 10-K filed with Commission on April 2, 2018.

10.14

Asset Purchase Agreement, dated October 31, 2017, by and between MesoScribe Technologies, Inc. and CVD MesoScribe Technologies Corporation, incorporated by reference from the Company’s Current Report on Form 8-K filed on November 6, 2017.

10.15

ADA and Environmental Indemnity Agreement by 555 N Research Corporation and CVD Equipment Corporation dated November 30, 2017, incorporated by reference to the Company’s Annual Report on Form 10-K filed with Commission on April 2, 2018.

 

10.16

Credit AgreementAssignment of Leases and Rents dated August 5, 2011,November 30, 2017 by and between CVD Equipment555 N Research Corporation and HSBC Bank USA, National Association, incorporated by reference to ourthe Company’s Annual Report on form 10-QForm 10-K filed with Commission on November 14, 2011.April 2, 2018.

 

10.17

Contract of Sale, dated May 31, 2012,Unlimited Guaranty between CVD Equipment Corporation and Glomel LLCHSBC Bank USA, National Association dated November 30, 2017, incorporated by reference to ourthe Company’s Annual Report on Form 10-Q10-K filed with Commission on August 14, 2012.April 2, 2018.

 

10.18

Amendment No. 3Town of Islip Industrial Development Agency and waiver to CreditCVD Equipment Corporation, Agency Compliance Agreement dated September 4, 2015as of November 1, 2017, incorporated by reference to the Company’s CurrentAnnual Report on Form 8-K10-K filed with the Commission on September 10, 2015.April 2, 2018.

 

21.110.19

ListTown of Subsidiaries.Islip Industrial Development Agency and CVD Equipment Corporation Amended and Restated Agency Compliance Agreement dated November 30, 2017, incorporated by reference to the Company’s Annual Report on Form 10-K filed with Commission on April 2, 2018.

 

23.110.20

ConsentFee and Leasehold Mortgage and Security Agreement from town of MSPC, Certified Public AccountantsIslip Industrial Development Agency and Advisors, A Professional555 N Research Corporation (S-1).to HSBC Bank USA, national Association, incorporated by reference to the Company’s Annual Report on Form 10-K filed with Commission on April 2, 2018.

 


 

23.210.21

Town of Islip Industrial Development Agency and FAE Holdings 411519R,LLC Amended and Restated Lease and Project Agreement dated as of November 1, 2017, incorporated by reference to the Company’s Annual Report on Form 10-K filed with Commission on April 2, 2018.

10.22

Amended and Restated Note by and between 555 N Research Corporation and HSBC Bank USA, National Association, incorporated by reference to the Company’s Annual Report on Form 10-K filed with Commission on April 2, 2018.

21.1**

List of Subsidiaries.

23.1**

Consent of MSPC, Certified Public Accountants and Advisors, A Professional Corporation (S-8).

 

23.323.2**

Consent of MSPC, Certified Public Accountants and Advisors, A Professional Corporation (S-8).

 

23.4

23.3**

Consent of MSPC, Certified Public Accountants and Advisors, A ProfessionalProfession Corporation (S-3).

(S-8)

 

31.131.1**

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.

 

31.231.2**

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.

 

32.132.1**

Section 1350 Certification of Principal Executive Officer.

 

32.2

32.2**

Section 1350 Certification of Principal Financial Officer.

 

101.INS*** XBRL Instance

 

101.SCH*** XBRL Taxonomy Extension Schema

 

101.CAL*** XBRL Taxonomy Extension Calculation

 

101.DEF*** XBRL Taxonomy Extension Definition

 

101.LAB*** XBRL Taxonomy Extension Labels

 

101.PRE*** XBRL Taxonomy Extension Presentation


* Management contract or compensatory plan or arrangement required

 

** Filed herewith

*** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, , as amended, and otherwise is not subject to liability under these sections.

 


 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

DATE:   April 1, 2019

DATE:March 30, 2017

CVD EQUIPMENT CORPORATION

 

    By: /s/ Leonard A. Rosenbaum

Name:  Leonard A. Rosenbaum

Title:    President and Chief Executive Officer

 

   By:/s/ Glen R. CharlesThomas McNeill

Name:  Glen R. CharlesThomas McNeill

Title:    Chief Financial Officer and Secretary

             Principal Financial and Accounting Officer

 

 

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated below.

 

NAME

POSITION

DATE

   

/s/ Leonard A Rosenbaum

President, Chief Executive Officer and Director

March 30, 20174/1/2019

Leonard A. Rosenbaum

(Principal Executive Officer)

/s/ Martin J. Teitelbaum

Director, General Counsel and Assistant Secretary

4/1/2019

Martin J. Teitelbaum

  
   

/s/Martin J. Teitelbaum

Director, General Counsel and Assistant Secretary

March 30, 2017

Martin J. Teitelbaum

/s/Conrad J. Gunther

Director

March 30, 20174/1/2019

Conrad J. Gunther

  
   

/s/Lawrence J. Waldman

Director

March 30, 20174/1/2019

Lawrence J. Waldman

  
   

/s/Raymond A. Nielsen

Director

March 30, 20174/1/2019

Raymond A. Nielsen

  

/s/ Dr. Robert M. Brill

Director

4/1/2019

Dr. Robert M. Brill

  

 


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARies

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

 

 

 

Page No.

  

Report of Independent Registered Public Accounting Firm

F-1

  

Financial Statements:

 
  

Consolidated Balance Sheets as of December 31, 20162018 and 20152017

F-2

  

Consolidated Statements of Operations for the years ended December 31, 20162018 and 20152017

F-3

  

Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 20162018 and 20152017

F-4

  

Consolidated Statements of Cash Flows for the years ended December 31, 20162018 and 20152017

F-5

  

Notes to Consolidated Financial Statements

F-6

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

To the Board of Directors and Stockholders

CVD Equipment Corporation and Subsidiaries

 Central Islip, New York

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of CVD Equipment Corporation and Subsidiaries (the "Company") as of December 31, 20162018 and 2015,2017, and the related consolidated statements of operations, changes in stockholders' equity, and cash flows for each of the two years in the two-year period ended December 31, 2016. These consolidated financial statements are2018, and the responsibility of the Company's management. Our responsibility isrelated notes (collectively referred to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

statements). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of CVD Equipment Corporation and Subsidiaries as of December 31, 20162018 and 2015,2017, and the results of their operations and their cash flows for each of the years in the two-year period ended December 31, 2016,2018, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinions.

/s/ MSPC

Certified Public Accountants and Advisors,

A Professional Corporation

We have served as the Company’s auditor since 2004.

/s/MSPC

Certified Public Accountants and Advisors, 

A Professional Corporation 

 

New York, New York

March 30,April 1, 2019


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

As of December 31, 2018 and 2017

  

2018

  

2017

 

ASSETS

        

Current Assets

        

Cash and cash equivalents

 $11,439,361  $14,210,909 

Accounts receivable, net

  4,065,220   2,058,617 

Contract assets

  1,357,797   8,397,024 

Inventories, net

  1,861,873   2,965,623 

Other current assets

  723,204   167,425 

Total Current Assets

  19,447,455   27,799,598 
         

Property, plant and equipment, net

  30,402,558   28,839,457 
         

Deferred income taxes

  2,104,414   1,609,186 

Other assets

  64,583   67,847 

Intangible assets, net

  495,552   662,162 

Total Assets

 $52,514,562  $58,978,250 
         
         

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current Liabilities

        

Accounts payable

 $713,194  $1,174,968 

Accrued expenses

  1,503,309   2,738,373 

Current maturities of long-term debt

  857,590   747,324 

Contract Liabilities

  536,524   466,313 

Deferred revenue

  459,899   291,953 

Total Current Liabilities

  4,070,516   5,418,931 
         

Long-term acquisition related contingent payments

  -   200,000 

Long-term debt, net of current portion

  12,051,720   12,705,683 

Total Long-Term Liabilities

  12,051,720   12,905,683 
         

Total Liabilities

  16,122,236   18,324,614 
         

Commitments and contingencies

  -   - 
         

Stockholders’ Equity:

        
         

Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,535,888 at December 31, 2018 and 6,458,714 at December 31, 2017

  65,358   64,587 

Additional paid-in capital

  26,148,256   25,209,316 

Retained earnings

  10,178,712   15,379,733 

Total Stockholders’ Equity

  36,392,326   40,653,636 
         

Total Liabilities and Stockholders’ Equity

 $52,514,562  $58,978,250 

 

The accompanying notes are an integral part of the consolidated financial statements

 



 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Balance SheetsStatements of Operations

As ofYears ended December 31,2018and 2017

 

  

2016

  

2015

 

ASSETS

        

Current Assets

        

Cash and cash equivalents

 $21,677,186  $13,073,331 

Accounts receivable, net

  607,522   3,091,251 

Costs and estimated earnings in excess of billings on contracts in progress

  2,596,518   4,635,018 

Inventories, net

  3,286,539   2,986,430 

Restricted cash

  --   200,000 

Deferred income taxes

  428,355   398,009 

Other current assets

  235,537   167,056 

Total Current Assets

  28,831,657   24,551,095 
         
         

Property, plant and equipment, net

  14,344,924   14,793,923 

Construction in progress

  94,058   33,306 
         

Deferred income taxes

  2,011,979   1,606,830 

Other assets

  68,450   86,215 

Intangible assets, net

  253,624   60,335 

Total Assets

 $45,604,692  $41,131,704 
         
         

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current Liabilities

        

Accounts payable

 $743,132  $308,004 

Accrued expenses

  1,942,818   3,445,880 

Current maturities of long-term debt

  300,000   580,000 

Billings in excess of costs and estimatedearnings on contracts in progress

  5,262,339   --- 

Deferred revenue

  77,633   307,683 

Total Current Liabilities

  8,325,922   4,641,567 
         

Long-term debt, net of current portion

  2,965,508   3,265,508 

Total Liabilities

  11,291,430   7,907,075 
         

Commitments and Contingencies (Note 16)

  -   - 
         

Stockholders’ Equity:

        

Common stock - $0.01 par value – 20,000,000 shares authorized at December 31, 2016 and 10,000,000 authorized at December 31, 2015: issued and outstanding 6,346,590 at December 31, 2016 and 6,198,135 shares at December 31, 2015

  63,466   61,981 

Additional paid-in capital

  24,131,474   22,895,202 

Retained earnings

  10,118,322   10,267,446 

Total Stockholders’ Equity

  34,313,262   33,224,629 
         

Total Liabilities and Stockholders’ Equity

 $45,604,692  $41,131,704 
  

2018

  

2017

 
         

Revenue

 $24,334,331  $41,128,639 
         

Cost of revenue

  19,156,201   23,528,427 
         

Gross profit

  5,178,130   17,600,212 
         

Operating expenses

        

Research and development

  606,618   437,157 

Selling and shipping

  1,620,089   1,404,938 

General and administrative

  8,205,942   8,539,244 
         

Total operating expenses

  10,432,649   10,381,339 
         

Operating (loss) income

  (5,254,519)  7,218,873 
         

Other income (expense):

        

Interest income

  159,953   80,518 

Interest expense

  (463,017)  (106,280)

Other income (expense)

  -   2,244 

Total other expense, net

  (303,064)  (23,518)
         

(Loss) income before income tax

  (5,557,583)  7,195,355 
         

Income tax (benefit) expense

  (356,562)  1,933,944 
         

Net (loss) income

 $(5,201,021) $5,261,411 
         
         

Basic (loss) income per common share

 $(0.80) $0.83 

Diluted (loss) income per common share

 $(0.80) $0.82 
         

Weighted average common shares Outstanding-basic

  6,495,597   6,375,848 
         

Weighted average common shares Outstanding-diluted

  6,495,597   6,387,464 

 

The accompanying notes are an integral part of the consolidated financial statements

 



 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements of Operations

Years ended December 31,Changes in Stockholders’ Equity

 

  

2016

  

2015

 
         

Revenue

 $20,955,347  $38,965,387 
         

Cost of revenue

  13,850,824   23,819,864 
         

Gross profit

  7,104,523   15,145,523 
         

Operating expenses

        

Research and development

  433,844   605,264 

Selling and shipping

  1,097,661   1,208,174 

General and administrative

  6,926,487   7,745,092 

Litigation settlement

  --   995,000 

Gain on settlement

  (628,905)  -- 
         

Total operating expenses

  7,829,087   10,553,530 
         

Operating (loss)/income

  (724,564)  4,591,993 
         

Other income (expense):

        

Interest income

  28,233   24,540 

Interest expense

  (79,861)  (92,101)

Other income/(expense)

  123,006   759 

Total other (expense)/income net

  71,378   (66,802)
         

(Loss)/income before income tax(benefit)/expense

  (653,186)  4,525,191 

Income tax (benefit)/expense

  (504,061)  1,320,195 
         

Net (loss)/income

 $(149,124) $3,204,996 
         
         

Basic (loss)/income per common share

 $(0.02) $0.52 

Diluted (loss)/income per common share

 $(0.02) $0.51 
         

Weighted average common shares

        

Outstanding-basic

  6,285,815   6,175,254 
         

Weighted average common shares

        

Outstanding-diluted

  6,285,815   6,283,307 
     Additional     Total 
  

Common Stock

  Paid In  Retained  Stockholders' 
  

Shares

  

Amount

  

Capital

  

Earnings

  

 Equity

 
                     

December 31, 2016

  6,346,590  $63,466  $24,131,474  $10,118,322  $34,313,262 
                     

Exercise of stock options

  36,800   368   145,852       146,220 
                     

Stock-based compensation

  75,324   753   931,990       932,743 
                     

Net income

              5,261,411   5,261,411 
                     

December 31, 2017

  6,458,714   64,587   25,209,316   15,379,733   40,653,636 
                     

Exercise of stock options

  -   -   -       - 
                     

Stock-based compensation

  77,174   771   938,940       939,711 
                     

Net loss

              (5,201,021)  (5,201,021)
                     

December 31, 2018

  6,535,888  $65,358  $26,148,256  $10,178,712  $36,392,326 

 

The accompanying notes are an integral part of the consolidated financial statements

 



 

CCVDVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements ofChanges inCash Flows

Years ended December 31,Stockholders’ Equity 2018 and 2017

 

          

Additional

      

Total

 
  

Common Stock

  

Paid-In

  

Retained

  

Stockholders’

 
  

Shares

  

Amount

  

Capital

  

Earnings

  

Equity

 
                     

Balance – January 1, 2015

  6,162,027  $61,620  $22,144,805  $7,062,450  $29,268,875 
                     

Exercise of stock options

  ---   ---   ---       --- 
                     

Stock-based compensation

  36,108   361   750,397       750,758 
                     

Net income

              3,204,996   3,204,996 
                     

Balance – December 31, 2015

  6,198,135   61,981   22,895,202   10,267,446   33,224,629 
                     

Exercise of stock options

  100.000   1,000   461,000       462,000 
                     

Stock-based compensation

  48,455   485   775,272       775,757 
                     

Net (loss)

              (149,124)  (149,124)
                     

Balance – December 31, 2016

  6,346,590  $63,466  $24,131,474  $10,118,332  $34,313,262 
  

2018

  

2017

 

Cash flows from operating activities:

        

Net (loss) income

 $(5,201,021) $5,261,411 

Adjustments to reconcile net (loss) income to net cash used in operating activities

        

Stock-based compensation

  939,711   932,743 

Depreciation and amortization

  1,141,161   867,277 

Deferred income tax benefit

  (495,228)  831,148 

Provision for inventory obsolescence

  135,819   606,856 

Provision for bad debts

  24,000   2,000 

Increase (decrease) in operating assets

        

Accounts receivable

  (2,030,603)  (1,453,094)

Contract assets

  7,039,227   (5,800,506)

Inventories

  967,931   (260,940)

Other current assets

  (555,779)  68,112 

Increase (decrease) in operating liabilities

        

Accounts payable

  (461,774)  431,836 

Accrued expenses

  (1,235,064)  795,552 

Contract liabilities

  70,211   (4,796,025)

Deferred revenue

  167,946   134,133 

Total adjustments

  5,707,558   (7,640,908)

Net cash provided (used in) by operating activities

  506,537   (2,379,497)
         

Cash flows from investing activities:

        

Capital expenditures

  (2,537,652)  (889,298)

Purchase of building

  -   (14,000,886)

Purchase of MesoScribe Technologies

  -   (419,813)

Other assets

  3,264   (10,503)

Net cash (used in) investing activities

  (2,534,388)  (15,320,500)
         

Cash flows from financing activities

        

Current maturities of long-term debt

  110,266   - 

Net proceeds from stock options exercised

  -   146,220 

Proceeds from mortgage payable

  -   10,387,500 

Payments of long-term debt

  (853,963)  (300,000)

Net cash (used in) provided by financing activities

  (743,697)  10,233,720 
         

Net decrease in cash and cash equivalents

  (2,771,548)  (7,466,277)
         

Cash and cash equivalents at beginning of year

  14,210,909   21,677,186 
         

Cash and cash equivalents at end of year

 $11,439,361  $14,210,909 
         

Supplemental disclosure of cash flow information:

        

Income taxes paid

 $472,542  $601,800 

Interest paid

 $463,850  $71,263 

 

The accompanying notes are an integral part of the consolidated financial statements

 


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements ofCash Flows

Years ended December 31,

  

2016

  

2015

 

Cash flows from operating activities:

        

Net (loss)/income

 $(149,124) $3,204,996 

Adjustments to reconcile net (loss)/income to net cash used in operating activities

        

Stock-based compensation

  775,757   750,758 

Depreciation and amortization

  813,657   826,529 

Deferred income tax benefit

  (435,495)  1,633,254 

Provision for doubtful accounts

  (16,395)  (30,826)

Increase/(decrease) in operating assets

        

Accounts receivable

  2,500,124   3,402,625 

Cost in excess of billings on contracts in progress

  2,038,500   (2,136,356)

Inventories, net

  (290,109)  1,855,628 

Other current assets

  (68,473)  27,700 

Increase/(decrease) in operating liabilities

        

Accounts payable

  435,129   (1,374,835)

Accrued expenses

  (1,503,062)  148,856 

Current maturities of long-term debt

  (280,000)  (140,000)

Billings in excess of costs and estimated earnings on contracts in progress

  5,262,339   (1,328,508)

Accrued litigation settlement

  ---   (4,925,000)

Deferred revenue

  (230,050)  (181,008)

Total adjustments

  9,001,922   (1,471,183)

Net cash provided by operating activities

  8,852,798   1,733,813 
         
Cash flows from investing activities:        

Restricted cash

  200,000   200,000 

Capital expenditures

  (112,493)  (248,305)

Purchase of assets Tantaline A/S

  (500,000)  --- 

Deposits

  1,550   960 

Net cash (used in) investing activities

  (410,943)  (47,345)
         

Cash flows from financing activities

        

Net proceeds from stock options exercised

  462,000   --- 

Payments of long-term debt

  (300,000)  (580,000)

Net cash provided by/(used in) financing activities

  162,000   (580,000)
         

Net increase in cash and cash equivalents

  8,603,855   1,106,468 
         

Cash and cash equivalents at beginning of year

  13,073,331   11,966,863 
         

Cash and cash equivalents at end of year

 $21,677,186  $13,073,331 
         
Supplemental disclosure of cash flow information:          
Income taxes paid $101,352   427,078 
Interest paid $79,861   92,101 

The accompanying notes are an integral part of the consolidated financial statements


CVD EQUIPMENT CORPORATION AND SUBSIDIARIESSUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

Note 1 – Business Description

 

CVD Equipment Corporation and its subsidiaries (the “Company”), a New York corporation, was organized and commenced operations in October 1982. Its principal business activities include the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used primarily to produce semiconductors and other electronic components. The Company engages in business throughout the United States and internationally.

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. In December 1998, a subsidiary, Stainless Design Concepts, Ltd., was formed as a New York Corporation. In April 1999, this subsidiary was merged into CVD Equipment Corporation. The Company has twofive wholly owned subsidiaries: CVD Materials Corporation, which provides marketing for our Application Laboratorymaterial coatings, process development support and process startup assistance through Tantaline ApS and CVD MesoScribe Technologies Corporation, FAE Holdings 411519R, LLC, a real estate holding company whose sole asset is its interest in the real estate and building housing our corporate headquarters.headquarters and 555 N Research Corporation whose sole asset is its interest in the real estate and building located at 555 North Research Place, Central Islip, NY. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the percentage-of-completioninput method, depreciation and amortization, valuation of inventories at the lower of cost or market; allowance for doubtful accounts receivable; valuation allowances for deferred tax assets, impairment considerations of long-lived assets and stock-based compensation and costs associated with product warranties.

Revenue Recognition

Product and service sales, including those based on time and materials type contracts, are recognized when persuasive evidence of an arrangement exists, product delivery has occurred or services have been rendered, pricing is fixed or determinable, and collection is reasonablycompensation.

 


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIESSUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

Note 2 - Summary of Significant Accounting Policies (continued)

Revenue Recognition

 

assured. Service sales, principally representing repair, maintenanceOn January 1, 2018, we adopted accounting standard ASC 606, Revenue from Contracts with Customers and engineering activitiesall the related amendments using the modified retrospective method for all customer contracts not yet completed as of the adoption date. The adoption of ASC 606 did not have a significant impact on our Consolidated Financial Statements and, as a result, comparisons of revenues and operating profits performance between periods are recognized overnot affected by the contractualadoption of this ASU. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period or as services are rendered.amounts were not adjusted.

 

RevenuesImpact to Previously Reported Results

(In thousands)

     

Adoption of

     
  

As Reported

  

ASC 606

  

As Adjusted

 

Costs and estimated earnings in excess of billings

 $8,397  $(8,397) $--- 

Contract assets

  ---   8,397   8,397 
             

Billings in excess of costs and estimated earnings

  466   (466)  --- 

Contract liabilities

  ---   466   466 

The Company designs, manufactures and sells custom chemical vapor deposition equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within three to eighteen months from commencement of order acceptance. The Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. Under this method, revenue arising from fixed price contracts areis recognized as work is performed based on the percentageratio of costs incurred to date to the total estimated costs at completion method, measured onof the basis of incurred costs to estimated total costs for each contract. This “cost to cost” method is used because management considers it to be the best available measure of progress on these contracts.performance obligations.

 

ContractIncurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs and depreciation costs.

Provisions for Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated lossestotal costs on uncompleted contractsany contract are madegreater than the net contract revenues, the Company recognizes the entire estimated loss in the period in which such lossesthe loss becomes known and can be reasonably estimated.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 2 - Summary of Significant Accounting Policies (continued)

“Contract assets,” include unbilled amounts typically resulting from sales under contracts when revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. The amount may not exceed their estimated net realizable value. Contract assets are determined. Changes in job performance, job conditions,classified as current based on our contract operating cycle.

“Contract liabilities,” include advance payments and estimated profitability, and final contract settlements may result in revisions to costs and income and are recognized in the period in which the revisions are determined.

The asset “Costs and estimated earningsbillings in excess of billingsrevenue recognized. Contract liabilities are classified as current based on contracts in progress” represents gross revenuesour contract operating cycle and reported on a contract-by-contract basis, net of revenue recognized, in excessat the end of amounts billed.each reporting period.

 

The liability “BillingFor outright sales of products, revenue is recognized when control of the promised products or services is transferred to our customers, in excessan amount that reflects the consideration we expect to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of costs and estimated earnings on contracts in progress” represents gross amounts billed in excess of revenues recognized.account under ASC 606.

 

Inventories

 

Inventories are valued at the lower of cost (determined on the first-in, first-out method) or market.net realizable value.

 

Income Taxes

On December 22, 2017, the Tax Cuts and Jobs Actwas adopted into law. The tax Act made broad and complex changes to the Internal Revenue Code of 1986, including, but not limited to, (i) reducing the U.S. federal corporate tax rate from 35% to 21%; (ii) eliminating the corporate alternative minimum tax (“AMT”) and changing how existing AMT credits are realized; (iii) creating a new limitation on deductible interest expense and (iv) changing rules related to uses and limitation of net operating loss carryforwards created in tax years beginning after December 31, 2017.

 

Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.

 

Investment tax credits are accounted for by the flow-through method, reducing income taxes currently payable and the provision for income taxes in the period the assets giving rise to such credits are placed in service. To the extent such credits are not currently utilized on the


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

Note 2 - Summary of Significant Accounting Policies (continued)

Company’s tax return, deferred tax assets, subject to considerations about the need for a valuation allowance, are recognized for the carryforward amount.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 2 - Summary of Significant Accounting Policies (continued)

 

The Company recognizes the tax benefit from an uncertain tax position only if it is more-likely-than-not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such

a position positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

The accounting guidance on accounting for uncertainty in income taxes also addresses derecognition, classification, interest and penalties on income taxes, and accounting in interim periods. The Company does not believe it has any uncertain tax positions through the year ending December 31, 20162018 which would have a material impact on the Company’s consolidated financial statements.

 

The Company and its subsidiaries file combined income tax returns in the U.S. Federal and New York State jurisdiction. In addition, the parent company files standalone tax returns in California, Delaware, Michigan, Minnesota, New Hampshire and Wisconsin. The Company is no longer subject to U.S. federal and state income tax examinations for tax periods before 2013.

The Company recognizes interest and penalties accrued related to unrecognized tax benefits, if any, in its income tax provision. The Company had no interest and penalties accrued at December 31, 2016 and 2015.

 

Impairment of Long Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists pursuant to the requirements of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 360-10-35, “Impairment or Disposal of Long-Lived Assets.” If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value. The Company had no recorded impairment charges in the consolidated statement of operations during each of the years ended December 31, 20162018 and 2015.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 20152017.

 

Note 2 - Summary of Significant Accounting Policies (continued)

Construction in Progress

Construction in progress consists of amounts expended for renovating the facility which was purchased on March 15, 2012, and equipment that is built internally for company use. Expenditures for maintenance and repairs are charged to operations as incurred; additions, renewals and betterments are capitalized.

Computer Software

 

The Company follows ASC 350-40, “Internal Use Software.” This standard requires certain direct development costs associated with internal-use software to be capitalized including external direct costs of material and services and payroll costs for employees devoting time to the software projects. TheseThere were no costs totaled $2,000for December 31, 2018 and $21,000$427,000 for the yearsyear ended December 31, 2016 and 2015, respectively,2017, and are included in Other Assets.Property, Plant and Equipment. All computer software is amortized using the straight-line method over its estimated useful life of three to five years. Amortization expense related to computer software totaled $18,000$144,500 and $16,000$36,000 for the years ended December 31, 20162018 and 2015,2017, respectively.

 


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 2 - Summary of Significant Accounting Policies (continued)

Intangible Assets

 

The cost of intangible assets is being amortized on a straight-line basis over their estimated initial useful lives which ranged from 5 to 20 years. Amortization expense recorded by the Company in 20162018 and 20152017 totaled $31,000$115,800 and $24,000,$46,000, respectively.

 

Research & Development

 

Research and development costs are expensed as incurred. In 2012 we expanded our laboratory staff and began conducting research and development independent of customer orders. In 20162018, we incurred approximately $2,448,000$607,000 of research and development expenses of which $434,000 were independent of external customer orders compared to 2015,2017, when we incurred approximately $1,727,000$437,000 of research and development expenses of which approximately $605,000 were independent of external customer orders.expenses.

 

Accounts Receivable

The Company sells products and services to various companies across several industries in the ordinary course of business. The Company performs ongoing credit evaluations to assess the probability of accounts receivable collection based on a number of factors, including past transaction experience, evaluation of their credit history and review of the invoicing terms of the contract to determine the financial strength of its customers. The Company has accounts receivables from certain customers that exceed 10%. As of December 31, 2018 and 2017, the accounts receivable balance includes amounts from two customers, which total 42% and three customers which total 60%, respectively.

 

Accounts receivable is presented net of an allowance for doubtful accounts of $2,000$24,000 and $19,000$2,000 as of December 31, 201652018 and 2015,2017, respectively. The allowance is based on historical experience and management’s evaluation of the collectability of accounts receivable. Management believes the allowance is adequate. However, future estimates may fluctuate based on changes in economic and customer conditions. The Company doesn’t require collateral from its customers.

 

Sales Concentrations

Revenue to a single customer in any one year can exceed 10.0% of our total sales. One customer represented 38.2% and 66.1% respectively, of our annual revenues in fiscal years 2018 and 2017. Previously, we have not been generally dependent on any single customer, and the loss of any customer would be replaced by others, however, the dynamic has changed and although, we believe that our relationship with our current largest customer may provide us with ongoing continuous sustainability for years to come, the loss of our largest customer would have to be replaced by others, and our inability to do so may have a material adverse effect on our business and financial condition.


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIESSUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Export sales to customers represented approximately 9.9% and 9.6% of sales for the years ended December 31, 2018 and 2017, respectively. Export sales in both 2018 and 2017 were primarily to customers in Europe and Asia. All contracts except those entered into by CVD Tantaline ApS are denominated in U.S. dollars. The Company does not enter into any foreign exchange contracts.

Product Warranty

 

The Company records warranty costs as incurred and does not provide for possible future costs. Management estimates such costs are immaterial, based on historical experience. However, it is reasonably possible that this estimate may differ in future periods.

 

Earnings Per Share

 

Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options and warrants.

 

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

 

Cash and Cash Equivalents

 

The Company had cash and cash equivalents of $21.7$11.4 million and $13.7$14.2 million respectively at December 31, 20162018 and 2015.2017, respectively. The Company invests excess cash in treasury bills, certificates of deposit or money market accounts, all with maturities of less than three months. Cash equivalents were $7.5 million and $0 for the years ended December 31, 2018 and December 31, 2017, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount at risk at December 31, 2018 and at December 31, 2017 was $6,920,000 and $12,198,000 respectively.

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with high credit-quality financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or money market instruments. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 2 - Summary of Significant Accounting Policies (continued)

The Company sells products and services to various companies across several industries in the ordinary course of business. The Company routinely assesses the financial strength of its customers and maintains allowances for anticipated losses based upon historical experience.

 


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

Note 2 - Summary of Significant Accounting Policies (continued)

Fair value of Financial Instruments

 

The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, net, accounts payable and accrued expenses, deferred revenue and customer deposits approximate fair

Note 2 - Summary of Significant Accounting Policies (continued)

value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.

 

Business Combination

The Company has accounted for its acquisitions of the assets of both Tantaline A/S and MesoScribe Technologies, Inc. using the acquisition method. The Company has allocated the purchase price to the assets acquired based on their estimated fair values at the acquisition dates.

Acquisition-Related Contingent Consideration

Acquisition-related contingent consideration represents an obligation of the Company to transfer additional assets or equity interests if specified future events occur or conditions are met. This contingency is accounted for at fair value either as a liability or equity depending on the terms of the acquisition agreement. The Company determines the estimated fair value of contingent consideration as of the acquisition date, and subsequently at the end of each reporting period.  In doing so, the Company makes significant estimates and assumptions regarding future events or conditions being achieved under the subject contingent agreement as well as the appropriate discount rate to apply. 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation” using the modified prospective method. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards.

 

Shipping and Handling

 

It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $28,000$61,200 and $57,000$42,000 for the years ended December 31, 20162018 and 2015,2017, respectively.

 

RecentlyAdoptedAccounting Pronouncement

In May 2014, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which changes the criteria for recognizing revenue. The standard requires an entity which recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard requires a five-step process for recognizing revenues including identifying the contract with the customer, identifying the performance obligations in the contract, determining the transaction prices, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when (or as) the entity satisfies a performance obligation. Publicly-traded companies were initially required to adopt the ASU for reporting periods beginning after December 15, 2016; however, the FASB, in August 2015, then issued Accounting Standards Update (“ASU”) No. 2015-14 to defer the effective date of ASU 2014-09 for all entities by one year. Currently companies may choose among different transition alternatives. Management is currently evaluating the impact that ASU 2014-09 will have on the Company’s


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIESSUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

consolidated financial statements and have not yet determined which method of adoption will be selected.Recently Adopted Accounting Pronouncement

 

In April 2015,February 2018, the FASB issued ASU No. 2015-03, “Interest-imputation2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of interest (Subtopic 835-30): SimplifyingCertain Tax Effects from Accumulated Other Comprehensive Income. The ASU permits companies to elect a reclassification of disproportionate tax effects in accumulated other comprehensive income (AOCI) caused by the PresentationTax Cuts and Jobs Act of Debt Issuance Costs”, which2017 to retained earnings. The ASU also requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, rather than as a deferred charge asset. ASU No. 2015-03additional disclosures. This update is effective for the Companyfiscal years beginning January 1, 2016after December 15, 2018 and is to be applied retroactively. Management isinterim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect thatof this ASU will have on the Company’sour consolidated financial statements and related disclosures.statements.

 

In November 2015,June 2016, the FASB issued ASU No. 2015-17, “Balance sheet Classification of Deferred Taxes”2016-13, Financial Instruments – Credit Losses (Topic 326), which simplifiesrequire that financial assets measured at amortized cost be presented at the presentationnet amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of deferredthe financial asset to present the net carrying value at the amount expected to be collected. The income taxes by requiringstatement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that deferred income tax liabilitieshave taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and assets be classified as noncurrentreasonable and supportable forecasts that affect the collectability of the reported amount. The amendments in our consolidated balance sheet. ASU No. 2015-17 isthis update are effective for reporting periodsfiscal years beginning after December 15, 2016, with early application2019 and interim periods within those annual periods. Early adoption for fiscal years beginning after December 15, 2018 is permitted. The Company will adoptWe are currently evaluating the effect of this method beginning in 2017.update on our consolidated financial statements.

 

In MarchFebruary 2016 the FASB issued ASU No. 2016-09, “Stock Compensation Improvements2016-02, "Leases (Topic 842)" (ASU 2016-02). The primary difference between previous GAAP and ASU 2016-02 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The guidance requires a lessee to Employee Share-Based Payment Accounting”, which simplifies several aspectsrecognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. When measuring assets and liabilities arising from a lease, a lessee (and a lessor) should include payments to be made in optional periods only if the lessee is reasonably certain to exercise an option to extend the lease or not to exercise an option to terminate the lease. Similarly, optional payments to purchase the underlying asset should be included in the measurement of lease assets and lease liabilities only if the lessee is reasonably certain to exercise that purchase option. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for share-based payments.such leases generally on a straight-line basis over the lease term. ASU 2016-092016-02 is effective for reporting periodsfiscal years beginning after December 15, 2016. Management2018. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 2 - Summary of Significant Accounting Policies (continued)

An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is currently evaluatingmodified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the effectpresent value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. In addition, FASB has amended Topic 842 prior to it becoming effective. The effective date and transition requirements for these amendments to Topic 842 are the same as ASU 2016-02. The Company has substantially completed its evaluation of the impact the adoption of this ASUguidance will have on the Company’sits consolidated financial statemetnsstatements, results of operations, and related disclosures.disclosures which will include recognizing a lease liability and a right-of-use asset representing its right to use the underlying asset for the lease term which the Company believes will not have a material impact on the financial statements.

 

We believe there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

 

Note 3Contracts in Progress

The following table represents a disaggregation of revenue from contracts for the years ended December 31, 2018 and December 31, 2017:

(In thousands)

 

2018

  

2017

 

Category

        

Aerospace

 $8,115  $26,787 

Industrial

  7,043   6,629 

Research

  4,114   2,617 

Point in time

  5,062   5,095 

Net revenue

 $24,334  $41,128 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated statements of operations. The table below outlines the impact on revenue of net changes in estimated transaction prices and input costs for systems related sales contracts (both increases and decreases) for the years ended December 31, 2018 and December 31, 2017 as well as the number of projects that comprise such changes.


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note3Contracts in Progress (continued)

 

CostsAlso included in the table is the net change in estimate as a percentage of the aggregate revenue for such projects.

(In thousands)

 

2018

  

2017

 

Increase in revenue from net changes in transaction prices

 $254  $148 

Decrease in revenue from net changes in input cost estimates

  (268)  (126)

Net (decrease) increase in revenue from net changes in estimates

 $(14) $22 
         

Number of projects

  10   2 

Net change in estimate as a percentage of aggregate revenue for associated projects

  (0.08%)  0.06%

For the years ended December 31, 2018 and estimated earningsDecember 31, 2017, revenue (decreased) increased by ($14,000) and $22,000 respectively, from net changes in transaction prices, input cost estimates, product cost overruns and product cost forecast changes related to redesign of certain systems.

Contract Assets and Liabilities

Contract assets consist of (i) retainage which represent the earned, but unbilled, portion for which payment is deferred by the customer until certain contractual milestones are met; and (ii) unbilled receivables which represent revenue that has been recognized in advance of billing the customer, which is common for long-term contracts. Contract liabilities consist of customer advances and billings in excess of billingsrevenue recognized.

For the year ended December 31, 2018, the decrease in contract assets of approximately $7 million was primarily driven by additional billed receivables during the period, for those projects that certain milestones had been reached. During the year ended December 31, 2018, the increase in contract liabilities of $70,000 was primarily due to invoicing for those projects.

Contract assets and contract liabilities on percentage of completioninput method type contracts in progress are summarized as follows:

  

2016

  

2015

 

Costs incurred on contracts in progress

 $4,678,192  $7,695,281 

Estimated earnings

  10,733,826   7,635,114 
   15,412,018   15,330,395 

Billings to date

  (18,077,839)  (10,695,377)
  $(2,665,821) $4,635,018 

 

 

2018

  

2017

 
        

Costs incurred on contracts in progress

 $24,913,254  $22,079,680 

Estimated earnings

  26,040,219   16,499,697 
  50,953,473   38,579,377 

Billings to date

  (50,132,200)  (30,648,666)
 

2016

  

2015

  $821,273  $(7,930,711)

Included in accompanying balance sheets

                

Under the following captions:

                

Costs and estimated earnings in excess of billings on contracts in progress

 $2,596,518  $4,635,018 
        

Billings in excess of costs and estimated earnings on contracts in progress

 $(5,262,339) $--- 

Contract assets

 $1,357,797  $8,397,024 

Contract liabilities

 $(536,524) $(466,313)


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIESSUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

Note4 - Inventories

Inventories consist of:                          

  

2016

  

2015

 
         

Raw materials

 $3,062,830  $2,718,328 

Work-in-process

  159,482   174,698 

Finished goods

  64,227   93,404 

Totals

 $3,286,539  $2,986,430 

 

Inventories consist of:

        
  

2018

  

2017

 
         

Raw materials

 $2,016,488  $3,156,016 

Work-in-process

  205,385   389,630 

Finished goods

  -   26,977 

Gross inventories

  2,221,873   3,572,623 

Less reserve for obsolescence

  (360,000)  (607,000)

Inventories, net

 $1,861,873  $2,965,623 

 

Note5 – Property, Plant and Equipment

 

Major classes of property, plant and equipment consist of the following:

 

 

2018

  

2017

 
 

2016

  

2015

         

Land

 $2,220,000  $2,220,000  $6,929,000  $6,929,000 

Buildings

  6,631,039   6,631,039   15,920,925   15,917,925 

Building improvements

  5,615,823   5,615,823   6,603,121   5,805,045 

Machinery and equipment

  2,671,333   2,381,964   3,385,357   3,246,877 

Furniture and fixtures

  547,144   721,919   611,190   563,959 

Computer equipment

  479,534   701,367   487,007   587,147 

Software

  441,376   427,441 

Transportation equipment

  65,994   65,994   65,995   65,994 

Lab equipment

  1,975,533   1,972,838   1,985,179   1,979,180 

Construction in Progress

  946,960   - 

Totals at cost

  20,206,400   20,310,944  $37,376,110  $35,522,568 
        

Less: Accumulated depreciation and amortization

  (5,861,476)  (5,517,021)  (6,973,552)  (6,683,111)
Property, plant and equipment, net $14,344,924  $14,793,923  $30,402,558  $28,839,457 
                

Depreciation and amortization expense (1)

 $813,657  $826,529  $1,141,161  $867,277 

(1)

Includes amortization expense of $31,356$115,800 and $24,759$45,645 for the yearsyear ending December 31,2016 2018 and 2015,the year ended December 31, 2017, respectively. Such amortization expense relates to other capitalized and intangible intangibles assets.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 6 – Intangible Assets

 

2016Intangible assets consisted of the following:

 

 

Weighted Average

      

Accumulated

  

Carrying

 

2018

                

Intangible Assets

 

Amortization Period

  

Cost

  

Amortization

  

Amount

  

Weighted Average

Amortization Period

  

Cost

  

Accumulated

Amortization

  

Carrying

Amount

 
                

Patents, Copyrights and Intellectual Property

  18   396,757   143,133   253,624   14  $796,080  $300,528  $495,552 

Licensing Agreement

  5   10,000   10,000   0   5   10,000   10,000   0 

Certifications

  3   58,722   58,722   0   4   58,486   58,486   0 

Other

  5   21,492   21,492   0 
                

Totals

     $486,971  $233,347  $253,624      $864,566  $369,014  $495,552 

 

2017

                

Intangible Assets

 

Weighted Average

Amortization Period

  

Cost

  

Accumulated

Amortization

  

Carrying

Amount

 

Patents, Copyrights and Intellectual Property

  18  $839,831  $177,669  $662,162 

Licensing Agreement

  5   10,000   10,000   0 

Certifications

  3   58,722   58,722   0 

Other

  5   21,492   21,492   0 

Totals

     $930,045  $267,883  $662,162 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

2015

  

Weighted Average

      

Accumulated

  

Carrying

 

Intangible Assets

 

Amortization Period

  

Cost

  

Amortization

  

Amount

 
                 

Patents, Copyrights and Intellectual Property

  16  $190,327  $129,992  $60,335 
                 

Licensing Agreement

  5   10,000   10,000   0 
                 

Certifications

  3   58,722   58,722   0 
                 

Other

  5   21,492   21,492   0 
                 
                 

Totals

     $280,451  $220,206  $60,335 

 

The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of December 31, 20162018 is as follows:

 

Year Ended

    

2019

 $121,613 

2020

  121,613 

2021

  121,613 

2022

  36,613 

2023

  36,613 

Thereafter

  57,487 

Total

 $495,552 

 

Year Ended

    

2017

 $16,977 

2018

  15,311 

2019

  15,310 

2020

  15,311 

2021

  15,310 
Thereafter  175,405 
Total $253,624 

Note7 – Financing Arrangements

 

The Company hashad a revolving credit facility with HSBC Bank, USA, N.A. (“HSBC”) providing up to $7 million, although the Company has never utilized this facility. This credit facility remains available untilexpired on September 1, 2018. The credit agreement also contains certain financial covenants, all of which the Company was in compliance with at December 31, 2016.

 


 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIESSUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

Note7 – Financing Arrangements (continued)

 

The Company has a loan agreement with HSBC which is secured by a mortgage against our Central Islip facility. The loan is payable in 120 consecutive equal monthly installments of $25,000 in principal plus interest and a final balloon payment upon maturity in March 2022. The balances as of December 31, 20162018 and December 31, 20152017 were approximately $3.3$2.7 million and $3.6$3.0 million respectively. Interest accrues on the Loan, at our option, at the variable rate of LIBOR plus 1.75% which was 2.1765% and 1.9455% at December 31, 2016 and 2015 respectively.or Prime less 0.5%.

 

On November 30, 2017, we purchased the premises located at 555 North Research Place, Central Islip, NY. The purchase price of the building was $13,850,000 exclusive of closing costs. The Company’s newly formed wholly-owned subsidiary, 555 N Research Corporation (the “Assignee”) and the Islip IDA, entered into a Fee and Leasehold Mortgage and Security Agreement (the ”Loan”) with HSBC in the amount of $10,387,500, which was used to finance a portion of the purchase price to acquire the premises located at 555 North Research Place, Central Islip, New York. The Loan was evidenced by the certain Note, dated November 30, 2017 (the “Note”), by and between Assignee and the Bank, and secured by a certain Fee and Leasehold Mortgage and Security Agreement (the “Mortgage”), dated November 30, 2017, as well as a collateral Assignment of Leases and Rents.

The Loan is payable in 60 consecutive equal monthly installments of $62,481 including interest. The Loan shall bear interest for each Interest Period (as defined in the Note), at the fixed rate of 3.9148%. The maturity date for the Note is December 1, 2022. As a condition of the Bank making the Loan, the Company was required to guaranty Assignee’s obligations under the Loan pursuant that certain Unlimited Guaranty, dated November 30, 2017 (the “Guaranty”).

At December 31, 2018, the Company was not in compliance with the one financial covenant (fixed charge coverage ratio) contained in the Mortgage. On March 26, 2019 the Company received a waiver from HSBC until April 1, 2020.


Note 8 – Long-term Debt

 

Long-term debt as of December 31 consists of the following:

  

2016

  

2015

 

HSBC

        

$2,100,000 5 year term loan payable in monthly installments of $35,000 plus interest on the unpaid principal balance which accrues at a fixed rate of 3.045%. This term loan was secured by $1 million, provided that, so long as no event of default occurred and is then continuing, HSBC would release $200,000 of the collateral on each anniversary of the closing date. As of December 31, 2016, this term loan had been paid in full.

 $---  $280,000 
         

HSBC

        

$6,000,000 Mortgage payable secured by real property

Buildings and improvements at 355 South Technology Drive, Central Islip, NY payable in monthly principle installments of $25,000 plus interest. Interest presently accrues at our option, at the variable rate of LIBOR plus 1.75% or HSBC’s prime rate minus 0.50% The loan matures on March 1, 2022.

  3,265,508   3,565,508 

Total long-term debt

  3,265,508   3,845,508 

Less: Current maturities

  300,000   580,000 

Long-term debt

 $2,965,508  $3,265,508 

Long-term debt as of December 31 consists of the following:

        
  

2018

  

2017

 

HSBC $10,387,500 Mortgage payable secured by real property Buildings and improvements at 555 N Research Drive, Central Islip, NY payable in monthly principle installments of $62,481 including Interest at a rate of 3.9148% maturing on December 1, 2022.

 $10,043,802  $10,387,500 
         

MesoScribe Technologies, Inc. $300,000 acquisition related contingent payment

  200,000   300,000 
         

HSBC $6,000,000 Mortgage payable secured by building Buildings and improvements at 355 South Technology Drive, Central Islip, NY payable in monthly principle installments of $25,000 plus interest. Interest presently accrues at our option, at the variable rate of LIBOR plus 1.75% or HSBC’s Prime rate minus 0.50% The loan matures on March 1, 2022.

  2,665,508   2,965,507 

Total long-term debt

 $12,909,310  $13,653,007 

Less: Current maturities

  (857,590)  (747,324)

Long-term debt

 $12,051,720  $12,905,683 

 

Future maturities of long-term debt as of December 31, 2016 are as follows:

2017

 $300,000 

2018

  300,000 

2019

  300,000 

2020

  300,000 

2021

  300,000 

Thereafter

  1,765,508 
Total long-term debt $3,265,508 

Future maturities of long-term debt as of December 31, 2018 are as follows:

 

2019

 $857,590 

2020

  674,593 

2021

  690,813 

2022

  10,686,314 

2023

  - 

Thereafter

  - 

Total long-term debt

 $12,909,310 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

Note9Earnings per Share

The calculation of basic and diluted weighted average common shares outstanding is as follows:

 

 

2016

  

2015

  

2018

  

2017

 

Weighted average common shares outstanding basic earnings per share

  6,285,815   6,175,254   6,495,597   6,375,848 
        

Effect of potential common share issuance:

                

Stock options

  ---   108,053   -   11,616 
                

Weighted average common shares outstanding

                

Diluted earnings per share

  6,285,815   6,283,307   6,495,597   6,387,464 


 

StockCVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 9Earnings per Share (continued)

At December 31, 2018, stock options to purchase 284,730407,930 shares of common stock were outstanding and 124,730257,930 were exercisable. Stock options to purchase 387,930 shares of common stock were outstanding and 207,930 were exercisable at December 31, 2016.2017. At December 31, 2016 none of the outstanding2017, 22,930 options were included in the diluted earnings per share calculation as their effect would have been anti-dilutive. At December 31, 2015 all outstanding optionsto purchase shares were included in the diluted earnings per share calculation because thetheir average market price was higher than the exercise price.

 

Note 10 – Income Taxes

The Tax Cuts and Jobs Act was enacted on December 22, 2017. The Act provides for numerous significant tax law changes and modifications including the reduction of the U.S. federal corporate income tax rate from 35% to 21%.

In accordance with the accounting standard ASC 740 “Income Taxes”, companies are required to recognize the tax law changes in the period of enactment.

As a result of the reduction of the corporate income tax rate to 21%, U.S. GAAP requires companies to remeasure their deferred tax assets and liabilities as of the date of enactment, with resulting tax effects accounted for in the period of enactment. The Company remeasured deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. The provisional amount recorded for the remeasurement and resulting write-down of the deferred tax balance was $689,000. At December 31, 2016,2018, the Company had approximately $27,000 in capital loss carryforwards, and $1,279,000$414,000 of federal research and development tax credits.

If not utilized, the investment tax credits expire from 2016 through 2030 and the research and development tax credits expire from 2031-2036.2032-2037. Based on the available objective evidence, including the Company’s history of taxable income and the character of that income, management believes it is more likely than not that these components of the Company’s deferred tax assets will be fully utilized. The Company has provided for a partial valuation allowance against its total net deferred tax assets at December 31, 2016 and December 31, 2015 of approximately $475,000 attributable to these components.

 


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

Note 10 – Income Taxes (continued)

The expense/(benefit) for income taxes includes the following:

 

 

2016

  

2015

  

2018

  

2017

 

Current:

                

Federal

 $(71,070) $---  $58,304  $1,091,216 

State

  2,504   3,070   80,367   11,580 

Total current tax provision

  (68,566)  3,070   138,671   1,102,796 

Deferred:

                

Federal

  (435,495)  1,317,125   (495,233)  831,148 

State

  -   ---   ---   --- 

Total deferred tax provision

  (435,495)  1,317,125   (495,233)  831,148 

Income tax (benefit)/expense

 $(504,061) $1,320,195  $(356,562) $1,933,944 


 

In March 2014, New York State eliminated the state income tax for qualified manufacturing companies such as CVD. CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 10 – Income Taxes (continued)

 

The tax effects of temporary differences giving rise to significant portions of the net deferred taxes are as follows:

 

  

2016

  

2015

 
         

Allowance for doubtful accounts

 $771  $6,345 

Inventory capitalization

  19,071   11,540 

Depreciation and amortization

  (211,014)  (228,610)

Investment tax credits

  475,000   475,000 

Research & development tax credits

  1,278,690   1,134,168 

Compensation costs

  1,000,073   730,909 

Vacation accrual

  333,396   323,860 

Accrued loss on legal settlement

  --   -- 

Net operating loss carryforward

  (7,280)  -- 

Capital loss carryforward

  26,627   26,627 

Gross deferred tax asset

  2,915,334   2,479,839 

Less valuation allowance

  (475,000)  (475,000)

Net deferred tax asset

 $2,440,334  $2,004,839 
         

Net current deferred tax asset

  428,355   398,009 

Net long-term deferred tax asset

  2,011,979   1,606,830 

Net deferred tax asset

 $2,440,334  $2,004,839 

  

2018

  

2017

 

Deferred income tax assets:

        

Allowance for doubtful accounts

 $5,060  $773 

Inventory capitalization

  6,197   6,813 

Depreciation and amortization

  -   70,272 

Research & development tax credits

  413,680   496,930 

Compensation costs

  1,035,983   838,643 

Vacation accrual

  167,644   179,309 

Interest expense carryforward

  66,149   --- 

Net operating loss carryforward

  832,565   --- 

Capital loss carryforward

  16,446   16,446 

Total deferred tax asset

  2,543,724   1,609,186 

Deferred incomes tax liability:

        

Property and equipment - tax over book depreciation

  (439,310)  --- 

Less valuation allowance

  ---   --- 

Net long-term deferred tax asset

 $2,104,414  $1,609,186 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2016

Note 10 – Income Taxes (continued)

 

The reconciliation of the federal statutory income tax rate to our effective tax rate is as follows:

  

2018

  

2017

 

Expected provision at federal statutory tax rate (21% and 34%, respectively)

 $(1,167,092) $2,446,421 

Foreign tax loss

  99,215   293,589 

Adjustment to 2017 tax return

  58,304   - 

State taxes, net of federal benefit

  80,367   11,580 

Stock-based compensation expense

  185,675   (161,429)

Net operating loss carryforward

  -   7,280 

Federal research & development credit

  (83,245)  (781,760)

Other permanent differences

  470,214   118,263 

Income tax expense/(benefit)

 $(356,562) $1,933,944 

 

  

2016

  

2015

 
         

Expected provision at federal statutory tax rate (34%)

 $(222,083 $1,538,565 

State taxes, net of federal benefit

  2,504   3,070 

Stock-based compensation expense

  (269,163  (252,288)
         

Net operating loss carryforward

  (21,412)  954,581 

Federal research & development credit

  (144,522)  (437,303)

Other permanent differences

  150,615   (486,430)

Income tax (benefit)/expense

 $(504,061) $1,320,195 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

NOTE Note 10 – Income Taxes (continued)

The Company’s foreign subsidiary, CVD Tantaline ApS incurred a loss of approximately $463,000, which would provide a $102,000 deferred tax asset as of December 31, 2018, based on the standard corporate tax rate of 22% in Denmark. For the year ended December 31, 2017 the Company had a loss of $865,000 with a deferred tax asset of $190,000. However, sufficient uncertainty exists as to the realizability of these assets such that a full valuation allowance has been necessary.

Note11 – Stockholders’ equity

 

1989 Non-Qualified Stock Option Plan

On June 15, 1989, the Company instituted a non-qualified stock option plan (the “Plan”). In connection therewith, 700,000 shares of the Company’s common stock were reserved for

issuance pursuant to options granted under the Plan through June 30, 2009. All options granted vested over a four-year period and expire between five to seven years after the date of grant. This 1989 Non-Qualified Stock Option Plan expired in June 2009.

2001 Non-Qualified Stock Option Plan

 

In November 2006, the Company registered a non-qualified stock option plan that the shareholders had approved in July 2001, covering key employees, officers, directors and other persons that may be considered as service providers to the Company. Options were awarded by the Board of Directors or by a committee appointed by the Board. Under the plan, an aggregateof 300,000 shares of Company common stock, $.01 par value, were reserved for issuance or transfer upon the exercise of options which were granted. Unless otherwise provided in the option agreement, options granted under the plan would vest over a four yearfour-year period commencing one year from the anniversary date of the grant. The stock option plan expired on July 22, 2011.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

 

NOTE 11 – Stockholders’ equity (continued)

2007 Share Incentive Plan

 

On December 12, 2007, shareholders approved the Company’s 2007 Share Incentive Plan (“Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the Share

Incentive Plan through December 12, 2017. In 2016, 42,3202017, 75,324 shares of stock were granted and issued to directors and key employees, additionally, options were granted to athree key employeeemployees for 100,000140,000 shares of the Company’s common stock. In 2015, 36,108The Plan expired in December, 2017.

2016 Share Incentive Plan

On December 9, 2016, shareholders approved the Company’s 2016 Share Incentive Plan (“2016 Incentive Plan”), in connection therewith 750,000 shares of the Company’s common stock wereare reserved for issuance pursuant to options or restricted stock that may be granted and issued to directors and key employees.under the 2016 Incentive Plan through December 9, 2026.

 

The purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall not be less than the fair market

value of the shares on the date such option is granted. The stock options generally expire seven to ten years after the date of grant. The Company recorded stock-based compensation of $776,000$940,000 and $751,000$933,000 for the years ended December 31, 20162018 and 2015,2017, respectively.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2018 and 2017

Note 11 – Stockholders’ equity (continued)

 

A summary of the stock option activity related to the 1989 and 2001 Stock Option Plans, the 2007 Share Incentive Plan and the 20072016 Share Incentive Plan for the period from January 1, 20152017 through December 31, 20162018 is as follows:

 

2001 Non-Qualified Stock Option Plan

  

Beginning

  

Granted

  

Exercised

  

Canceled

  

Ending

     
  

Balance

  

During

  

During

  

During

  

Balance

     
  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 

Year ended December 31, 2017

                        

Number of shares

  59,730   -   36,800   -   22,930   22,930 

Weighted average exercise price per share

 $4.51   -  $3.97   -  $5.36  $5.36 

Year ended December 31, 2018

      -                 

Number of shares

  22,930   -   -   -   22,930   22,930 

Weighted average exercise price per share

 $5.36   -   -   -  $5.36  $5.36 

1989 Non-Qualified Stock Option Plan

 

  

Beginning

  

Granted

  

Exercised

  

Canceled

  

Ending

     
  

Balance

  

During

  

During

  

During

  

Balance

     
  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 
                         

Year ended December 31, 2015

                        

Number of shares

  35,250   -0-   -0-   0   35,250   35,250 

Weighted average exercise price

                        

Per share

 $4.62   -0-   -0-   -0-  $4.62  $4.62 

Year ended December 31, 2016

                        

Number of shares

  35,250   -0-   35,250   -0-   -0-   -0- 

Weighted average exercise price

                        

Per share

 $4.62   -0-  $4.62   -0-   -0-   -0- 

2007 Share Incentive Plan

  

Beginning

  

Granted

  

Exercised

  

Canceled

  

Ending

     
  

Balance

  

During

  

During

  

During

  

Balance

     
  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 

Year ended December 31, 2017

                        

Number of shares

  225,000   140,000   -   -   365,000   185,000 

Weighted average exercise price per share

 $9.43  $10.82   -   -  $12.35  $13.76 

Year ended December 31, 2018

                        

Number of shares

  365,000   -   -   -   365,000   235,000 

Weighted average exercise price per share

 $12.35   -   -   -  $12.35  $13.15 

2016 Share Incentive Plan

  

Beginning

  

Granted

  

Exercised

  

Canceled

  

Ending

     
  

Balance

  

During

  

During

  

During

  

Balance

     
  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 

Year ended December 31, 2017

                        

Number of shares

  -   -   -   -   -   - 

Weighted average exercise price per share

  -   -   -   -   -   - 

Year ended December 31, 2018

                        

Number of shares

  -   20,000   -   -   20,000   - 

Weighted average exercise price per share

  -  $8.07   -   -  $8.07   - 

 


 

CVD EQUIPMENTEQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

NoteNOTE 11 – Stockholders’ equity (continued)

2001 Non-Qualified Stock Option Plan

  

Beginning

  

Granted

  

Exercised

  

Canceled

  

Ending

     
  

Balance

  

During

  

During

  

During

  

Balance

     
  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 
                         

Year ended December 31, 2015

                        

Number of shares

  124,480   -0-   -0-   -0-   124,480   124,480 

Weighted average exercise price

                        

Per share

 $4.57   -0-   -0-   -0-  $4.57  $4.57 

Year ended December 31, 2016

                        

Number of shares

  124,480   -0-   64,750   -0-   59,730   59,730 

Weighted average exercise price

                        

Per share

 $4.57   -0-   4.62   -0-  $4.51  $4.51 

2007 Share Incentive Plan

  

Beginning

  

Granted

  

Exercised

  

Canceled

  

Ending

     
  

Balance

  

During

  

During

  

During

  

Balance

     
  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 
                         

Year ended December 31, 2015

                        

Number of shares

  100,000   -0-   -0-   -0-   100,000   20,000 

Weighted average exercise price

                        

Per share

 $11.17   -0-   -0-   -0-  $11.17  $11.17 

Year ended December 31, 2016

                        

Number of shares

  100,000   125,000   -0-   -0-   225,000   65,000 

Weighted average exercise price

                        

Per share

 $11.17   8.04   -0-   -0-  $9.43  $9.97 

 

The Company has 284,730407,930 of outstanding stock options under the three plans at December 31, 2016.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

NOTE 11 – Stockholders’ equity (continued)2018.

 

The following table summarizes information about the outstanding and exercisable options at December 31, 2016.2018.

 

   

Options Outstanding

          

Options Exercisable

     

Options Outstanding

  

Options Exercisable

 
       

Weighted

  

Weighted

          

Weighted

             

Weighted

  

Weighted

          

Weighted

     
       

Average

  

Average

          

Average

             

Average

  

Average

          

Average

     

Exercise

Exercise

 

Number

  

Remaining

  

Exercise

  

Intrinsic

  

Number

  

Exercise

  

Intrinsic

 

Exercise

  

Number

  

Remaining

  

Exercise

  

Intrinsic

  

Number

  

Exercise

  

Intrinsic

 

Price Range

Price Range

 

Outstanding

  

Contractual

  

Price

  

Value

  

Exercisable

  

Price

  

Value

 

Price Range

  

Outstanding

  

Contractual

  

Price

  

Value

  

Exercisable

  

Price

  

Value

 
                              
$3.00-3.99   34,000   1.95  $3.65  $171,020   34,000  $3.65  $171,020 
$4.00-4.49   15,930   4.04  $4.25  $70,570   15,930  $4.25  $70,570 -7.00   15,930   1   $4.25   $0   15,930   $4.25   $0 
$5.00-7.99   9,800   5.04  $7.90  $7,644   9,800  $7.90  $7,644 
$8.00-12.00   225,000   6.64  $9.43  $0   65,000  $9.43  $0 
$7.01-10.00   27,000   2   $8.03   $0   7,000   $7.90   $0 
$10.01-12.00   240,000   7.3   $10.88   $0   110,000   $11.05   $0 
$12.01-15.00   125,000   3.5   $15.00   $0   125,000   $15.00   $0 

 

No options were exercised for the year ended December 31, 2018. The intrinsic value of the 100,00034,000 options exercised during the year ended December 31, 20162017 was $203,000. There were no options exercised during the year ended December 31, 2015.$256,000.

 

Restricted Stock Awards

 

The following table summarizes restricted stock awards for the years ended December 31, 20162018 and 2015:2017:

 

     

Weighted

      

Weighted

 
 

Shares of

  

Average Grant

      

Average Grant

 
 

Restricted

  

Date Fair

  

Shares of

  

Date Fair

 
 Stock  Value   

Restricted Stock

  

Value

 

Unvested outstanding at January 1, 2015

  8,000  $10.97 

Unvested outstanding at December 31, 2016

  0  $0 

Granted

  9,300  $9.70 

Vested

  (9,300) $9.70 

Forfeited/Cancelled

        

Unvested outstanding at December 31, 2017

  0  $0 
                

Granted

  9,211  $13.66   11,000  $10.53 

Vested

  (13,211) $12.84   (11,000) $10.53 

Forfeited/Cancelled

  -             
        

Unvested outstanding at December 31, 2015

  4,000  $10.97 
        

Granted

  17,524  $8.45 

Vested

  (21,524) $12.84 

Forfeited/Cancelled

  -     
        

Unvested outstanding at December 31, 2016

  -0-     

Unvested outstanding at December 31, 2018

  0  $0 

 

The total fair value of shares of restricted stock awards vested for the years ended December 31, 20162018 and 20152017 was approximately $276,000$116,000 and $170,000$90,000 respectively.


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

NOTE 11 – Stockholders’ equity (continued)

The fair value of the outstanding restricted stock awards will beis recorded as stock compensation expense over the vesting period. As of


CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2015 there was $44,000 of unrecognized compensation costs related to restricted stock awards, which is to be recognized over a period of 0.35 years.2018 and 2017

 

Note 11 – Stockholders’ equity (continued)

Restricted Stock Units

 

The following table summarizes restricted stock units for the years ended December 31, 20162018 and December 31, 2015:2017:

 

     

Weighted

      

Weighted

 
 

Shares of

  

Average Grant

  

Shares of

  

Average Grant

 
 

Restricted

  

Date Fair

  

Restricted

  

Date Fair

 
 

Stock Units

  

Value

  

Stock Units

  

Value

 

Unvested outstanding at January 1, 2015

  103,319  $11.71 
        

Unvested outstanding at December 31, 2016

  114,090  $10.47 

Granted

  24,210  $14.61   23,680  $9.29 

Vested

  (24,892) $11.55   (63,775) $9.94 

Forfeited/Cancelled

  (8,057) $10.54   (125) $14.61 
                

Unvested outstanding at December 31, 2015

  94,580  $12.55 
        

Unvested outstanding at December 31, 2017

  73,870  $10.05 

Granted

  60,400  $8.56   39,260  $8.75 

Vested

  (33,890) $12.43   (67,067) $9.26 

Forfeited/Cancelled

  (7,000) $11.68   0   0 
                

Unvested outstanding at December 31, 2016

  114,090  $10.47 

Unvested outstanding at December 31, 2018

  46,063  $8.25 

 

The total fair value of vested restricted stock units was $421,000$621,000 and $288,000$637,000 respectively for the years ended December 31, 20162018 and 2015.2017.

 

The fair value of the outstanding restricted stock units will be recorded as stock compensation expense over the vesting period. As of December 31, 2016,2018, there was $1,194,000$335,000 of total unrecognized compensation costs related to restricted stock units, which is expected to be recognized over a weighted-average period of 1.181.49 years.

 

During the years ended December 31, 20162018 and 2015,2017, the Company recorded into selling and general administrative expense approximately $776,000$940,000 and $751,000$933,000 of stock-based compensation expense for the cost of employee and director services received in exchange for equity instruments based on the grant-date fair value of those instruments in accordance with the provisions of ASC 718.

 

 

CVD EQUINPMENT CORPORATION AND SUBSIDIARIESote

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2016 and 2015

NOTE 12 – Defined Contribution Plan

 

On August 1, 1998, theThe Company adoptedmaintains a 401(k) Plan for the benefit of all eligible employees. All employees as of the effective date of the 401(k) Plan became eligible. An employee is eligible to become a participant after three months of continuous service.

 

Participants may elect to contribute from their compensation any amount up to the maximum deferral allowed by the Internal Revenue Code. Employer contributions are optional. During the years ended December 31, 20162018 and 2015,2017, the Company incurred administrative and audit fees totaling $14,636$8,425 and $13,080,$13,325, respectively. No discretionary employer contribution has been made for 20162018 and 2015.

Note 13Significant Risks and Uncertainties

Cash and Cash Equivalents

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount at

risk at December 31, 2016 and at December 31, 2015 was $20,157,000 and $11,966,000respectively.

Sales Concentrations

Revenue to a single customer in any one year can exceed 10.0% of our total sales. One customer represented 45.3% and 49.6% respectively, of our annual revenues in fiscal years 2016 and 2015. Another customer represented 13.7% of our revenue in 2015. Previously, we have not been generally dependent on any single customer, and the loss of any customer would be replaced by others, however, the dynamic has changed and although, we believe that our relationship with our current largest customers will provide us with ongoing continuous sustainability for years to come, the loss of current key customers would have to be replaced by others, and our inability to do so may have a material adverse effect on our business and financial condition.

Export sales to unaffiliated customers represented approximately 11.9% and 9.0% of sales for the years ended December 31, 2016 and 2015, respectively. Export sales in both 2016 and 2015 were primarily to customers in Europe and Asia. All contracts are denominated in U.S. dollars. The Company does not enter into any foreign exchange contracts.2017.

 


 

CVD EQUIPMENTEQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

Note 143 – Segment Reporting

 

The Company adopted ASC 280, “Segment Reporting.” The Company operates through (2)three segments, CVD, SDC and SDC.CVD Materials. The CVD divisionsegment is utilized for silicon, silicon germanium, silicon carbide and gallium arsenide processes. SDC is the Company’s ultra-high purity manufacturing division in Saugerties, New York. The accounting policies of CVD and SDC are the same as those described in the summary of significant accounting policies (see Note 2). The Company evaluates performance based on several factors, of which the primary financial measure is earnings before taxes. Included in the CVD Materials segment are our wholly owned subsidiaries, CVD Tantaline Aps and CVD MesoScribe Technologies Corporation.

 

The following table presents certain information regarding the Company’s segments as of December 31, 20162018 and December 31, 2017 and for the yearyears then ended:

 

  

CVD

  

SDC

  

Eliminations

  

Consolidated

 

Assets

 $44,783,126  $4,558,111  $(3,680,845) $45,660,392 
                 

Revenue

 $18,568,132  $2,934,831  $(547,616) $20,955,347 

Interest Expense

  78,322   1,539       79,861 

Depreciation andAmortization

  750,680   62,978       813,658 

Capital expenditures

      5,850         

Pretax earnings/(loss)

      (441,610)        

The following table presents certain information regarding the Company’s segments as of December 31, 2015 and for the year then ended:

  

CVD

  

SDC

  

Eliminations

  

Consolidated

 

Assets

 $39,529,971  $3,619,304  $(2,017,571) $41,131,704 
                 

Revenue

 $35,473,057  $5,674,258  $(2,181,928) $38,965,387 

Interest Expense

  85,765   6,336       92,101 

Depreciation and Amortization

  764,467   62,062       826,529 

Capital expenditures

  212,140   36,165       248,305 

Pretax (loss)/earnings

  3,616,280   1,046,911       4,663,191 

2018

                        

(In thousands)

 

CVD

  

SDC

  

Materials

  

Corporate

  

Eliminations *

  

Consolidated

 

Assets

 $40,467  $4,870  $7,187      $(9) $52,515 
                         

Revenue

 $17,860  $5,503  $1,993      $(1,022) $24,334 

Operating (loss)/income

  (1,754)  958   (1,295)  (3,164)      (5,255)

Pretax (loss)/income

  (1,691)  987   (1,690)  (3,164)      (5,558)

 

2017

                        

(In thousands)

 

CVD

  

SDC

  

Materials

  

Corporate

  

Eliminations *

  

Consolidated

 

Assets

 $42,152  $5,850  $9,368  $1,609  $(1) $58,978 
                         

Revenue

 $34,965  $7,427  $733      $(1,996) $41,129 

Operating (loss)/income

  9,232   2,008   (1,406)  (2,615)      7,219 

Pretax (loss)/income

  9,243   2,011   (1,444)  (2,615)      7,195 

*All elimination entries represent intersegment transactions eliminated in consolidation for external reporting.


 

CVD EQUIPMENTEQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 20162018 and 20152017

 

Note 15 Purchase14– Purchases of assets

 

On December 16, 2016, we purchased certainOctober 31, 2017, CVD Mesoscribe Technologies Corporation, a New York corporation and newly formed and wholly-owned indirect subsidiary of CVD Equipment Corporation (the “Company”) and MesoScribe Technologies, Inc., a Delaware corporation (“Seller”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, among other things, Buyer acquired (the “Acquisition”) substantially all of the operating assets formerly owned by Tantaline A/Sand business of Nordborg, Denmark through our wholly owned subsidiary, CVD Materials Corporation. Formed in 2007,the Seller (excluding cash, accounts receivable and other specified excluded assets), as a spin off from The Danfoss Group, Tantaline A/S established itself as a leadermore particularly described in the commercialization of tantalum treated parts for corrosion resistance. We have now established in Nordborg a new and wholly owned CVD subsidiary operating under the name Tantaline CVD Aps (“Tantaline”).Asset Purchase Agreement.

 

F-26 Pursuant to the Asset Purchase Agreement, the purchase price for the assets acquired in the Acquisition was $800,000, of which $500,000 was paid on the Closing Date and $300,000 may be paid to Seller as additional acquisition related contingent consideration based upon the achievement of certain revenue thresholds and other criteria set forth in the Asset Purchase Agreement with respect to each of the two consecutive twelve month measurement periods following the Closing Date. The additional consideration is classified as Acquisition related contingent payments, of which $200,000 is the current portion. For the initial twelve-month measurement period, the Company did not meet the threshold required and the $100,000 contingent payment was recorded into earnings.

 

The Company accounted for this acquisition using the acquisition method. The Company allocated the purchase price to the acquired assets based on their estimated fair values at the acquisition date as summarized in the following table.

Inventory

$25,000

Machinery and equipment

350,000

Intellectual property

425,000

Net tangible assets acquired

$800,000

F-27